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ABSTRACT 
This dissertation research involved investigations into possible drug-nutrient or 
disease-nutrient transport interactions in the nursing mother-neonate dyad. The overall 
hypothesis was that cefepime would inhibit L-carnitine transport at the lactating 
mammary gland and in developing neonates. Additionally, inflammation would alter 
energy substrate transporter expression in mammary tissue.  
The first objective was to investigate the potential for drug-nutrient transport 
interactions at the lactating mammary gland. A continuous cefepime infusion to lactating 
rats reduced L-carnitine transfer into milk at early but not mid lactation. In conjunction 
with higher milk L-carnitine and cefepime concentrations and higher expression levels 
of Octn2, the data suggests cefepime competitively inhibited Octn2-mediated L-
carnitine transport into milk.  
The second objective was to assess the influence of lactation stage on milk-to-
serum ratios (M/S) for an actively transported drug, cefepime, and its impact on the 
calculation of neonatal exposure indices. Higher cefepime M/S on day 4 lactation versus 
day 10 coupled with lower systemic clearance values for cefepime in postnatal day 4 
versus day 10 pups resulted in >7-fold higher exposure index values at postnatal day 4. 
These data confirm the need to determine M/S at different lactation stages for actively 
transported drugs to avoid over- or underestimation of neonatal exposure risk.  
The third objective was to examine a drug-nutrient transporter interaction in 
neonates. Cefepime administered twice daily according to different dosing schedules 
(postnatal days 1-4, 1-8, 8-11, 8-20 and 1-20) caused significant alterations in the 
ontogenesis of several mechanisms involved in the L-carnitine homeostasis. These 
alterations likely represented adaptive responses to cefepime inhibition of L-carnitine 
transport. Furthermore, these changes seemed to depend on duration and timing of 
exposure relative to postnatal maturation.  
The fourth objective was to examine the effects of inflammatory stimuli on 
energy substrate transporter expression in mammary tissue. Inflammatory stimuli altered 
expression of glucose, fatty acid and L-carnitine transporters in mammary tissue in vitro 
and in vivo.   
 iii
Collectively, this research provided experimental evidence for significant 
disease- or drug-nutrient transport interactions in the nursing mother-neonate dyad. 
Further research may identify a need for dietary modification during pharmacological 
management of disease in the nursing mother-neonate dyad.  
 iv
ACKNOWLEDGMENTS 
 
I wish to express my sincere thanks and gratitude to my supervisor Dr. J. Alcorn 
who provided me with continuous guidance, encouragement, constructive criticism and 
advice throughout the course of study. This appreciation is also extended to the other 
members of my advisory committee, Dr. A. A. Olkowski, Dr. G. Zello, Dr. P. Paterson, 
Dr. D. Maenz, and committee chair, Dr. E. Krol for providing me with encouragement, 
valuable suggestions and advice in many aspects of my research project. Thanks for Dr 
Chris Wojnarowicz for his expert assistance on the histopathological study. Also, thanks 
for Carolyn Aziz for all the help she provided me with my in vivo rat pup study.  
I am also very appreciative of all my Lab mates who were helpful and supportive 
to me over the years of study. Valery, Jennifer, Brian, Katie, Fawzy, Sam, and Fei, thank 
you.  Thanks for all my friends. A special thank for my friend Ying Kuang for always 
listening and supporting.  
I dedicate this dissertation to my husband Robert, my daughter Maya, and my 
parents for their support, encouragement and understanding. Without their sacrifice and 
support, I would not have been able to succeed in my academic career.
 v
TABLE OF CONTENTS 
PERMISSION TO USE ..................................................................................................... i 
ABSTRACT...................................................................................................................... ii 
ACKNOWLEDGMENTS ............................................................................................... iv 
TABLE OF CONTENTS .................................................................................................. v 
LIST OF TABLES ........................................................................................................... ix 
LIST OF FIGURES ......................................................................................................... xi 
LIST OF ABBREVIATIONS.........................................................................................xiii 
1 Introduction................................................................................................................ 1 
2 Literature Review ...................................................................................................... 2 
2.1 The Risk-Benefit Ratio: Breastfeeding vs. Maternal Disease/Medication....... 2 
2.2 Breastfeeding: The Trends, Benefits and Problems ......................................... 3 
2.3 Breast Milk and Neonatal Nutrition ................................................................. 5 
2.3.1 Breast Milk as a Source of Nutrition to the Nursing Neonate ..................... 5 
2.3.2 Early Life Nutritional Programming ........................................................... 7 
2.3.3 Transport of Milk Constituents in the Mammary Gland ............................. 9 
2.3.3.1 Nutrient Transporters in the Mammary Gland ................................... 10 
2.4 Effects of Drug/Disease on Mammary Gland Function during Lactation...... 12 
2.4.1 Mammary Gland Physiology and Biochemical Activities during  
Lactation .................................................................................................... 12 
2.4.2 Effects of Maternal Medication on Mammary Gland Function ................ 14 
2.4.2.1 Direct Effects of Maternal Medication on the Lactating  
Mammary Gland................................................................................. 14 
2.4.2.2 Indirect Effects of Maternal Medication on Milk Production ............ 15 
 vi
2.4.2.2.1 Effects of Maternal Drugs on Hormonal Milieu  
Supporting Lactation............................................................... 15 
2.4.2.2.2 Drug-Nutrikinetic Interactions Affecting Milk Secretion....... 15 
2.4.3 Effects of Maternal Disease on Mammary Gland Function ...................... 16 
2.4.3.1 Inflammatory Conditions of the Mammary Gland ............................. 16 
2.4.3.2 Effects of Inflammation on Transporter Function ............................. 17 
2.5 Risk of Drug Exposure via the Breast Milk ................................................... 18 
2.5.1 Relative Infant Dose and Infant Exposure Index ...................................... 18 
2.5.2 Mechanisms of Drug Transport into Milk ................................................ 20 
2.5.3 Neonatal Pharmacokinetics ...................................................................... 21 
2.5.4 Ontogeny of Nutrient Transporters ............................................................ 22 
2.5.5 Drug-Nutrient Interactions in the Nursing Neonate .................................. 23 
2.5.6 Drug-Nutrient Transport Interactions: Cefepime-L-Carnitine Transport 
Interaction as Proof-of-Concept ................................................................ 23 
2.5.6.1 L-Carnitine: Function and Biosynthesis ............................................. 24 
2.5.6.2 L-Carnitine and the Neonate .............................................................. 25 
2.5.6.3 L-Carnitine Transporters..................................................................... 26 
2.5.6.4 L-Carnitine Deficiency ....................................................................... 27  
2.5.6.5 L-Carnitine and Cefepime Transport Interaction................................ 28  
3 Perspectives ............................................................................................................. 29 
4 Hypothesis ............................................................................................................... 30 
5 Objectives ................................................................................................................ 30 
6 Acute Administration of Cefepime Lowered L-Carnitine Concentrations in Early  
Lactation Stage Rat Milk ......................................................................................... 33 
7 Lactation-Stage Influences Drug Milk-to-Serum Values and Neonatal  
 vii
Exposure Risk .......................................................................................................... 40 
7.1 Abstract........................................................................................................... 41 
7.2 Introduction .................................................................................................... 42 
7.3 Materials and Methods ................................................................................... 44 
7.4 Results ............................................................................................................ 47 
7.5 Discussion....................................................................................................... 50 
8 Systematic Evaluation of L-Carnitine Homeostasis Mechanisms during  
Postnatal Development in Rat.................................................................................. 54 
8.1 Abstract........................................................................................................... 54 
8.2 Introduction .................................................................................................... 55 
8.3 Materials and Methods ................................................................................... 57 
8.4 Results ............................................................................................................ 62 
8.5 Discussion....................................................................................................... 67 
9 Drug-Nutrient Transport Interaction during Ontogeny: The Cefepime L-Carnitine 
 Example .................................................................................................................. 71 
9.1 Abstract........................................................................................................... 71 
9.2 Introduction .................................................................................................... 72 
9.3 Materials and Methods ................................................................................... 73 
9.4 Results ............................................................................................................ 80 
9.5 Discussion....................................................................................................... 89 
10 Lipopolysaccharide and Lipoteichoic Acid Differentially Alter Glucose, Fatty Acid 
and Carnitine Transporter  
Expression in MCF12A Cells .................................................................................. 94 
10.1 Abstract........................................................................................................... 94 
10.2 Introduction .................................................................................................... 95 
 viii
10.3 Materials and Methods ................................................................................... 97 
10.4 Results .......................................................................................................... 100 
10.5 Discussion..................................................................................................... 105 
11 Lipopolysaccharide -Induced Inflammation Downregulates Mammary Gland 
Glucose, Fatty Acid, and L-Carnitine Transporter Expression at Different Lactation 
Stages ..................................................................................................................... 110 
11.1 Abstract......................................................................................................... 111 
11.2 Body of Manuscript...................................................................................... 112 
12 General Conclusions and Future Directions .......................................................... 120 
12.1 General Conclusions..................................................................................... 120 
12.2 Future Directions .......................................................................................... 124 
REFERENCES.............................................................................................................. 125 
APPENDIX A: Supplemental Table 1 .......................................................................... 159 
 
 
 
 ix
LIST OF TABLES 
Table 1. Free L-carnitine concentrations in serum after termination (4 h) of saline 
(control) or cefepime (treated) (250 mg/h with a 50 mg loading dose) intravenous 
infusion to Sprague-Dawley rats at day 4 or 10 lactation ......................................... 36 
Table 2. mRNA expression concentrations of L-carnitine transporters (OCTNs, ATB0,+ 
and CT2) in Sprague-Dawley rat whole mammary gland tissue at lactation day 4 
and day 10 ................................................................................................................. 37 
Table 7.1. Summary of mean ± SEM pharmacokinetic parameters for cefepime after 
intravenous (20 mg/kg by intracardiac injection under isoflurane anaesthesia) and 
oral (40 mg/kg by gastric gavage) administration in rat pups (postnatal day 4 and 
day 10) (n=6/time point blood collection) .............................................................. . 49 
Table 7.2. Additional parameters used for the calculation of EIDose and EIConc values for 
postnatal day 4 and day 10 Sprague-Dawley rat pups .............................................. 50 
Table 8.1. Primer sequences for quantitative RT-PCR of rat enzymes and transporters 
involved in L-carnitine homoestasis ......................................................................... 61 
Table 9.1. Primer sequences for quantitative RT-PCR of all the selected targets ........... 76 
Table 9.2. Mean ± SEM fold difference relative to control in mRNA expression level of 
L-carnitine transporters (Octns) in kidney, heart and intestine, Bbh in liver and Cpts 
in heart from rat pups treated with 5 mg cefepime or saline twice daily by 
subcutaneous injection according to different dosing schedules .............................. 81 
Table 9.3. Mean ± SEM scores of cardiac lesions in rat pups treated with saline (Control) 
or 5 mg cefepime (Treated) by twice daily subcutaneous injection according to 
different dosing schedules (n=6)............................................................................... 87 
Table 9.4. Pearson's correlation coefficients between postnatal ages and all parameters 
assessed in rat pups treated with saline (Control) or 5 mg cefepime (Treated) by 
twice daily subcutaneous injection (rat pups were from day 4, day 8, day 11 (n=6 
for each age) and day 20 (n=12)) .............................................................................. 88  
Table 10.1. Primer sequences for quantitative RT-PCR of L-carnitine, glucose, and fatty 
 x
acid transporters in MCF12A cells.......................................................................... 102 
Table 10.2. Mean ± SEM fold difference relative to control in mRNA expression  
 levels of various transporters in MCF12A cells incubated with 1 μg/mL 
lipopolysaccharide (LPS) or Lipotechoic Acid (LTA) for 6 or 12 hours ................ 103 
Table 11.1. Primer sequences for quantitative RT-PCR of transporters in rat  
 lactating mammary gland........................................................................................ 117 
Table 11.2. Fold differences in mRNA expression of LPS treated relative to saline 
administration of glucose, fatty acid and carnitine transporters in Sprague-Dawley 
dams at lactation day 4 and 11 ................................................................................ 118 
Table 11.3. Mean ± SEM mRNA expression levels of glucose, fatty acid and carnitine 
transporters in whole mammary gland tissue from Sprague-Dawley dams treated 
with saline (Control) or 1 mg/kg body weight LPS (Treated) at lactation day 4 and 
day 11 .....................................................................................................................119
 xi
LIST OF FIGURES 
Figure 2.1. The known major pathways exist in the mammary gland by which 
compounds are secreted into the breast milk ...........................................................  10 
Figure 2.2. Schematic representation of L-carnitine homoeostasis ................................ 25 
Figure 1. Western blot analysis of OCTN transporters isolated from reference tissue and 
mammary gland (MG) at lactation day 4 and day 10 combining both control and 
cefepime treated (250 mg/h for 4 h with a 50 mg loading dose) dams..................... 37 
Figure 2. Localization of OCTN1, OCTN2, and OCTN3 proteins in the lactating 
mammary gland of a lactation day 4 control rat by immunohistochemistry ............ 38 
Figure 7.1. Mean ± SEM serum concentration versus time curves of cefepime after 20 
mg/kg IV dose or 40 mg/kg oral dose in Sprague Dawley rat pups (n=6) at postnatal 
day 4 (A) and postnatal day 10 (B) ........................................................................... 48  
Figure 8.1. Mean ± SEM free L-carnitine levels in rat pup serum (A) and heart (B) (n=6) 
at different postnatal ages ......................................................................................... 63 
Figure 8.2. Mean ± SEM organic cation/carnitine transporter (Octn1 – white bar; Octn2 
– light grey bar; Octn3 – dark grey bar) mRNA expression levels in rat pup heart 
(A), kidney (B), and intestine (C) at different postnatal ages ................................... 64 
Figure 8.3. Correlation between kidney Octn2 mRNA expression levels and serum free 
L-carnitine concentrations......................................................................................... 65 
Figure 8.4. Mean ± SEM liver gamma-butyrobetaine hydroxylase (Bbh) mRNA 
expression level (A) and activity (B) in rat pups at different postnatal age groups.. 65 
Figure 8.5. Mean ± SEM mRNA expression level of heart carnitine palmitoyltransferase 
1b (Cpt1b) and carnitine palmitoyltransferase 2 (Cpt2) in rat pups at different 
postnatal age groups... 66 
Figure 8.6. Mean ± SEM heart carnitine palmitoyltransferase 1 (Cpt1) carnitine 
palymitoyltransferase 2 (Cpt2) activity in rat pups at different postnatal  
 age groups ...................... ......................................................................................... 66 
 xii
Figure 8.7. Mean ± SEM heart high energy phosphate substrate concentration in rat 
pups at different postnatal age groups ...................................................................... 67 
Figure 9.1. Mean ± SEM L-carnitine levels in serum (A) and heart (B) from rat pup 
treated with 5 mg cefepime or saline twice a day by subcutaneous injection 
according to different dosing schedules.................................................................... 80 
Figure 9.2. Mean ± SEM activities of various enzymes including liver Bbh (A) and 
heart Cpt1 (B) and Cpt2 (C) in rat pups treated with 5 mg cefepime or saline twice 
daily by subcutaneous injection according to different dosing schedules ............... 83 
Figure 9.3. Heart high energy phosphate substrate profiles in rat pups treated with 5 mg 
cefepime or saline twice daily by subcutaneous injection according to different 
dosing schedules ....................................................................................................... 85 
Figure 9.4. Representative histo-pathological features of the mural ventricular 
myocardium of rat pup heart..................................................................................... 87 
Figure 10.1. Concentration-dependent cell viability of the human immortalized 
mammary epithelial cell line, MCF12A, to LPS and LTA...................................... 104 
Figure 10.2. Mean ± SEM concentrations of ATP, ADP, AMP and oxygen consumption 
rate in MCF12A cells incubated with vehicle, 1 μg/mL LPS or 1 μg/mL LTA for 24 
hours........................................................................................................................ 104 
 
 
 
 xiii
LIST OF ABBREVIATIONS 
 C    Average concentration 
ΔCt   Difference between Ct of target gene and Ct of β-actin  
°C    Degree of Celsius 
µL   Microliter 
µm   Micrometer 
µmole   Micromole 
ABC   ATP-binding cassette 
ADP   Adenosine diphosphate 
Ag2O   Silver (I) oxide 
AMP   Adenosine monophosphate 
ANOVA  Analysis of variance 
ATB0,+   Amino acid transporter B0,+  
ATP   Adenosine triphosphate 
AUC   Area-under-the-plasma-concentration-versus-time curve 
Bbh   γ-Butyrobetaine hydroxylase 
BSA   Bovine serum albumin 
BW   Body weight 
Cl   Clearance 
ClO   Oral clearance 
ClS   Systemic clearance 
Cmilk   Milk concentration 
CN   Cyano 
Cpt   L-Carnitine palmitoyl transferase 
 xiv
Cr   Creatine 
CrP   Creatine phosphate 
Cserum   Serum concentration 
CSS,ave   Average steady state plasma concentrations 
Ct   Cycle threshold value 
Ct2   L-Carnitine transporter 2 
DMT   Divalent metal transporter  
DTNB   5,5’-Dithio-bis (2-nitrobenzoic acid) 
EDTA               Ethylenediamine tetracetic acide 
EGTA   Ethylene glycol tetraacetic acid 
EIconc Exposure index that relates neonatal plasma concentrations to 
maternal plasma concentrations 
EIdose Exposure index that relates neonatal dose as a percent of maternal 
dose 
F   Bioavailability  
FABP Fatty acid binding protein 
FAO Food and Agriculture Organization 
FAS   Ferrous ammonium sulfate 
FAT Fatty acid transport proteins 
FATP   Fatty acid transport protein 
FD   Fold difference 
Finfant   Infant bioavailability 
Fneonate   Neonatal bioavailability 
FPN    Ferroportin 
g   Gram 
 xv
GLM   general linear model 
GLUT   Na+-independent sugar transporter 
h   Hour 
HEPES  4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid sodium salt 
HPLC   High performance liquid chromatography 
HTML   3-hydroxy- N6-trimethyl-lysine 
i.d.   Internal diameter 
IFN   Interferon 
IgG   Immunoglobulin G 
IL   Interleukin 
IP   Intraperitoneal  
IV   Intravenous 
k   Elimination rate constant 
KCl    Potassium chloride 
KH2PO4  Potassium phosphate monobasic 
L   Liter 
LPS   Lipopolysaccharide 
LTA   Lipoteichoic acid 
M/P   Milk to plasma drug concentration 
M/S   Milk to serum drug concentration 
Mat   Maternal 
MCF12A  Human mammary gland epithelia cell line 12A 
MG   Mammary gland 
mg   Milligram 
MgCl2   Magnesium chloride 
 xvi
Min   Minute 
mL   milliter 
mM   Millimolar 
mRNA   Messenger ribonucleic acid 
Na2HPO4  Sodium phosphate dibasic 
NaCl   Sodium chloride 
Neo   Neonate 
nm   nanometer 
NS   No significance  
NTCP   Sodium-taurocholate co-transporting polypeptide  
o.d.   Outside diameter 
OAT   Organic anion transporter 
OATP    Organic anion transporting polypeptide 
OCT   Organic cation transporter 
OCTN   Organic cation/carnitine transporter 
OD   Optical density 
PEPT    Di/tri-peptide transporter 
pH   Potential of hydrogen 
PMSF   Phenylmethanesulphonylfluoride 
P-value  Probability of significance 
PVDF   Polyvinylidene fluoride 
RID   Relative infant dose 
RIPA   Radioimmuno precipitation assay 
RT-PCR  Reverse transcription polymerase chain reaction 
RUF   Relative unit of fluorescence  
 xvii
SCD   Secondary L-carnitine deficiency 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   Standard error of the mean 
SGLT    Sodium dependent secondary active Na+/glucose transporters  
SLC    Solute carrier 
t1/2   Elimination half-life 
TAN   Total adenine nucleotides 
TML   N6-trimethyl-lysine; 
TNF-α   Tumor necrosis factor-α 
UV   Ultraviolet 
V   Voltage 
Vd    Volume of distribution 
Vmilk/τ    Milk consumption rate 
WHO   World Health Organization 
 
 
 
 1
1 Introduction  
Mothers often take medication(s) for acute or chronic conditions while 
breastfeeding. While much attention in this area has focused on identifying the 
amount and mechanism of drug transfer into breast milk and the exposure risk to the 
nursing neonate, less attention has been paid to the potential effect of maternal 
disease and medications on nutrient transport in the mammary gland and the nursing 
neonate. Disease/drug-nutrient transporter interactions at the lactating mammary 
gland can affect the levels of specific nutrients and drugs in the breast milk (1). Such 
interactions can also take place in the nursing neonate when the drug is delivered via 
breast milk thus affecting nutrient availability and disposition in the neonate. Both 
these interactions can alter a neonate’s nutritional status, which, in turn, can change 
the neonate’s developing biochemical and physiological processes. Since the 
mammary gland and neonate experience rapid changes throughout the lactation 
period (2-4), such interactions may have different impacts depending on stage of 
lactation and neonatal development. Few studies have considered this possibility.  
This dissertation work endeavors to advance our understanding of the 
possible interactions between maternal drug use/disease status and nutrient transport 
in the lactating mother-neonate dyad. These interactions are significant when they 
may change the breast milk composition of critical nutrients and nutrient status in the 
developing neonate. For this purpose, cefepime, an antibacterial drug, and L-
carnitine, a conditionally essential nutrient, were used as a proof-of-concept for the 
ability of a drug to interfere with nutrient transport. Both cefepime and L-carnitine 
are substrates of the Organic Cation/Carnitine Transporters (OCTNs), The interaction 
between cefepime and L-carnitine at the transporter level may concomitantly 
increase cefepime but reduce L-carnitine levels in the breast milk and alter L-
carnitine disposition in the developing neonate. Furthermore, the effects of an 
inflammatory stimulus on mammary gland nutrient transporter expression will 
identify the influence of disease on nutrient transport by the lactating mammary 
gland. The drug/disease-nutrient transport interaction will be assessed at different 
stages of lactation/neonatal development to identify the importance of considering 
the timing of the interaction relative to lactation stage and neonatal maturation. 
 2
2 Literature Review 
2.1 The Risk-Benefit Ratio: Breastfeeding vs. Maternal Disease/Medication 
Exclusive breastfeeding up to six months of age and continued breastfeeding 
for older infants are encouraged by the WHO (5). However, maternal medication 
usage to treat diseases during breastfeeding raises significant concerns, which can 
pose a difficult risk-benefit analysis. One major concern is neonatal exposure to the 
medication through breast milk. One must weigh the potential risk of neonatal 
exposure to the medication via breast milk against the benefit of breastfeeding for 
both mother and neonate. However, the risk of neonatal exposure also must be 
weighed against the risk of untreated maternal disease, which also may have negative 
effects on the neonatal growth and development and maternal health.  
Under most circumstances, the benefits to both mother and neonate of 
continued breastfeeding with maternal medication use outweigh the risks (6). Several 
strategies and approaches have been proposed to minimize neonatal exposure and 
risk to medications via breast milk (7). However, these recommendations generally 
fail to consider the possible effects of maternal disease/medication use on breast milk 
nutrient composition and the potential consequences of such effects to the nursing 
neonate. Changes in nutrient availability to the developing neonate may pose a 
significant risk to the current and long-term health of the developing individual 
particularly when altered nutrition occurs during critical developmental stages. The 
potential for such interactions makes the risk-benefit analysis of maternal 
disease/medication use during breastfeeding more complex.  
An appropriate risk-benefit analysis requires the identification of all potential 
risks and benefits to the mother-neonate dyad associated with treatment of maternal 
disease, the therapeutic measures recommended for maternal disease management, 
and the breastfeeding process itself.  The ultimate goal of these risk-benefit 
assessments is to acquire a strategy that minimizes exposure risk and ensures optimal 
nutrient provision to the neonate, and provides the best therapeutic measures to the 
mother (8).  However, these benefit-risk assessments are only achievable when 
sufficient scientific information and experienced clinical knowledge are available to 
the assessors. Currently, most research in this area focus on the drug present in the 
breast milk and the possible exposure risk to the nursing neonate. Unfortunately, the 
information on the risk of maternal diseases/medications on nutrient provision via 
breast milk, as well as neonatal exposure risk when the drug is present in the breast 
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milk at different postnatal ages for different durations of exposure is extremely 
limited. Research that addresses the impacts of diseases or drugs in nursing mother-
neonate dyad on nutrient status during early life will add valuable information to the 
risk-benefit analysis, which can eventually help the health professional as well as the 
breastfeeding mother.    
  
2.2 Breastfeeding: The Trends, Benefits and Problems 
Women are returning to the practice of breastfeeding, a trend motivated 
principally by the multiple and unique advantages of human breast milk (8). Today, 
most healthy women initiate breastfeeding upon birth of their child (9-10), and in 
Saskatchewan, for example, the breastfeeding initiation rate is as high as 86% (11)  
The optimal duration of exclusive breastfeeding suggested by the World Health 
Organization (WHO) is six months based upon evidence gathered worldwide on 
infectious diseases morbidity and mortality (5).    
Breastfeeding has a unique biological and psychological influence on the 
health of both mother and nursing neonate. Breastfeeding provides for the unique 
nutritional needs of the newborn during the transition from the in utero to ex-utero  
life and offers non-nutritional components that assist in adaptation to life outside the 
womb (12-13). These bioactive non-nutritional substances, not provided in infant 
formula, confer protection from bacterial and viral infections, which reduce mortality 
and morbidity in infants associated with respiratory and gastrointestinal diseases, and 
aid in the growth and development of the newborn (14-17). Epidemiological data 
also indicate that breastfed infants have lower rates of obesity into childhood and 
adolescence compared to formula-fed infants (18) and improved cognitive functions 
(13).  
For the nursing mother, breastfeeding promotes the bonding between the 
mother and baby. Breastfeeding is also associated with decreased incidence of cancer 
and osteoporosis (19). It also helps to prevent post-partum hemorrhage (20). 
Breastfeeding mothers have less risk for anemia and long term obesity compared to 
bottle-feeding mothers (21-22). In diabetic mothers, breastfeeding helps reduce 
insulin requirements (23).  
In addition to the health advantages, the economic benefits of breastfeeding 
to both parents and the health system are felt through reductions in direct and indirect 
 4
costs (24). Direct savings can be achieved through breastfeeding since there is little 
or no need for infant formula. The cost for purchasing infant formula can add up to 
$1,200–$1,500 or more for a baby’s first year(25). Direct benefits also arise from 
reductions in physician visits, hospital stays, and other expenditures related to the 
treatment of illness (24, 26). Indirect costs may appear in the form of lost wages due 
to breastfeeding mothers attending a sick child.    
Occassionally, circumstances arise when breastfeeding can pose a risk to the 
neonate.  Presence of drugs in milk has raised significant concerns when mothers 
decide to breastfeed (8).  According to current guidances, infant exposure doses that 
constitute less than 10% of the mother’s medication dose on a body weight basis are 
arbitrarily considered to be safe (27-28).  This guideline is supported by the general 
lack of overt adverse events reported in nursing infants when breastfeeding mothers 
take medications (29). However, long-term adverse outcomes in neonates following 
such exposures are not available. In addition, the neonate’s immature renal function 
and hepatic xenobiotic metabolism capacity does raise some concerns about the 
safety of neonatal exposures to drugs in breast milk (30-31). Compared to the adult, 
neonates have less capacity to eliminate drugs from the body due to the 
underdeveloped elimination pathways. For example, expressions of several members 
in cytochrome P450 family of drug metabolizing enzymes increase during postnatal 
development (32). Thus, drugs delivered to the nursing neonate can accumulate in 
the body and eventually lead to toxic levels and adverse effects.  
Another concern is the ability of drugs to affect nutrient availability and 
disposition in the neonate and nutrient composition of the breast milk. Since early 
life nutrition is critical to the well-being of the neonate, drug induced nutrient 
alterations may result in detrimental consequences either acutely or more subtly by 
predisposing neonates to adult onset chronic disease (33). Moreover, the dynamic 
changes in the mammary gland function during the lactation stage (34) make the 
safety prediction based on maternal dose more difficult(35). During the lactation 
period, the synthesis and secretory functions of the mammary epithelial cells as well 
as the milk content experience rapid changes. Drugs delivered into the mammary 
gland have the ability to cross the mammary gland barrier via the nutrient secretion 
pathways, thereby inhibiting these transport mechanisms (29). The change of the 
mammary gland nutrient transport function with lactation stage can influence the 
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amount of drug excretion into the breast milk and the degree of inhibition of nutrient 
transport. Such phenomena can make risk assessment of drug exposure during 
lactation difficult.  
 
2.3 Breast Milk and Neonatal Nutrition 
The postnatal period is marked by rapid growth and development of the 
neonate. This rapid growth places high demands on the supply of various nutrients 
from the breast milk (12). Immediately after birth, the maternal umbilical supply of 
substrates stops abruptly, and the newborn must adapt to an ex utero supply of 
nutrients, namely the breast milk. The nutrients delivered to the neonate must ensure 
continuous growth and maturation by assuring the provision of adequate Calories, 
appropriate balance in fluid homeostasis, as well as essential macro- and 
micronutrients and other non-nutrient components. Studies have shown that neonatal 
plasma concentrations of various nutrients during the early postnatal period correlate 
with the availability of nutrients from breast milk (36-37). 
 
2.3.1 Breast Milk as a Source of Nutrition to the Nursing Neonate 
Human lactation evolved in attempts to provide adequate and unique 
nourishment to the nursing neonate regardless of circumstance and environment 
(38).The composition of human milk is very complex with thousands of constituents 
that include proteins, carbohydrates, lipids, vitamins, minerals, nonnutrient bioactive 
substances, as well as cells (39). A number of these constituents can be generally 
categorized into macronutrient and micronutrients based on their physical and 
physiologic properties.  
Since “macro” means large, macronutrients are nutrients that are needed in 
large amounts. Macronutrients contained in human milk are lipids, proteins and 
nonprotein nitrogen, and carbohydrates (39). Lipids constitute 3% to 5% of human 
breast milk (40), the second highest constituent of breast milk, with water being the 
principal component. The lipids in the breast milk vitally impact neonatal growth and 
development by providing a dense energy source and essential fatty acids such as 
docosahexaenoic acid (DHA) (41). The majority of milk lipids is derived from 
maternal circulation and storage with a small portion synthesized de novo by the 
mammary gland (41). Therefore, maternal dietary lipid intake can have a profound 
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influence on the milk lipid content. Interestingly, lipid composition changes with 
lactation stage and total fat content increases with duration of lactation (42-43).  
Milk proteins are also important macronutrients of breast milk. Proteins 
account for 0.9% of human milk content (44).  The major proteins include casein, 
various immunoglobulins and a variety of glycoproteins. Milk proteins are mostly 
synthesized in the mammary gland with the minor portion supplied by the maternal 
circulation (45). Milk proteins provide essential amino acids needed for neonatal 
growth and development (46). Immunoglobulins protect the nursing neonate against 
certain pathogens (46). Both the quantity and quality of milk proteins changes with 
the stage and duration of lactation. In general, protein content decreases during the 
course of lactation (46).  The nonprotein nitrogen in breast milk consists of 
compounds including free amino acids, nucleotides, and nucleic acids (47).  Though 
various lipids are the major energy-yielding substrates in breast milk, carbohydrates 
also provide energy for the newborn (39), and are essential for central nervous 
system kidney, brain, muscle (including the heart) function.  
Micronutrients are nutrients needed only in small amounts. These nutrients 
are the “magic wands” that enable the body to produce enzymes, hormones and other 
substances essential for proper growth and development (48). The main 
micronutrients contained in breast milk are vitamins, minerals such as calcium, 
magnesium and phosphorus, and trace minerals including iron, copper, and zinc (39). 
These micronutrients can modify hormones, growth factors and cell signaling 
pathways, with subsequent effects on development during early life (49). Although 
these compounds are required only in small amounts, severe consequences ensue in 
their absence. Micronutrient imbalance or deficiency during gestation or postnatal 
life can have detrimental effects on the individual (49). Often the effects of 
micronutrient deficiencies go unnoticed despite their insidious effects. As a result, 
micronutrient deficiencies have been labeled as the “hidden hunger” (50-51).   
Conditionally essential nutrients are nutrients that can be synthesized in a 
healthy individual in sufficient quantities to meet physiological requirements.  
However, during certain stages of the life cycle, such as newborns or advanced age, 
or under certain conditions (e.g. stress, disease, intoxication, etc), such nutrients 
become essential dietary components because their requirements may exceed an 
individual's capacity to synthesize them (52). Conditionally essential nutrients with 
bioactive functions in human milk include nucleotides, L-carnitine and choline. For 
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example, L-carnitine can be synthesized in the human liver, but insufficient amounts 
may be produced in neonates, adolescents and adults under certain physiological 
conditions such as recurrent pulmonary infections (53-55). Thus, exogenous sources 
of L-carnitine become necessary to maintain normal L-carnitine levels in the body.  
Compared to infant formulas, human breast milk is unique and remarkably 
dynamic. Generally, the quantitative levels of nutrients in infant formula are kept 
within a homogenous range. However, the volume and composition of breast milk 
changes depending on the stage of lactation. For example, the fat and protein levels 
in human breast milk change considerably in the first several weeks of lactation (42-
43). The dynamic change in breast milk has been associated with the changing 
demands of the developing neonate (56). Another unique aspect of human breast 
milk is its interindividual variability. Breast milk composition varies widely among 
women, particularly women from different ethnic and nutritional backgrounds. Most 
recommendations for infant formulations are based on data obtained from mature 
human milk of mothers with Caucasian ethnicity and typically western diets (57). 
These recommendations ignore the factor that both genetic and maternal dietary 
choice can affect breast milk composition (58). Infant formula manufactured 
according to these recommendations may not be the optimal nutrient source for the 
developing infants. Consequently, it may lead to unfavorable development in the 
nursing infants which may eventually lead to health problems in later life (59). 
Furthermore, various environmental and maternal conditions can alter breast milk 
composition, which can result in significant intraindividual variability compared to 
infant formula (60-61). 
 
2.3.2 Early Life Nutritional Programming 
Nutrients during critical windows of development in fetal, neonatal, infant 
and child development have important metabolic programming effects that may 
influence both the present and future health of the developing individual. Nutrition-
induced alterations in biochemical and physiological processes during these 
vulnerable periods of susceptibility cause permanent adaptations in later life  (59). A 
mild nutritional alteration that does not substantially affect development during early 
life stages may prepare the developing individual’s physiology to improve survival in 
the predicted adult environment through appropriate phenotypic modifications (62). 
Alternatively, such adaptations may pose a serious risk for chronic disease when this 
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“predicted” adult environment is altered unexpectedly (63). Predisposition to the 
metabolic syndrome, which progresses to cardiovascular disease and diabetes, has 
been associated with inappropriate fetal or neonatal nutrition (64).   
The association between prenatal nutrition and chronic disease development 
in adulthood has been extensively investigated (65). The “fetal origins hypothesis” 
proposed by Barker et al. well describes the association between adverse intrauterine 
conditions and diseases such as hypertension and insulin resistance in the adulthood 
(66-67).  However, early postnatal life also represents a critical developmental stage 
during which altered nutrition can ‘program’ an individual’s future health. 
Epidemiological studies support the importance of early postnatal nutrition on the 
susceptibility to chronic disease including hypertension, obesity and type 2 diabetes 
(19, 68-69). Breast milk remains the preferred source of optimal nutrition in 
postnatal life and many advocate breast milk as superior to infant formula. For 
example, a reduced risk for high blood pressure during adult life is associated with 
the low sodium content and high levels of long chain polyunsaturated fatty acids in 
breast milk compared to infant formula (70-71). 
Most studies examining the influence of postnatal nutrition largely focus on 
the consequence of maternal dietary manipulations in macronutrient intakes such as 
fat and protein. For example, rat pups exposed to maternal undernutrition (protein-
free diet) during the sucking period resulted in permanent changes in insulin and 
glucocorticoid secretion, which may eventually predispose these pups to chronic 
disease in adult life due to impairment in the inflammatory response (63).  However, 
few studies have investigated the consequence of micronutrient alterations and its 
long term consequences (49). Vitamins and minerals play crucial roles in metabolism 
and growth. Sufficient amounts are critical for the healthy development of the 
embryo, fetus and neonate (49). Certain micronutrient deficiencies such as zinc 
during pregnancy can result in fetal malformation and other defects (72). The effects 
of micronutrient alterations during early developmental stages become more 
problematic when interactions occur between these micronutrients and maternal 
drug/disease (73). Certain diseases and therapeutic drug usage during pregnancy or 
lactation may alter micronutrient status in the maternal circulation and their transfer 
across the placental or mammary epithelial barriers, which can lead to changes in 
fetal or neonatal micronutrient status. Such changes may have long term health 
effects. 
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2.3.3 Transport of Milk Constituents in the Mammary Gland 
Optimal infant nutrition is crucial for neonatal growth and development. 
Early accelerated growth during critical developmental windows may induce obesity 
and reduce life span in rats (74).  Malnutrition, including both excess or 
undernutrition, during neonatal development may have implications on later health. 
This suggests the various nutrient levels in the breast milk need to match neonatal 
requirements at each stage of development. A variety of mechanisms in the lactating 
mammary gland ensure appropriate nutrient levels during each stage of lactation.  
Five major pathways exist in the mammary gland by which compounds are 
secreted into the breast milk (Figure 2.1). These include: 1) Exocytosis; 2) 
Transmembrane transporters; 3) Milk fat globule secretion; 4) Paracellular route, and 
5) Transcytosis (75-76). During lactation, the paracellular pathway in the mammary 
gland is limited due to the formation of tight junctions, and transcellular transport 
pathways become the major routes of milk constituent secretion (77-78). Aqueous 
solutes including the major milk proteins are transported into breast milk through the 
exocytotic routes (79-80). Lipids and lipid-associated proteins are secreted via milk 
fat globule secretion, which is unique to the mammary epithelial cells (81). Most of 
the macromolecular substances such as immunoglobulins are transferred into milk 
via transcytosis (82). In addition, various ions and small molecules such as glucose 
and amino acids can be transferred from maternal circulation to the milk via specific 
transporters at the cellular, Golgi or secretory membranes (75-76). 
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Figure 2.1. The known major pathways exist in the mammary gland by which 
compounds are secreted into the breast milk. I Exocytosis; II Transmembrane 
transporters; III Milk fat globule secretion; IV Paracellular route, and V Transcytosis. 
(Adapted from McManaman and Neville (75)). 
 
2.3.3.1 Nutrient Transporters in the Mammary Gland 
Nutrient transporters play crucial roles in movement of nutrients across 
polarized epithelial barriers, and cellular availability and disposition of nutrients in 
the body. In the mammary gland, nutrient transporters are responsible for transfer 
into and the milk composition of a variety of nutrients. As well, the same nutrient 
transporters are responsible for nutrient absorption, distribution and elimination in 
the nursing neonate. 
To date, numerous transporters have been identified in the lactating mammary 
gland (76, 83-84). Various members of the Solute Carrier (SLC) and the ATP-
Binding Cassette (ABC) transporter families are expressed during lactation. Such 
transporters may play important roles in maintenance of mammary gland function as 
well as milk secretion. With the onset of lactation, mammary gland epithelial cells 
have a high demand for precursor molecules such as glucose and fatty acids to 
facilitate production of high amounts of lactose and lactose-derived oligosaccharides 
as well as triglycerides in the breast milk (84-85). Mammals express two different 
Lumen 
Blood Supply 
I II III IV V 
Basement Membrane 
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types of glucose transporters: facilitative glucose transporters (GLUTs) and sodium 
dependent secondary active Na+/glucose transporters (SGLTs) (75). Members from 
both GLUT and SGLT families are expressed in lactating mammary epithelial cells 
(84-85). Fatty acid uptake pathways include fatty acid binding proteins (FABPs) 
located in the plasma membrane, fatty acid translocators and fatty acid transport 
proteins (FAT) (86). Therefore, glucose and fatty acid transporters in the mammary 
gland play critical roles in milk production and mammary epithelial cell function 
(87). Interestingly, the transfer of glucose and galactose into mammary epithelial 
cells is the rate-limiting step in the milk lactose biosynthesis pathway (88).  
In addition, other macronutrients needed for milk production, such as amino 
acids and peptides, are delivered to the mammary gland through various amino acid 
transporters and the oligopeptide (PEPT) transporters, respectively (89). An 
increasing amount of information is becoming available on micronutrient transport in 
the mammary gland (90). Essential metals such as zinc, iron, and copper are actively 
transported into milk via specific transporter systems (91-92). Other vitamins, 
minerals and hormones also possess specific transporter systems for their transfer 
into milk (93-94).  
Nutrient transporter expression in the lactating mammary gland does not 
seem to remain static through lactation, but rather expression levels change with 
lactation stage (95). For example, the mRNA expression level of the amino acid 
transporter B0,+ (ATB0,+) decreases from early to peak lactation stages in sows (96). 
GLUT1 expression increased until the mid-lactation in mice (97-98). The expression 
levels of the two iron transporters, divalent metal transporter 1 (DMT1) and 
ferroportin1 (FPN1), in rat mammary epithelial cells decreased throughout the course 
of lactation (99) and this decrease correlated with the normal decline in milk iron 
during lactation (100). Also, the normal decline in milk copper concentration is 
attributed to the decrease in expression of the copper specific transporter, Atp7B, in 
the rat (101). Such studies suggest that changes in transporter expression may reflect 
alterations in milk composition of such nutrients through lactation.  
Transporters responsible for nutrient transfer across the mammary epithelial 
barrier also can transfer xenobiotics (drugs, toxicants) into breast milk. A variety of 
drugs are secreted into breast milk via these nutrient transporters. Cationic drugs 
have a tendency to accumulate in breast milk via the organic cation transporters, 
which occasionally leads to toxicity in the nursing neonate (102-103). In vitro studies 
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suggest certain cationic drugs can inhibit nutrient transport across the mammary 
epithelium. Both verapamil and desipramine caused complete inhibition of L-
carnitine uptake in a normal mammary gland epithelial cell line (MCF12A) via 
inhibition of hOCTN2 and ATB0,+, and decreased glycine uptake through inhibition 
of ATB0,+ (104). Such cationic drug-nutrient transporter interactions demonstrated in 
vitro may have the potential to change breast milk nutrient composition in vivo. 
Furthermore, given the changing expression levels of nutrient transporters with stage 
of lactation, the magnitude and significance of such interactions can vary depending 
on lactation stage. When the affected nutrients are obligatory for neonatal 
development, the drug-nutrient transporter interaction may pose a detrimental risk to 
the nursing neonate.  
 
2.4 Effects of Drug/Disease on Mammary Gland Function during Lactation 
The mammary gland undergoes significant physiological and biochemical 
adaptations during pregnancy and lactation to ensure neonatal survival. Any 
significant disruption of mammary gland function during lactation can cause 
alterations in both milk volume and composition, which can be unfavorable to 
neonatal development. Mothers with illness or disease often use drugs for treatment 
of their condition during breastfeeding. Both disease and medications taken by the 
breastfeeding mother have the potential to impact mammary gland function and, 
therefore, cause changes in breast milk.  
 
2.4.1 Mammary Gland Physiology and Biochemical Activities during 
Lactation 
The Class “Mammalia” was named for species that use a mammary gland to 
feed their offspring (105). The mammary gland provides a vital survival and 
evolutionary advantage to mammalian species (106-107).  The mammary gland 
undergoes development predominantly after birth unlike other organs of the 
mammalian system. The most pronounced morphogenesis of the mammary gland 
occurs during pregnancy and lactation. During pregnancy, a variety of changes 
including extensive growth of duct and alveoli, proliferation of mammary glandular 
tissue, mammary epithelial cell differentiation, and vascularization occur preparing 
the mammary gland for its specialized secretory functions in lactation (17, 108). The 
functional development of this organ is fundamentally dependent upon hormones and 
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growth factors such as estrogen, progesterone, and prolactin (109).   
The basic milk production units in the mammary gland are the alveoli, which 
are mainly constructed of epithelial cells. These epithelial cells contribute 
signficantly to the production and transport of milk constituents into the alveolar 
lumen (110). Each alveolus unit is surrounded by a network of myoepithelial cells, 
contractile cells that force the milk from the alveoli into the ductile system. Other 
types of cells found in the mammary gland include fibroblasts, adipocytes and 
immune cells  (111). With the onset of milk secretion (lactogenesis), the highly 
differentiated mammary epithelial cells undergo a further rapid series of changes. 
The tight junctions between the epithelial cells close in the first week post-partum to 
form a highly impermeable barrier between milk and interstitial fluid (78). These 
tight junctions polarize the mammary epithelium into distinct apical and basolateral 
cell surfaces and prohibit the paracellular movement of the major milk macro- and 
micronutrients between the extracellular spaces to the lumen of the mammary alveoli 
(78).  In addition, the synthetic activities of the mammary alveolar cells increase with 
advancing lactation leading to changes in milk volume and composition (3).  
During lactation, mammary epithelial metabolic activities also increase 
dramatically to meet the requirement for milk synthesis and secretion in the 
mammary gland. For example, high proportions of substrates including glucose and 
fatty acids are circulated into the mammary gland to synthesize the major milk 
components, lactose and lipids(112). In lactating rats, mammary epithelial cells 
consume 80-90% of the glucose obtained from the maternal circulation (113). 
Glucose contributes significantly to the energy requirement for milk production in 
lactating mammary epithelial cells and is the primary precursor for lactose synthesis 
(113). Since mammary epithelial cells cannot synthesize glucose de novo (114), the 
transport of glucose from the maternal circulation into the mammary epithelium 
becomes crucial and this transport is mediated principally by the GLUTs.  
Although glucose contributes significantly to the energy requirement for milk 
production in the mammary epithelial cells, fatty acids provide the remaining energy 
source. Fatty acids are also precursors for triglycerides in the breast milk (115). The 
availability of fatty acids to the mammary gland depends on both de novo 
biosynthesis in the mammary epithelial cell and uptake from maternal circulation  
(116). Fatty acid uptake pathways include fatty acid binding proteins located in the 
plasma membrane, fatty acid translocators and fatty acid transport proteins (86). 
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Failure to make these biochemical adjustments in the mammary gland to meet the 
requirements of mammary gland function may lead to unfavorable consequences 
with reductions in both mammary gland synthetic and secretion activities.  
 
2.4.2 Effects of Maternal Medication on Mammary Gland Function 
Neonates have a narrow tolerance range for changes in nutrient supply from 
the breast milk (56). Maternal medications that result in inadequate or excessive 
supply of nutrients in the breast milk may lead to short- or long-term disadvantages 
in neonatal development. Therefore, information on how maternal medications may 
affect breast milk quantity and quality is critical.  
In theory, xenobiotics have the potential of disrupting the development or 
maturation of the mammary secretory epithelium (56, 117).  Xenobiotics may affect 
milk volume and composition through direct action on the mammary gland tissues 
(118-119), or indirectly through systemic changes in the lactating mother (e.g. 
alteration of the hormonal milieu necessary for milk secretion; alteration of 
availability of substrates of synthesis/secretion of milk constituents) (117). 
  
2.4.2.1 Direct Effects of Maternal Medication on the Lactating Mammary 
Gland  
Much evidence is available regarding the effects of drugs on milk quantity 
and quality through direct effects on mammary gland development (120-122). The 
mammary gland has a complicated functional architecture to ensure its critical 
secretion functions. Any interruption in the formation of this architecture may result 
in unfavorable consequences in milk secretion. Steroids and other growth stimulating 
drugs are known to alter mammary gland growth and development (118).  
The tight junction formed during lactation ensures the transepithelial gradient 
necessary for milk secretion. Drugs such as 5-hydroxytryptophan have the potential 
to compromise tight junction integrity, which leads to marked changes in breast milk 
composition (121). Other drugs may directly affect mammary gland biosynthetic 
functions. For instance, the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, 
inhibits milk protein synthesis, including casein and α-lactalbumin, in a mammary 
gland cell culture system (120, 122). 
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2.4.2.2 Indirect Effects of Maternal Medication on Milk Production 
Maternal medications can indirectly affect mammary gland function via 
interference with the hormones of lactation or with the “nutrikinetic” processes 
involving biosynthesis and transport of milk substrates.  
 
2.4.2.2.1 Effects of Maternal Drugs on Hormonal Milieu Supporting Lactation 
A small group of medications have an adverse effect on milk production by 
interference with the two major hormones that support lactation: prolactin and 
oxytocin. Drugs with androgenic or estrogenic properties and vitamin B6 can reduce 
prolactin levels and thereby decrease milk production (7). Alcohol is a potent 
inhibitor of oxytocin release, which consequently results in decreased milk 
production (123). Since infant weight gain and development are directly associated 
with milk production, the potential problems associated with reduced milk supply are 
of importance (14). Drugs can also change the composition of milk.  In addition to its 
impact on milk production, alcohol can decrease lactose and increase the lipid 
content of breast milk (14). Alterations in prolactin levels also impact milk zinc 
secretion via affects on the zinc transporters (90).   
 
2.4.2.2.2 Drug-Nutrikinetic Interactions Affecting Milk Secretion 
Alternatively, drugs can interfere with maternal nutrient availability and other 
“nutrikinetic” processes in the mother thereby reducing the availability of such 
nutrients for the breast milk (124-125). Drugs can: 1) Directly inhibit the 
biosynthesis of specific nutrients. For example, mildronate treatment decreased L-
carnitine levels in rat milk by inhibition of gamma-butyrobetaine hydroxylase (γ-
BBH), the enzyme catalyzing the last step of L-carnitine biosynthesis (125). 2) 
Inhibit gastrointestional nutrient absorption. For example, cholestyramine, bile acid 
sequestrant used to treat hypercholesterolemia reduced the absorption of the fat-
soluble vitamins, A, D, E and K, resulting in a deficiency of these vitamins in 
pregnant mothers and their fetuses (126-127).  3) Interfere with nutrient metabolism 
in the maternal body. Vitamin B6 levels are lower in the breast milk from mothers 
who take oral contraceptive agents compared to nonusers (128). Oral contraceptive 
agents interfere with vitamin B6 metabolism in the body, thereby reducing maternal 
levels (129) and levels in the breast milk. 4) Increase nutrient elimination. For 
example, excessive aspirin doses can cause increased urinary folate excretion 
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following displacement from plasma protein binding sites(130). The interaction 
between aspirin and folate may eventually lead to maternal folate deficiency and, 
thus, decreased folate concentration in the milk (131). 5) Compete with nutrients for 
the transporters in the maternal body to cause nutrient excess or deficiency in the 
mother depending on transporter function. Limited information is available for the 
potential risk of drug-nutrient transporter interactions on breast milk nutrient levels. 
However, drug-nutrient interactions at the transporter level have been identified in 
vitro (104). As the sole source of nutrition for the neonate, alteration in the breast 
milk composition of various nutrients through indirect or direct drug effects may 
have a critical impact on neonatal health and development (132).  
 
2.4.3 Effects of Maternal Disease on Mammary Gland Function 
Maternal medication use occurs when a need exists for the treatment of 
maternal illness or disease. Generally, mothers with chronic disease are encouraged 
to breastfeed (14). However, some maternal diseases are contraindicated for 
breastfeeding or can be associated with long-term adverse consequences for the 
nursing neonate (14). Epidemiologic studies indicate an association between 
maternal diabetes and adult obesity and glucose intolerance in the breastfed offspring 
(133). Breastfed neonates from mothers with asthma have a higher risk for asthma 
due to the presence of immunologically active substances in the breast milk (134). 
Moreover, literature reported several cases of vitamin B12 deficiency and other 
related symptoms in breastfed infants of mothers who had low vitamin B12 levels due 
to latent pernicious anaemia secondary to hypothyroidism (135-136).  
 
2.4.3.1 Inflammatory Conditions of the Mammary Gland and Breast Milk  
Mastitis, an inflammatory response in mammary tissue often caused by 
bacterial infections, is a common condition observed during the first 6 months of 
breastfeeding (137). Incidence rates in breastfeeding mothers vary 2 to 33% in the 
United States (138). Mothers with mastitis are usually encouraged to continue 
breastfeeding; however, breastfeeding-associated inflammatory breast diseases 
contribute most to an early cessation in breastfeeding (139). The most common 
infective agents responsible for mastitis are Escherichia coli (gram-negative) and 
Staphylococcus aureus (gram positive). Infection induced by E. coli is usually acute, 
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which usually resolves within a few days (140). However, mastitis caused by S. 
aureus often results in a chronic low-grade infection in the mothers (141).  
Mastitis disrupts mammary gland function, which can lead to changes in both 
the quantity and quality of breast milk. Inflammation of the mammary gland can 
result in physical damage to the mammary epithelium that decreases its synthetic and 
secretory capacity (142) and enhances its permeability (78, 143). Acute mastitis can 
also cause an opening of tight junctions (78, 143), which would lead to enhanced 
permeability of mammary epithelium. Leaky tight junctions are implicated in the 
lower lactose and a higher sodium levels in mastitic breast milk (144).Mastitis also 
leads to an increase in milk proteins, such as albumin and immunoglobulins, and 
decreases in caseins (142). Inflammation and the offending pathogens can alter the 
metabolic activity of mammary epithelial cells. This could result in reductions in α-
lactalbumin and β-lactoglobulin often observed during mastitis (142) and possibly 
other breast milk constituents. Moreover, these mastitic pathogens can produce 
enzymes that have the capacity to decompose milk constituents. For instance, 
proteinases produced by the mastitic pathogens can degrade milk casein (142). 
Consequently, through physical damage and alterations in metabolic activity of the 
mammary epithelium, inflammatory disease of the mammary gland can produce 
significant changes in breast milk composition and volume.  
 
2.4.3.2 Effects of Inflammation on Transporter Function  
Inflammatory stimuli can induce immunological processes in the mammary 
gland. This is a highly studied area of research. However, the ability of inflammatory 
states to alter nutrient transport in the mammary epithelium has received limited 
attention. In vitro studies have identified the ability of inflammatory cytokines to 
alter transporter expression in cell culture (145-146). In an intestinal cell culture 
system, interferon-γ (IFN- γ) increased di/tri-peptide transporter (hPEPT1) 
expression and dipeptide transport (145). In primary hepatocytes, the 
proinflammatory cytokines TNF-alpha and IL-6 decreased sodium-taurocholate co-
transporting polypeptide (NTCP) and organic anion transporting polypeptide (OATP) 
1B1 protein expression and transport activities (146). Numerous studies have also 
identified inflammation-mediated changes in transporter expression in vivo. For 
example, intestinal fructose transporter GLUT5 expression and activity decreased 
during intestinal inflammation across various species (147). LPS 
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(Lipopolysaccharide, a gram-negative bacterial cell wall component) challenged 
mice demonstrated marked downregulation of renal tubular glucose transporters 
SGLT2, SGLT3 and GLUT2 with concomitant decreases in plasma glucose 
concentrations (148). Moreover, the effects of inflammation on various drug 
transporters and the pharmacokinetic consequences of altered drug transporter 
expression have been extensively studied (149). Clearly, changes in nutrient 
transporter expression with inflammation can alter nutrient absorption, distribution 
and elimination, which, in the lactating mother, may affect nutrient availability to the 
mammary gland. Although most of the data is obtained from tissue or cell lines other 
than mammary gland, such data suggest that inflammatory stimuli may alter 
transporter expression and activity in the lactating mammary epithelium and 
influence the composition of breast milk.  
 
2.5 Risk of Drug Exposure via the Breast Milk 
Any medication taken by the nursing mother has the potential to cross the 
mammary epithelial barrier into milk and be passed on to the nursing neonate (150-
152). For instance, all psychotropic medications taken by nursing mothers have been 
detected in their milk and measurable quantities have been identified in their nursing 
neonates (153). However, many medications are not found at detectable levels in the 
breast milk (7) and most medications taken by breastfeeding women do not cause 
overt adverse events in the nursing neonate (29). Nevertheless, some drugs 
accumulate to significant levels in breast milk (154). Even low level exposures cause 
some concern as neonates can be more susceptible to the same substances compared 
to the adult (155). Furthermore, immature elimination mechanisms in the neonate 
can result in significant drug accumulation even following low exposures via the 
breast milk (30-31, 155). Thus, drugs present in breast milk at low levels may still 
pose a significant exposure risk to nursing neonates (30-31).   
 
2.5.1 Relative Infant Dose and Infant Exposure Index  
The major factors that determine neonatal exposure to drugs via the breast 
milk are the amount of drug present in the breast milk and the capacity of the neonate 
to eliminate the drug (as measured by systemic clearance) (8). A measure of drug 
distribution into breast milk is the milk-to-plasma drug concentration ratio (M/P ratio) 
(156). The M/P ratio has been widely used as the index for neonatal drug exposure 
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via the breast milk (157). However, as an exposure index, it offers little information 
regarding the actual exposure of the neonate. Currently, the relative infant dose is the 
most commonly used exposure index for assessing drug safety during breastfeeding. 
RID is the percentage of absolute infant dose relative to the maternal dose corrected 
for body weight (Equation 2.1). The absolute infant dose is calculated from the 
average maternal plasma drug concentration (Cave,maternal,plasma), the M/P ratio and the 
milk consumption rate (Vmilk/τ). Drugs with RID less than 10% of the maternal dose 
are generally considered as safe(27).   
 
 
RID = Absolute Infant Dose (mg/kg/day)
Maternal Dose (mg/kg/day)
× 100% 
= 
Fmat × CSS,mat × M P( )× Vmilk τ( )infant
CSS,mat × ClS,mat
= 
Fmat × M P( )× Vmilk τ( )infant
ClS,mat
 (Equation 2.1) 
The RID has limitations as an exposure index. The RID fails to describe the 
systemic exposure of the nursing neonate to the drug, as neonatal pharmacokinetic 
processes including oral absorption and clearance must also be considered. A better 
measure of exposure risk is use of an index that considers both the bioavailable dose 
received by the nursing neonate and the ability of the neonate to eliminate that dose, 
i.e. the EIconc. The EIconc is an exposure index that relates neonatal plasma 
concentrations to maternal plasma concentrations. This exposure index assumes no 
qualitative differences in the plasma concentration versus response relationship 
between the neonate and the mother. Hence, equivalent concentrations at 
pharmacological levels suggest the neonate also experiences a similar 
pharmacological response (8). The EIconc considers the ability of a neonate to 
eliminate the exposure dose. 
 
EIConc  = 
Cserum
infant
Cserum
maternal  = 
Finfant
Clsystemic
infant
M
P
⎛
⎝⎜
⎞
⎠⎟
Vmilk
τ
⎛
⎝⎜
⎞
⎠⎟    (Equation 2.2) 
Assessment of neonatal exposure risk is a difficult task due to changes in 
mammary gland function and the composition of breast milk during lactation period 
(35, 158)  as well as the changes in the neonatal pharmacokinetics. The actual dose 
present in the breast milk can change with stage of lactation, although this factor 
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usually is not considered in assessments of M/P ratios. For example, fat and protein, 
two major components of breast milk that can influence milk levels of certain drugs, 
change with stage of lactation. Indeed, higher levels of several drugs including 
tricyclic antidepressants have been found in the hind milk (later milk) compared to 
the fore milk (initial milk) due to the higher level of fat content in the hind milk 
(159).  In addition, transporters expressed in the lactating mammary epithelium 
experience change in both expression and activity with stage of lactation (97-98), 
which can lead to different drug concentrations in the breast milk. Changes in milk 
drug concentrations alter the M/S ratio and thereby change the exposure dose to the 
nursing neonate (158, 160). Therefore, lactation stage should be an important 
consideration in the risk assessment of drug exposure via breast milk.  
Additionally, neonatal development is marked by dramatic changes in body 
composition, organ function and underlying physiological and biochemical processes 
that are important determinants of drug pharmacokinetics (158, 160). These changes 
have the potential to alter the extent of drug absorption (Fneonate) and/or eliminate 
(Clinfant,systemic) drugs from their body, which can affect the exposure risk. Thus, 
postnatal ages should also be considered when drug exposure risk is assessed. Risk 
assessment is also further complicated by the lack of data on long-term adverse 
outcomes in neonates breastfed by mothers using medications (29).   
 
2.5.2 Mechanisms of Drug Transport into Milk  
The extent of drug transfer into breast milk depends on various factors 
including the physiochemical and pharmacokinetic characteristics of the drug, 
mechanism of its transport across the mammary epithelium, and the volume and 
composition of breast milk (161). Most drugs cross the blood-mammary-barrier via 
passive transport processes. However, some drugs cross this barrier via carrier-
mediated transport processes (154). Depending upon their localization in the 
polarized epithelium (i.e. apical or basolateral expression) and their primary function 
(i.e. uptake vs. efflux), transporters (see section 2.3.3.1) may either accumulate drugs 
into breast milk or serve a protective role by preventing their access to the breast 
milk. In vivo studies have identified a role for transporters in the accumulation of 
several organic cations like cimetidine and ranitidine (29). Jonker et al. provided 
definitive evidence for the role of transporters as a critical determinant of the extent 
of drug accumulation into breast milk (162). In this study the authors demonstrated 
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the role of Breast Cancer Resistance Protein (BCRP, ABCG2) in the active secretion 
of the drugs, cimetidine and topotecan, as well as the dietary carcinogen PhIP, into 
milk. However, for many of the transporters known to be expressed in the lactating 
mammary gland (76, 83), their role in drug and nutrient transport requires 
elucidation. As to the other mechanisms of solute transport in the mammary gland 
(see section 2.3.3), these mechanisms play little to no role in drug transfer into the 
breast milk.  
 
2.5.3 Neonatal Pharmacokinetics  
The magnitude of the risk posed to the neonate following exposure to drug 
via the breast milk depends on the amount of drug in the milk and the 
pharmacokinetic and pharmacodynamic properties of the drug in the neonate (156, 
161). Our understanding of qualitative (pharmacodynamic) differences in response to 
drugs during postnatal development is quite limited. In the absence of age-dependent 
differences in pharmacodynamics, exposure risk often correlates with drug 
concentration in the blood and total exposure is usually measured by the metrics, 
area-under-the-plasma-concentration-versus-time curve (AUC) or average steady 
state plasma concentrations (CSS,ave). These exposure metrics depend upon the size of 
the bioavailable dose and the efficiency of the elimination mechanisms, which is 
given as systemic clearance (ClS) (Equation 2.3). 
 
 
AUC0
∞  = 
F × Dose
ClS
     or     CSS,ave =
F × Dose τ
ClS
  (Equation 2.3) 
The physiological and biochemical changes that occur during postnatal 
maturation results in dramatic developmental changes in drug pharmacokinetics. The 
most critical determinant of exposure risk is the extent of maturation of the drug 
elimination mechanisms (i.e. ClS). Most hepatic and renal elimination mechanisms, 
the principal pathways involved in drug elimination, undergo tremendous 
enhancements in function and efficiency with development (30-31). Consequently, 
the stage of maturation of these mechanisms in the nursing neonate will determine 
their capacity to eliminate an exposure dose. With limited maturation, even small 
exposure doses can lead to significant drug accumulation in the neonate to levels that 
are potentially toxic. 
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Since drug elimination mechanisms undergo constant maturation in the 
postnatal period, the timing of the exposure relative to the age of the neonate must 
factor into any consideration of exposure risk. For a given dose or amount of drug 
present in the breast milk, risk of adverse effects may be higher in the newborn than 
an older neonate because of the newborn’s reduced capacity to eliminate the drug. 
Hence, neonatal pharmacokinetic processes can be a critical determinant of exposure 
risk. 
 
2.5.4 Ontogeny of Nutrient Transporters  
The ontogeny of nutrient transporters in neonates reflects their developmental 
need for nutrients required for growth and metabolism (163). Many nutrient 
transporters are expressed prenatally, and the ontogenic changes that occur with 
development include changes in turnover number, expression density, affinity 
constant, and/or expression of different isoforms in various organs (163). During 
breastfeeding, fatty acids provide the primary source of energy to the nursing neonate. 
Various transporters involved in the usage of fatty acid undergo change during the 
early postnatal period to guarantee the successful fuel switch from glucose to fatty 
acid. For example, the renal re-absorption of L-carnitine, an obligatory factor for 
fatty acid β-oxidation, is enhanced during the postnatal period (164). Cardiac fatty 
acid transporter expression increases significantly following parturition (37). 
Glucose transporter expression profiles change in various organs to meet the various 
glucose substrate demands of these organs (37, 165-166). In addition to the 
transporters responsible for energy substrate uptake and utilization, other nutrient 
transporters undergo ontogenic changes, although our understanding of such changes 
is quite limited.  
Though developmental changes in nutrient transporters are mostly genetically 
programmed (167), the development of these transporters can still be reprogrammed 
by interactions with dietary factors (163). This suggests alterations in the breast milk 
composition of nutrients during early development may impact nutrient transporter 
ontogeny in the nursing neonate. For example, GLUT5 expression levels, which 
mediates fructose uptake from the gastrointestinal tract, increases during weaning 
under normal conditions (168). However, introduction of a high-fructose diet in early 
life further enhances its expression in the intestinal epithelium (168). Also, dietary fat 
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content has the capacity to affect intestinal membrane lipid composition and fluidity 
and thus affect activity of Na+-dependent D-glucose transport (169).  
These nutrient transporters also play an important role in drug 
pharmacokinetics. Numerous commonly used drugs (such as antibiotics, antivirals, 
and non-steroidal anti-inflammatory agents) and physiologically important 
endogenous compounds (i.e. folate, choline, L-carnitine) are substrates of the same 
transporters. The ontogenic development of these transporters during postnatal life 
can be very important from both an endogenous function and pharmacokinetic point 
of view. For example, P-glycoprotein, an efflux transporter for digoxin, steadily 
increases in expression in kidney during the nursing period. These ontogenic changes 
are highly correlated with the enhancements in digoxin renal clearance with postnatal 
development (170).  
 
2.5.5 Drug-Nutrient Interactions in the Nursing Neonate 
All these drugs excreted into breast milk will be passed on to the nursing 
neonate. The majority of the available literature in the area of drug nutrient 
interactions in the infant population focus on the effect of food on the 
pharmacokinetic processes of the medications in the infancy and childhood (171). 
Little information is there regarding the effects of these drugs on the nutrients levels 
in the neonates. Drugs present in the breast milk can induce changes in nutrient 
supply to the nursing neonates by changing the taste of milk which can suppress the 
appetite, cause gastric irritation, and change neonatal GI functions (172). They can 
also interact with all the above nutrikinetic processes in the nursing neonates and 
therefore alter the nutrient level in the breastfed infants.  Normally, drug induced 
nutritional deficiencies are slow to develop (173). However, insufficient supply of 
certain essential nutrients during critical developmental stages can lead to nutritional 
deficiency in the developing child.  For example, exposure to the antiepileptic drug 
valproic acid (VPA) during adolescence can lead to folate deficiency though the 
mechanism underlying it is unknown yet (172). 
 
2.5.6 Drug-Nutrient Transport Interactions: Cefepime-L-Carnitine Transport 
Interaction as Proof-of-Concept 
Whether xenobiotics may influence breast milk composition by interference 
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with nutrient transport processes is not clearly understood. In addition to the 
interaction at the mammary gland, the presence of a xenobiotic in the breast milk 
may result in drug-nutrient transport interactions in the neonate. As proof-of-concept, 
my research project proposes the use of L-carnitine, a conditionally essential nutrient, 
and cefepime, a moderate L-carnitine transporter inhibitor, to determine whether a 
significant drug-nutrient transport interaction can occur in vivo.  
 
2.5.6.1 L-Carnitine: Function and Biosynthesis 
L-Carnitine, a water soluble quaternary amine that exists as a zwitterions under 
physiological condition, performs a crucial role in the β-oxidation of fatty acids. L-
Carnitine controls the influx of long-chain fatty acids into mitochondria via the L-
carnitine acyltransferase enzyme system (174-175). L-Carnitine can also affect the 
intermediary metabolism of fats, carbohydrates, and amino acids by acting as an 
intramitochondrial acyl-group acceptor, thus helping to regulate acyl-CoA/CoA 
ratios (176) and the mitochondrial respiratory chain (174),  and can facilitate the 
oxidation of pyruvate due to stimulation of pyruvate dehydrogenase complex (174). 
L-carnitine, and its endogenous metabolite acetylcarnitine, may have a special 
function in the brain as they influence acetylcholine synthesis by controlling the 
acetyl moiety level (177). 
Normally, L-carnitine is maintained at a steady level in the blood (178). This 
homeostasis is maintained by L-carnitine biosynthesis in the liver and brain, dietary 
L-carnitine, and renal reabsorption of filtered L-carnitine (Figure 2.2) (179).  The 
mammalian L-carnitine pool is heavily dependent on exogenous intake: only about 
25% of the L-carnitine source for the body comes from the liver and the kidney in 
man, whereas the remaining 75% comes from the diet (174). The precursors of L-
carnitine are the two essential amino acids lysine and methionine (180). All enzymes 
in the pathway of L-carnitine biosynthesis are ubiquitous in mammalian tissues.  
However, γ-butyrobetaine hydroxylase, the enzyme that catalyzes the final step of 
the L-carnitine synthesis, is present only in a few tissues including liver (180). 
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Figure 2.2. Schematic representation of L-carnitine homoeostasis. TML: N6-
trimethyl-lysine; HTML: 3-hydroxy- N6-trimethyl-lysine; γ-BB: γ- butyrobetaine; γ-
BBH: γ- butyrobetaine hydroxylase; OCTN2, novel organic cation transporter 2. *L-
Carnitine biosynthesis in other tissues is limited due to limited tissue distribution of 
γ-BBH. (Adapted from Vaz and Wanders (180)) 
 
2.5.6.2 L-Carnitine and the Neonate  
In mammalian fetal tissues, metabolic energy is obtained mainly from 
carbohydrate metabolism (174). After birth, the newborn depends on a new source of 
nutrition (i.e. milk), which is high in fat and low in carbohydrate (37). The newborn 
must be able to respond to this change in energy substrates supply. Parturition signals 
the increase in expression of fatty acid transporters and enzymes of fatty acid 
metabolism in heart to allow fatty acids to become the major energy source for 
cardiac muscle (37). Improvements in fatty acid utilization are necessary to ensure 
normal growth and development (53). Fatty acid oxidation disorders are associated 
with the sudden infant death syndrome (181).  Fatty acid oxidation also plays an 
important part in the thermogenic function of brown adipose tissue to maintain the 
thermal homeostatsis (53).  The L-carnitine dependent oxidation of long chain fatty 
acids is particularly important for the provision of acetyl units required for the 
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synthesis of complex lipids in the developing brain (182). The utilization of long 
chain fatty acids as a fuel source is dependent upon adequate concentrations of L-
carnitine (183).  The dramatic increase in fatty acid oxidation rates that occur in early 
postnatal heart development has been attributed to an increase in L-carnitine levels 
(184). 
As in adults, the free L-carnitine concentration in the plasma of neonates 
probably represents an equilibrium between intestinal absorption, hepatic 
biosynthetic activity, uptake and release by tissues, and renal clearance (53). The 
plasma L-carnitine concentration of full term neonates increase during the first two 
weeks of life and reach adult levels by six months of age (185).  At birth, the 
fetoplacental transfer of L-carnitine is interrupted.  Before the onset of feeding the 
neonate heavily depends on fetal L-carnitine stores and on endogenous biosynthesis 
(174).  However, the ability of neonates to biosynthesize L-carnitine is limited due to 
low levels of hepatic γ-butyrobetaine hydroxylase (γ-BBH) (186).  The activity of γ-
BBH increases with age and is only 10% -12% that of the normal adult levels at birth 
(53, 185). Thus, neonates are developmentally immature with regard to L-carnitine 
biosynthesis, and depend heavily on exogenous sources of L-carnitine. Merlegh et al. 
found that the L-carnitine content of pooled milk, despite its variability, was 
sufficient to maintain plasma levels in newborns without L-carnitine supplementation 
(187). However, any maternal drug affecting L-carnitine levels in the maternal 
system and thereby milk L-carnitine levels has the potential to cause inadequate or 
deficient L-carnitine levels in nursing neonates. 
 
2.5.6.3 L-Carnitine Transporters 
Uptake of L-carnitine into tissues may involve the OCTNs, ATB0,+ and CT2 
transporter systems. OCTNs, although showing rather high similarity of about 70% 
or more in amino acid sequences, function in distinct manners (188). OCTN1 is a 
multispecific, bidirectional, sodium-independent organic cation transporter in a pH-
dependent manner, which has low affinity for L-carnitine transport in species 
including human and rat (189-191). It is expressed abundantly in rat intestine, liver 
and kidney (191). OCTN2 appears to be the major Na+-dependent L-carnitine 
transporter common to mice, rat and human (192).  The unique aspect of OCTN2 is 
its dual mode of transport: it transports L-carnitine via a Na+-coupled process 
whereas transport organic cations via Na+-independent (179, 193-194). OCTN2 is 
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widely expressed in human tissues such as heart, skeletal muscle, kidney, intestine, 
and placenta and brain (194-195). A mutation in OCTN2 gene has been considered as 
the causative factor for secondary L-carnitine deficiency (SCD). Compared to the 
wide distribution of OCTN1 and OCTN2, OCTN3 is unique in its limited tissue 
distribution which is by predominant expression in testis and Na+ independent L-
carnitine transport (192, 196-197). Duran et al. suggested that OCTN3 could mediate 
the passive, Na+ and pH-independent L-carnitine transport activity (198). OCTN3 
have a higher specificity for L-carnitine transport than OCTN1 and OCTN2 (192). 
Other than the OCTNs, ATB0,+ is also low-affinity transporter with a wide 
distribution in the intestinal tract and lung, as well as mammary gland (199-200). In 
addition, L-carnitine transporter 2 (CT2) is another novel L-carnitine transporter 
found recently.  CT2 expresses specially in human testis with a reasonably high 
affinity toward L-carnitine (201). The localization of these transporters in tissues and 
at epithelial barriers is critical in understanding their endogenous role. For instance, 
OCTN2 is present on the apical membrane of rat intestinal epithelium, which 
suggests that OCTN2 is responsible for  transporting L-carnitine into enterocytes 
(198). OCTN3 is expressed in peroxisomal membranes where it plays a critical role 
in peroxisomal β-oxidation pathways (202).   
L-Carnitine concentrations in breast milk are higher than maternal plasma 
levels in the first two months after delivery (186).  High M/P ratios usually suggest 
the active transport of that compound into breast milk. The L-carnitine transporters 
likely function in concert at the mammary epithelial barrier to produce a net 
accumulation of L-carnitine in breast milk during early lactation.  In addition, the L-
carnitine transporters also transfer other cation compounds such as therapeutic agents, 
drugs of abuse, and other xenobiotics that might be used by the mother during 
lactation.  Thus, a thorough understanding of the L-carnitine transport system in the 
mammary gland and neonatal intestine would facilitate the evaluation of the 
pharmacological effects and toxicological potential of these compounds. These 
compounds have the potential to alter the L-carnitine tissue profile in the neonate, 
which, in turn, may have long-term effect on neonatal development.  
 
2.5.6.4 L-Carnitine Deficiency  
L-carnitine deficiency was first described as a new syndrome in humans in 
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1973 (203). Until now, two types of L-carnitine deficiency have been observed: 
primary and secondary L-carnitine deficiencies. These are commonly classified by 
the etiopathogenesis and organ involvement (203). Primary L-carnitine deficiency is 
caused by disturbances in the L-carnitine system itself and leads to impaired fatty 
acid oxidation (203). Primary L-carnitine deficiency is an autosomal recessive 
disorder of fatty acid oxidation, which can be associated with a novel mutation in 
SLC22A5, the gene encoding OCTN2 (55, 204-205).  Patients with primary L-
carnitine deficiency have increased renal excretion of L-carnitine (205), and patients 
experience recurrent hypoketotic hypoglycemia and/or dilated cardiomyopathy (206-
207). Secondary L-carnitine deficiencies are associated with an impaired 
mitochondrial oxidation of acyl-coenzyme A intermediates, a limited supply of 
substrates for L-carnitine biosynthesis, or a dietary insufficiency  (208).  Secondary 
L-Carnitine deficiency is defined as free plasma L-carnitine concentrations less than 
20 μmole/L or 0.39 mg/dL (209-210).  
Toxicity caused by L-carnitine deficiency results from the accumulation of fatty 
acids or decreased energy production (211). Impairment in mitochondrial fatty acid 
oxidation can lead to severe hypoglycemia and dilated cardiomyopathy (212).  In 
addition, patients with inborn errors of long chain fatty acid oxidation present with a 
variety of severe clinical problems, such as cardiomyopathy, retinopathy, and 
peripheral neuropathy, presumably due to the accumulation of toxic long chain acyl 
CoA esters (213). Symptoms related to a defect in OCTN2 may include fatty liver, 
growth retardation, hypoglycemia and hyperammonemia (178, 204, 214). Many 
individuals with L-carnitine deficiency are generally normal at birth and may appear 
healthy for several years until overt clinical signs appear (215).  Early identification 
of L-carnitine deficiency can be lifesaving because L-carnitine supplementation 
during early stage can reverse certain pathological changes associated with cardiac, 
neural, and hepatic systems (215).    
 
2.5.6.5 L-Carnitine and Cefepime Transport Interaction  
Cefepime is a semi-synthetic cephalosporin used for parenteral human 
therapy (216).  It is a powerful β-lactam antibiotic with excellent activity against a 
wide range of clinically important pathogens, particularly those strains resistant to 
other cephalosporins (217). Therapeutically, certain β-lactam antibiotics can induce a 
secondary L-carnitine deficiency due to inhibition of renal L-carnitine reabsorption 
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by OCTN2, thereby promoting the loss of L-carnitine in the urinary filtrate (218-
219).  In in vitro studies, cefepime competitively inhibits L-carnitine uptake via 
OCTN2 (219). Given these data, administration of cefepime to a lactating mother 
could result in the following significant drug-nutrient interactions: 1) Compete with 
L-carnitine for intestinal absorption and decrease L-carnitine bioavailability; 2) 
Compete with L-carnitine for renal tubular reabsorption and increase urinary loss of 
L-carnitine; 3) Inhibit L-carnitine transfer in the lactating mammary gland. The first 
two interactions have the potential to decrease maternal serum levels of L-carnitine 
and thereby decrease L-carnitine delivered to the mammary gland and into the breast 
milk. The third type of interaction can directly decrease milk L-carnitine levels. 
These drug nutrient interactions can occur simultaneously in the maternal system and 
result in more pronounced reductions in L-carnitine concentrations in breast milk, 
which could further compromise the nursing neonate’s L-carnitine status. 
 
3 Perspectives 
Breastfeeding is highly recommended by international organizations such as 
WHO and FAO and is promoted by various health care professionals.  However, 
maternal disease and its treatment may raise concerns regarding the safety of 
breastfeeding, which, in turn, may affect the decision of mothers to breastfeed their 
child.  My research is designed to identify disease/drug-nutrient transporter 
interactions at the lactating mammary gland and in the nursing neonate. Such 
interactions can affect the levels of specific nutrients and drugs in the breast milk and 
nutrient availability and disposition in the neonate. Both these interactions can alter a 
neonate’s nutritional status and consequently influence neonatal development as well 
as long-term health issues. In a practical sense, my research can provide valuable 
information for medication use during breastfeeding and during neonatal 
development for both pharmaceutical companies and various health organizations. 
Specifically, pharmaceutical companies can use this information to inform mothers 
about necessary precautions when using medications during breastfeeding. For 
example, my research may identify a need for dietary modification or 
supplementation when taking medications while breastfeeding to minimize the risk 
of nutrient deficiency in the breast milk. Moreover, my research may provide 
information regarding potential risks associated with maternal disease that alter 
mammary gland function and milk composition. This may then lead to better 
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nutritional supplementation for mothers with certain diseases, such as inflammation, 
who are still encouraged to breastfeed.  
 
4 Hypothesis 
Nutrient transporters expressed in mammary gland epithelium change during 
the lactation period to meet the nutritional requirements of the nursing neonate. 
Drugs may interfere with transporter function to cause changes in nutrient levels of 
breast milk. In addition, early life exposure to drugs may cause interactions that alter 
the nutrient homeostasis in the neonate and thereby interfere with normal 
biochemical and physiological development. Maternal health status may also affect 
mammary gland function and thereby change the milk composition. The effect of 
drug exposure and inflammatory conditions on nutrient transport in the lactating 
mother-neonate dyad is the focus of my research and I have the following hypotheses:  
Hypothesis I: Nutrient transporter expression in the mammary gland epithelium 
changes with lactation period. 
Hypothesis II: Drugs interfere with transporter function in the lactating 
mammary gland to cause changes in nutrient levels of breast milk.   
Hypothesis III: Drug exposure during neonatal development modifies metabolic 
and biochemical pathways involving specific nutrients.  
Hypothesis IV: Inflammatory stimuli alter mammary gland energy substrate 
transporter expression. 
 
5 Objectives 
Conditionally essential nutrients are critical for neonatal development. Co-
administrated drugs may functionally interact with the transporters responsible for 
the transport of such nutrients across the lactating mammary epithelium and for 
absorption and disposition within the developing neonate. Such interactions may 
account for systemic and/or secondary deficiency in neonates. Therefore, it is 
important to clarify the transporters involved in the transfer of such nutrients into 
milk and uptake into and disposition within the neonate at different stages of 
lactation/neonatal development. By evaluating the potential interaction at various 
stages of lactation, we can gain further insight into when the interaction may be most 
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detrimental to the health of the nursing neonate. Furthermore, this information will 
also help us to understand the physiological roles of these nutrients in the neonatal 
development.   
In my study, L-carnitine is used as an example of a critical nutrient in breast 
milk.  Milk L-carnitine levels decrease as lactation stage advances. This may be 
associated with lactation stage dependent changes in L-carnitine transporter 
expression in the lactating mammary gland. Therefore, mRNA expression levels of 
various L-carnitine transporters in the lactating mammary gland will be analyzed at 
different lactation stages. In addition, the exact localization of these transporters in 
the polarized epithelium of the mammary gland is fundamental to our understanding 
of their physiological function in the mammary gland. Thus, the localization of 
selected L-carnitine transporters in the lactating mammary gland will also be 
identified (Objective 1).  
L-Carnitine transporters also transport a variety of xenobiotics. Hence, 
xenobiotics can either inhibit nutrient (L-carnitine) transport or be transported into 
the breast milk. Therefore, an inhibitor of L-carnitine transport will be administered 
to lactating rat mothers at different lactation stages to determine whether an 
interaction changes L-carnitine milk levels and whether lactation stage affects the 
magnitude of this interaction (Objective 2).  
Drugs present in breast milk will eventually be delivered to the nursing 
neonate. Compared to the adult, neonates undergo significant development and 
maturation. These changes are known to alter drug pharmacokinetics in the neonates 
compared to the adults, which may predispose the neonate to adverse effects. Thus, it 
becomes important to evaluate the pharmacokinetics of the chosen L-carnitine 
transport inhibitor in the neonate at different postnatal time points (Objective 3). 
With inefficient clearance processes even subtle amounts of xenobiotics in the milk 
may pose a long term health risk to the developing neonate, particularly when the 
exposure occurs during a “critical window” of development. As such, my aim is to 
identify potential biomarkers of toxicity to the L-carnitine inhibitor cefepime at 
different postnatal ages and for different duration of exposures (Objective 4).  
In addition to maternal medication, maternal diseases are also a concern 
during breastfeeding. For example, inflammatory states such as mastitis are common 
during breastfeeding. Inflammation may create an unfavorable change in nutrient 
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composition of the breast milk and negatively affect lactation. In acknowledgment of 
this I also intend to estimate the potential effects of inflammation on the function of 
mammary gland energy substrate transporters using an in vitro human mammary 
gland epithelial cell culture system (Objective 5). Since the mammary gland 
epithelial functions during lactation are different compared to non-lactation stages, I 
will examine the effects of inflammation on energy substrate transporter expression 
in vivo using lactating rats at different lactation stages (Objective 6).  
In summary, my proposed objectives are:  
1. To characterize localization and expression levels of L-carnitine transporters 
in rat mammary gland at different lactation stages.  
2. To measure L-carnitine levels in rat milk and serum in presence and absence 
of cefepime at different lactation stages. 
3. To study cefepime pharmacokinetics following acute cefepime 
administration at different developmental stages in rats. 
4. To measure biomarkers of L-carnitine homeostasis following chronic 
cefepime exposures at different developmental stages to identify potential 
programming effects with postnatal drug administration.  
5. To measure energy substrate transporter mRNA expression levels in 
MCF12A when challenged by LPS or LTA.  
6. To measure energy substrate transporter mRNA expression levels in 
mammary gland of lactating rats treated with LPS at different stages. 
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7.1 Abstract 
Drug milk-to-serum concentration ratio (M/S) is a key determinant of Exposure 
Indices used to assess the risk associated with neonatal exposure to drugs present in 
breast milk when nursing mothers take medications. The primary purpose of our study 
was to assess experimentally the influence of lactation stage dependent differences in 
M/S for an actively transported drug on the calculation of two Exposure Indices, EIDose 
and EIConc. Cefepime was given to rat pups by intravenous (20 mg/Kg) or oral (40 
mg/Kg) bolus administration at postnatal age day 4 and 10. Blood samples were 
collected via cardiac puncture at 0, 10, 20, 30, 45, 60, 120, 240, 360, and 480 min post-
administration (1 pup/time point, n=6/time). Cefepime concentrations were measured by 
HPLC-UV. Following IV administration, the elimination rate constant, half-life, and 
systemic clearance were significantly higher in 10 day-old versus 4 day-old rat pups. 
Cefepime M/S was higher at day 4 lactation versus day 10 (data from Ling and Alcorn 
2008). The EIConc was quantitatively higher than the EIDose at both lactation stages. The 
~7-fold decrease in cefepime M/S values at lactation day 10 resulted in ~7-fold 
reduction in the calculated EIDose (considering age-dependent changes in body weight 
and the volume of milk consumed per day) and ~13-fold reduction in the EIConc 
(considering age-dependent increases in systemic clearance and the volume of milk 
consumed per day). Our study experimentally confirms the need to evaluate M/S at 
different lactation stages for actively transported drugs to avoid over- or underestimation 
of the neonatal exposure risk. 
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7.2 Introduction 
All chemicals have the potential to cross the lactating mammary epithelial barrier 
into milk (150-152). Any chemical (i.e. drugs, environmental toxicants) transferred into 
breast milk may pose a health risk to a nursing neonate. To assess this risk, the literature 
proposes several Exposure Indices that variably consider the key determinants affecting 
neonatal exposure to chemicals in breast milk (8, 150, 220). Both maternal factors (i.e. 
the bioavailable (F) maternal dose, maternal elimination capacity or systemic clearance 
(ClS), and the milk-to-serum concentration ratio (M/S)) and neonatal factors (i.e. the 
volume of milk consumed during nursing (Vmilk/τ), the bioavailable neonatal dose, and 
neonatal systemic clearance) determine neonatal exposure risks during breastfeeding. 
The most commonly referred to Exposure Index, EI(Dose), bases risk assessment on the 
dose a neonate receives from the mother during nursing. To provide some relative 
measure of risk the EI(Dose) expresses neonatal dose as a percentage of the maternal dose 
as shown in Equation 7.1 (8):  
 
EI(Dose) = Absolute Neonatal Dose (mg/Kg/day)Maternal Dose (mg/Kg/day) ×100%
=
FMat × CSS,Mat × M S( )× Vmilk τ( )Neo
ClS,Mat
  (Equation 7.1) 
 
where FMat is the maternal bioavailability, CSS,Mat is the steady state maternal 
serum concentration, M/S is the milk concentration-to-serum concentration ratio, 
(Vmilk/τ)Neo is the volume of milk consumed by the neonate per day, and ClS,Mat is the 
maternal systemic clearance. For pharmaceutical agents, current guidelines suggest that 
drugs are safe to use during breastfeeding if the EI(Dose) is less than 10% (221). Since this 
risk assessment tool identifies the % of the maternal dose made available to the neonate 
it largely ignores the important contribution of neonatal pharmacokinetic processes as 
key determinants of neonatal exposure risk to chemicals present in the breast milk (8). 
However, this Exposure Index is more easily applied since published literature on 
maternal pharmacokinetics, milk-to-serum ratios and milk consumption rates may be 
available for a variety of drugs and a few environmental toxicants  (222).. 
A more comprehensive Exposure Index is the EIConc,  (223), where risk is based 
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on the systemic exposure of the neonate to the chemical. To provide a relative measure 
of risk, the EIConc expresses neonatal steady state serum concentration as some 
percentage of the maternal steady state serum concentration as shown in Equation 7.2  
(8):  
EI Conc( ) =
Steady State Serum Concentration( )Neo
Steady State Serum Concentration( )Mat ×100%
= FNeo × M S( )× Vmilk τ( )Neo
ClS,Neo
  (Equation 7.2) 
where FNeo is the neonatal bioavailability and ClS,Neo is the neonatal systemic 
clearance. Systemic exposure often is a better indicator of toxicological outcomes than 
the size of the exposure dose as not only size of dose but the pharmacokinetic processes 
acting on that dose determine the concentration of a chemical at the toxicological site of 
action. As a risk assessment tool, the EIConc  likely provides a better prediction of risk to 
the nursing neonate. However, this Exposure Index demands knowledge of neonatal 
pharmacokinetics, information that is often lacking in paediatric populations. This is 
further complicated by the dynamic changes in body composition, organ function and 
physiological and biochemical processes that occur with maturation and which cause 
age-dependent changes in pharmacokinetic characteristics of chemicals in the body 
(160).  
McNamara and Abassi (8) recently reviewed the theoretical use of these 
exposure indices and how the different determinants of exposure risk influence the 
values of EI(Dose) and EIConc. This review highlighted the importance of including 
neonatal pharmacokinetics to more accurately reflect the risk as the EIConc  bases the risk 
assessment on systemic concentrations and not simply on the ingested dose (8). What 
was of further interest was the importance of the M/S on the value of these exposure 
indices (see Equations 7.1 and 7.2) where the higher the M/S value (i.e. greater the 
compound distribution into milk), the higher the exposure. The M/S has been evaluated 
for a number of drugs. However, these are often determined without consideration of 
stage of lactation. Although the literature acknowledges the M/S variability between 
colostrum and mature milk (224-226), foremilk and hindmilk (227-229) and within a 
dosing interval  (227), limited discussion exists about the stage of lactation (i.e. early, 
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mid, late) and its impact on the M/S value (35). 
Many drugs distribute into milk via passive processes. In such cases the physico-
chemical properties of the compound, fat partitioning, and plasma protein binding 
determines the milk levels of a compound (35) and often M/S values do not exceed unity. 
However, some drugs are substrates for transporters expressed in the lactating mammary 
epithelium (83, 95, 162). Actively transported drugs can achieve M/S values well 
exceeding 2 (158, 230). Recently our laboratory has shown clear evidence of changes in 
M/S values of an actively transported drug substrate with lactation stage due to 
lactation-stage dependent changes in the expression of transporters in the lactating 
mammary epithelium (1). Reports of transporter expression in the lactating mammary 
gland also clearly indicate significant changes in transporter expression levels with 
lactation stage (75, 97-98). Herein we provide experimental support for the need to 
consider lactation stage in the M/S determination of actively transported compounds and 
in the assessment of neonatal exposure risk with EI(Dose) and EIConc  using cefepime, a β-
lactam antibiotic substrate of organic cation/carnitine (Octn) transporters, and the 
lactating rat dam-pup dyad. 
 
7.3 Materials and Methods 
Animals and Chemicals. Female Sprague-Dawley rats ordered at gestation day 
17 (for pups at postnatal day 4) (n=12) and lactation day 3 (for pups at postnatal day 10) 
(n=12) were obtained from Charles River Canada (St. Constant, PQ) and were housed 
singly in a temperature and humidity controlled facility (22°C ± 2°C) on a 12-hour light: 
dark cycle (0700 h – 1900 h). All rats had free access to food (Prolab® RMH 3000, 
Purina, Inc., Richmond, IN) and water throughout the study and were allowed a 7-day 
acclimatization period. All procedures were conducted in accordance with the Canadian 
Council of Animal Care guidelines for the care and use of laboratory animals and were 
approved by the Animal Research Ethics Board of the University of Saskatchewan. 
Cefepime was purchased as a sterile crystalline powder equivalent to 2 g of cefepime per 
vial from the Royal University Hospital at the University of Saskatchewan (Saskatoon, 
SK). HPLC solvents were HPLC grade and all other chemicals were highest analytical 
grade possible. A MilliQ Synthesis (Millipore, Bedford, MA) water purification system 
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provided purified deionized water.  
Cefepime Pharmacokinetics in Rat Pups. Rat pups at postnatal age day 4 and 
day 10 were removed from their dams at least two hours prior to cefepime 
administration. These dams were used to assess steady state milk levels of cefepime at 
lactation day 4 and day 10 as reported in Ling et al. (1). Cefepime was reconstituted with 
sterile saline just prior to administration and diluted according to pup body weight. For 
intravenous injection, 20 mg/kg body weight in 50 μL was administrated via intracardiac 
puncture under isoflurane anaesthesia using a 27-gauge needle. For oral administration, 
40 mg/kg body weight in 100 μL was administrated via a 24-gauge 1 inch gavage needle. 
Blood samples were collected from pup heart via cardiac puncture (under isoflurane 
anaesthesia) at 0, 10, 20, 30, 45, 60, 120, 240, 360, 480 min after administration and the 
pups were immediately euthanized. Each rat pup in a litter was assigned to a single time 
point following drug administration (i.e. destructive sampling scheme). Each litter was 
considered as n=1 and a total of 6 litters were used for each route of administration. 
Blood samples were allowed to clot for 30 min at room temperature and serum was 
collected following centrifugation at 1000 × g for 10 minutes. Serum was stored in 
eppendorf micrcocentrifuge tubes at -20°C until analysis.  
Cefepime Analysis. Milk and serum cefepime concentrations were measured by 
HPLC-UV. In screw-top glass culture tubes, 20 μL of rat plasma or milk was added with 
180 µL acetonitrile: methanol (9:1), vortex-mixed for 5 min and centrifuged at 10,000 × 
g for 20 min. The supernatant was transferred to HPLC vials and 10 μL was injected 
onto a CN (cyano) column (HyperClone 5 µm, 250 × 4.6 mm, Phenomenex, Torrance, 
CA) with methanol: purified deionized water (1:1) as mobile phase delivered at 1 
mL/min. UV detection wavelength was set at 260 nm. The standards were prepared in 
male rat serum as above. The standard curve was linear (r2 > 0.99) in the range of 3.1 
mg/L-100 mg/L. Intra- and interassay accuracy and precision ranged from 5%-14%. 
Quality control samples at three different concentrations performed in duplicate were 
assessed as acceptance criteria for individual HPLC analyses.    
Pharmacokinetic Analysis. The pharmacokinetic parameters of cefepime were 
characterized using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA). Plots of 
average serum cefepime concentration following oral or IV administration to Sprague 
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Dawley rat pups at postnatal day 4 and postnatal day 10 were shown in Figure 7.1.The 
area under the serum concentration-time curve (AUC) for both oral and IV 
administration was calculated by the linear trapezoidal method with extrapolation to 
infinity determined using the ratio of the last serum concentration and elimination rate 
constant (i.e. Clast/k). The elimination rate constant (k) was determined by linear 
regression analysis of the postdistributive log-linear terminal serum concentration-time 
determinations. The elimination half-life (t1/2) was determined by the ratio 0.693/k.  The 
systemic clearance (ClS) was calculated as DoseIV/AUC∞.  Cefepime absolute 
bioavailability (F) after oral administration was determined by as 
(AUCOral×DoseIV)/(AUCIV×DoseOral).  The apparent volume of distribution (Vd) was 
determined as DoseIV/(k×AUC∞). 
Calculation of Exposure Indices. The exposure index related to maternal dose 
(EIDose) was calculated as: 
EIDose = CSS,milkDoseMat
M
S
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟ 
Vmilk
τ
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟ ×100%     (Equation 7.3) 
where CSS,milk is the steady state drug concentration in rat milk ; DoseMat is the 
continuous intravenous infusion dose administered to the dam (mg/hour/kg), M/S is the 
ratio of steady state milk concentration to steady state serum concentration in the dam. 
The values for CSS,milk, DoseMat, and M/S were obtained from Ling and Alcorn, 2008 (1). 
Vmilk/τ is the neonatal milk consumption rate (mL/day), which was obtained from “Rat 
Breeding Guide”. The exposure index related to maternal concentration (EIconc) was 
calculated as: 
 EIConc = FNeoClNeo
M
S
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟ 
Vmilk
τ
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟ ×100%     (Equation 7.4)
 
where FNeo is the absolute bioavailability in rat pup; ClNeo is the systemic 
clearance in the rat neonate (L/h/kg); M/S is the ratio of steady state milk concentration 
to steady state serum concentration obtained from Ling and Alcorn, 2008 (1); and Vmilk/τ 
is the neonatal milk consumption rate (mL/day), which was obtained from “Rat 
Breeding Guide”(231).  
Statistical Analysis. Data is presented as mean ± SEM. Means between different 
age groups within the same route of administration were compared using unpaired t-test. 
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Means for F were compared using unpaired t-test. Significance level was set at 0.05.  
 
7.4 Results 
Table 7.1 presents the mean pharmacokinetic parameter estimates for cefepime 
following oral and intravenous administration to rat pups 4 and 10 days of age. 
Following IV administration elimination rate constant, half-life and systemic clearance 
were significantly higher in 10 day-old rat pups relative to postnatal day 4 pups. 
Although not statistically significant, oral bioavailability was also increased in postnatal 
day 10 pups. The volume of distribution (Vd) of cefepime was similar between the two 
rat pup age groups.  
Table 7.2 presents additional parameters required for the calculation of Exposure 
Indices.   Note that the cefepime M/S was higher at early lactation stage (day 4) relative 
to day 10 of lactation (1). At postnatal day 4 the EIDose and EIConc were similar and 
represented about 3% of maternal exposures. The ~7-fold decrease in M/S values of 
cefepime at day 10 of lactation resulted in ~7-fold reduction in the calculated EIDose 
(considering the age-dependent changes in body weight and the volume of milk 
consumed per day) and ~13-fold reduction in the EIConc (considering the age-dependent 
increases in systemic clearance and the volume of milk consumed per day).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 48
0 3 6 9
0
20
40
60
80
IV
Oral
A
Time (hours)
C
ef
ep
im
e 
se
ru
m
 c
on
ce
nt
ra
tio
n 
( μg
/m
L)
0 3 6 9
0
20
40
60
80 B
IV
Oral
Time (hours)
C
ef
ep
im
e 
se
ru
m
 c
on
ce
nt
ra
tio
n 
( μ
g/
m
L)
 
Figure 7.1. Mean ± SEM serum concentration versus time curves of cefepime after 
20mg/kg IV dose or 40mg/kg oral dose in Sprague Dawley rat pups (n=6) at postnatal 
day 4 (A) and postnatal day 10 (B).  
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Table 7.1. Summary of mean ± SEM pharmacokinetic parameters for cefepime after 
intravenous (20 mg/kg by intracardiac injection under isoflurane anaesthesia) and oral 
(40 mg/kg by gastric gavage) administration in rat pups (postnatal day 4 and day 10) 
(n=6/time point blood collection).   
IV Oral 
Parameters 
Day 4 Day 10 Day 4 Day 10 
AUC           
(μg×h mL-1) 118 ± 11
 101 ± 9.6 54.1 ± 7.8 66.3 ±14 
k (h-1) 0.367 ± 0.02 0.518 ± 0.03# 0.235 ± 0.02 0.356 ± 0.11 
Cl (mL/h) 1.68 ± 0.19 4.26 ±0.45# 7.59 ± 1.68 15.8 ± 3.8 
Cl (L h-1 kg-1) 0.179 ± 0.02 0.207 ± 0.02 0.812 ± 0.11* 0.747 ± 0.18* 
F ----- ----- 0.239 ± 0.04 0.360 ± 0.08 
t1/2 (h) 1.93 ± 0.13 1.36 ± 0.08# 3.67 ± 0.57 3.09 ± 0.98 
Vd (L kg-1) 0.506 ± 0.07 0.404 ± 0.04 1.33 ± 0.30* 3.58 ± 1.6* 
IV: Intravenous; AUC: Area-under-the-plasma-concentration-versus-time curve; k: 
Elimination rate constant; Cl: Clearance; F: Bioavailability; t1/2: Elimination half-life; Vd: 
Volume of distribution.    
Means between different age groups within the same route of administration were 
compared using unpaired t-test. Means for F were compared using unpaired t-test.  
#α<0.05. 
*Oral clearance and volume of distribution estimated as ClS/F and Vd/F, respectively. 
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Table 7.2. Additional parameters used for the calculation of EIDose and EIConc values for 
postnatal day 4 and day 10 Sprague-Dawley rat pups.   
Parameters Day 4 Day 10 
Average Pup Body weight (g) 9.24 21.0 
Milk consumption rate (mL/24h)a 5 8 
Cefepime CSS,milk (mg/mL)b 0.394 0.139 
Cefepime DoseMat (mg/kg/h)b 250 250 
Cefepime M/S ratiob 0.89 0.12 
EIDose 0.70% 0.05% 
EIConc 2.64% 0.34% 
aValues obtained from “Rat Breeding Guide” (231). 
bValues obtained from Ling and Alcorn, 2008 (1). 
 
7.5 Discussion 
 Following maternal exposure to chemicals, exposure indices that relate risk to 
the nursing neonate as a percentage of maternal dose (EIDose) or of maternal steady state 
serum concentration (EIConc) incorporate milk-to-serum values of the chemical as a 
significant determinant of the exposure risk (8). For most compounds the literature 
reports single M/S values and the reported value is assumed to reflect the distributional 
characteristics of the drug throughout most of the lactation period (232). Our study 
clearly demonstrates through experimentation that the M/S value of an actively 
transported chemical changes considerably with stage of lactation, which, in turn, 
significantly impacts the magnitude of the exposure risk calculated by the EIDose or 
EIConc. 
The magnitude of the risk posed to the neonate following exposure to chemicals 
via the breast milk depends on the amount of drug in the milk and the pharmacokinetic 
and pharmacodynamic properties of the drug in the neonate (156, 161). Given the 
proportional relationship between M/S and the EIDose or EIConc (see Equations 7.1 and 
7.2), M/S estimates have a significant impact on the value of the EI. M/S estimates are 
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available for some drugs and environmental toxicants, but most, if not all, are 
determined without regard to lactation stage. The literature does acknowledge 
differences in M/S between colostrum and mature milk (225, 233) and hind milk versus 
fore milk (159, 229). However, the breast milk levels of many solutes (i.e. critical 
nutrients, drugs) also depend upon the activity of SLC and ABC transporters located on 
the apical and/or basolateral membranes of the polarized lactating mammary epithelium 
(29, 76). Although the role of most transporters in the mammary gland is largely 
unknown, recent reports on transporter expression profiles during advancing lactation 
clearly identify lactation-stage dependent changes in the mRNA and functional 
expression levels of various transporters (1, 94-95, 234). Changes in expression can 
result in alterations in the distributional characteristics and extent of accumulation of 
drugs and environmental toxicants that are substrates for transporters expressed at the 
lactating mammary gland. Coupling this with the known ontogeny of transporters and 
other elimination mechanisms in the developing neonate (30-31), the assessment of 
exposure risk to the nursing neonate can be impacted significantly by postnatal age of 
the neonate and stage of lactation.   
Previously we had reported the acute interaction between the β-lactam antibiotic, 
cefepime, and L-carnitine transport into rat milk (1). In this study, short-term cefepime 
intravenous infusion to the rat dam caused a significant decrease in L-carnitine transfer 
into milk that may be associated with the extent of expression of organic cation/carnitine 
transporters in the lactating mammary gland. The reduction in L-carnitine milk levels 
was most significant at early lactation stage (2-fold reduction in milk L-carnitine levels) 
as compared to mid lactation, which seemed to match a 2-fold higher organic 
cation/carnitine transporter 2 expression in early lactation and the higher M/S values of 
cefepime at this lactation stage (0.89 vs 0.12). Both the EIDose and EIConc predict a 
greater risk of exposure to younger neonates given the higher cefepime M/S values at 
early lactation stage relative to mid-lactation (Table 7.2). The ~7.5-fold difference in the 
M/S values between day 4 and day 10 of lactation (1) also suggests the Exposure Indices 
would be over- or underestimated depending upon the stage of lactation at which the 
M/S value for a given chemical is determined.  
In addition to the bioavailable dose to the neonate via the breast milk, neonatal 
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elimination capacity is an additional critical determinant of exposure risk (8). In the 
present study, bioavailability was not statistically significantly changed between the two 
age groups but rat neonates showed an enhanced capacity to eliminate cefepime with 
age resulting in a considerable decrease in the EIConc at postnatal day 10 relative to 
postnatal day 4 (Table 7.2).  These data suggest that for a given dose via the breast milk 
the internal dosimetry metrics (i.e. blood concentrations, area under the blood 
concentration versus time curve) change with age of the neonate. The potential for drug 
accumulation and, hence, susceptibility for adverse outcomes may also change with 
neonatal age. These experimental data confirm the current discourse on the importance 
of the developmental maturation of pharmacokinetic processes in the assessment of 
exposure risks during postnatal development.  
Our study provides experimental evidence of the importance of lactation stage in 
the determination of milk-to-serum ratios and brings into question the accuracy of milk-
to-serum ratios of some chemicals reported in the literature. This becomes a critical 
consideration when Exposure Indices are used in the risk/benefit analysis concerning the 
safety of medication use during breastfeeding or the safety of maternal environmental 
exposures to a nursing neonate. For drugs, the published Guidances on drug use during 
breastfeeding (235) significantly impact health care professionals in their considerations 
of drugs and breastfeeding mothers.  Since these Guidances principally focus on drug 
transfer into breast milk and the amount of drug the neonate becomes exposed to during 
breastfeeding (8, 102) our study suggests the need to consider lactation stage in the 
risk/benefit analysis for drugs that are known transporter substrates. What may be safe to 
use at one stage of lactation may not be considered safe to use at an earlier or later 
lactation period due to differences in milk-to-serum ratios of a drug. An additional 
consideration in the risk/benefit analysis is the recent publications that demonstrate the 
importance of Solute Carrier and ATP Binding Cassette transporter expression at the 
lactating mammary in nutrient and drug transport into breast milk  (1, 90, 94, 236). . We 
recently showed a significant drug-nutrient transport interaction at the lactating 
mammary gland (1), and our present data suggest the outcomes of a drug-nutrient 
transport interaction may vary qualitatively and quantitatively at different lactation 
stages.  Furthermore, these new evidences in general are disconcerting because drugs 
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considered ‘safe’ during breastfeeding are known to inhibit nutrient transport at other 
blood-epithelial barriers that have lead to adverse outcomes (237-238) possibly requiring 
nutritional interventions to alleviate a nutrient deficiency (239-240) . The outcome of 
drug-nutrient transport interactions at the lactating mammary gland and in the 
developing neonate following breast milk exposures to drug is relatively poorly 
investigated. 
Chemicals transferred into milk may pose a significant health risk to the nursing 
neonate. Exposure indices that estimate neonatal drug exposure following maternal 
exposures to chemicals variably consider the key determinants of risk. Our study 
confirms the importance of considering the ability of neonate to eliminate an exposed 
dose due to age-dependent changes in elimination mechanisms as a critical determinant 
of exposure risk. More importantly, our study experimentally confirms the importance of 
M/S and the need to consider lactation stage for compounds that are substrates for 
transporters expressed at the lactating mammary epithelium. For such chemicals an 
evaluation of M/S at different lactation stages is necessary to avoid an over- or 
underestimate of the risk when M/S values are assumed to remain constant throughout 
most of the lactation period. Investigations are needed concerning the role of 
transporters in the transfer of chemicals across the blood-mammary epithelial barrier, 
their role in defining M/S, and how the M/S may change with lactation stage as the 
functional expression of these transporters change with advancing lactation. Such 
considerations also prompt questions concerning the influence of drugs and other 
exogenous factors on nutrient transport at the lactating mammary gland and on M/S 
values. 
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8 Systematic Evaluation of L-Carnitine Homeostasis Mechanisms during 
Postnatal Development in Rat 
 
8.1 Abstract 
 
The conditionally essential nutrient, L-carnitine, plays a critical role in a number 
of physiological processes vital to normal neonatal growth and development. We 
conducted a systematic evaluation of the developmental changes in tissue organic cation 
transporter (Octn) expression and free L-carnitine levels, liver γ-butyrobetaine 
hydroxylase (Bbh) expression and activity, heart carnitine palmitoyltransferase (Cpt) 
expression and activity, and heart high energy phosphate substrates at different postnatal 
ages to better understand the interrelationship between these pathways during postnatal 
development.  mRNA expression of Octns, Bbh and Cpts was measured using 
quantitative real time RT-PCR. Bbh and Cpt activity was measured by validated methods. 
L-Carnitine levels were determined by HPLC-UV. Both serum and heart L-carnitine 
levels increased with postnatal development. Increases in serum L-carnitine correlated 
strongly with postnatal increases in renal Octn2 expression, and was further matched by 
postnatal increases in intestinal Octn1 expression and hepatic γ -Bbh activity (P<0.05). 
Postnatal increases in heart L-carnitine levels were strongly correlated to postnatal 
increases in heart Octn2 expression. Although cardiac ATP levels remained constant 
through postnatal development, Cr and ADP showed developmental increases with 
advancing age of the neonate. mRNA levels of Cpt1b and Cpt2 significantly increased at 
day 20, which was not accompanied by a similar increase in activity. In conclusion, 
several L-carnitine homeostasis pathways underwent significant ontogenesis during 
postnatal development in the rat. However, the exact relationship between these 
pathways and their contribution to L-carnitine homeostasis during development is not 
completely known and further studies are required to clarify their contributions. 
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8.2 Introduction  
L-Carnitine is a conditionally essential nutrient that functions in a number of 
physiological processes vital to normal neonatal growth and development (241). With 
transition to extrauterine life the carbohydrate rich, low-fat umbilical blood supply is 
replaced by the high fat, low glucose diet of the breast milk. This switch in nutrition 
source requires physiological adaptations to quickly occur in the newborn to enhance 
gluconeogenic processes and fatty acid oxidation pathways to meet the energy demands 
of the tissues (241). L-Carnitine plays an important role in the enhancement of fatty acid 
utilization and oxidation processes during this adaptive period and throughout 
development (37, 242). By regulating the movement of long chain fatty acids into 
mitochondria making them available for β-oxidation, L-carnitine has an obligatory 
function in cellular energy production. Additionally important is L-carnitine’s role in the 
removal of toxic fatty acyl-CoA metabolites from the mitochondria and maintaining an 
appropriate balance between free carnitine and its acylated forms (243). Given its vital 
role in cellular metabolism, increasing evidence points towards the importance of L-
carnitine homeostasis in maintaining normal mitochondrial function and in the 
prevention of disease (243-245). Normal neonatal growth and development, then, may 
require the maintenance of appropriate L-carnitine homeostasis with postnatal 
maturation (246). 
L-Carnitine homeostasis represents a balance between 1) de novo biosynthesis, 2) 
intestinal absorption from dietary sources, 3) uptake and release by the tissues, and 4) 
renal reabsorption and excretion (244, 247). During postnatal life, the enzymes and 
transporters involved in these homeostatic pathways undergo developmental maturation 
to ensure the requirements of L-carnitine by the developing neonate. Limited 
information is available on the systematic evaluation of these homeostatic pathways as 
well as the possible interrelationship between these pathways and L-carnitine levels in 
the body during postnatal development.  
L-Carnitine, a water soluble trimethylated quaternary amine amino acid, is 
obtained from dietary sources and de novo biosynthesis from the amino acids lysine and 
methionine (247). However, neonates are developmentally immature with regard to L-
carnitine biosynthesis due to low levels (approximately 10-12% adult levels) of hepatic 
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γ-butyrobetaine hydroxylase, the enzyme that mediates the last step in L-carnitine 
biosynthesis (53, 186, 203). The activity of γ-butyrobetaine hydroxylase (Bbh) increases 
with age and reaches adult values later in postnatal development (248). Consequently, 
neonates are highly dependent on dietary sources of L-carnitine.  
Dietary L-carnitine is absorbed across the gastrointestinal mucosa by active 
transport systems at the luminal enterocyte membrane and by passive processes at the 
basolateral enterocytic membrane (247). Membrane transporters also mediate the tissue 
distribution and renal reabsorption and excretion of L-carnitine and thus play a critical 
role in L-carnitine homeostasis. The organic cation/carnitine transporters (OCTN) have 
been extensively studied for their important roles in L-carnitine transport (198, 249). 
OCTN1 is a multispecific, bidirectional organic cation transporter that functions in a pH-
dependent and sodium-independent manner with wide tissue distribution and low 
affinity for L-carnitine (190). OCTN2 is the major high affinity sodium-dependent L-
carnitine transporter with wide tissue distribution (179, 192). OCTN2 plays a major role 
in regulating plasma and tissue pools of carnitine in the body (244). OCTN3 is a 
peroxisomal membrane transporter mediating the intracellular transport of L-carnitine 
with high specificity (198). OCTN3 has limited tissue distribution with expression 
identified in the testis, intestine, and kidney (198, 202, 250). These transporters may 
undergo changes in expression with postnatal maturation, but limited data is available on 
their ontogeny in different tissues (164, 179, 251).  
As major components of the L-carnitine shuttle system, L-carnitine 
acyltransferase enzyme systems play important roles in fatty acid metabolism and 
energy production and maintaining an appropriate balance between free and acylated 
fatty acids (244, 252). Cpt1 on the mitochondrial outer membrane catalyses the first step 
of mitochondrial import of long chain fatty acids by converting them from fatty acyl-
CoA to acylcarnitines (253). Different tissues express different isoforms of Cpt1 (254-
255). On the inner mitochondrial membrane Cpt2 reconverts the acylcarnitines to the 
respective CoA esters releasing free carnitine and making fatty acids available for β-
oxidation (256). Limited information is available on the ontogeny of Cpt enzymes.  
Given our laboratory’s interest in understanding the impact of exogenous 
influences (i.e. drugs) on the ontogenesis of nutrient homeostasis pathways, particularly 
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when transporters play a significant role, we first required an understanding of the 
normal developmental pattern of key processes in the nutrient homeostatic pathway. As 
a conditionally essential nutrient L-carnitine homeostasis mechanisms undergo a genetic 
programming to increase utilization of fatty acids during the lactation period and a 
transporter system plays a key role in maintenance of normal L-carnitine homeostasis. 
However, the data on L-carnitine homeostatic pathways is limited and any available data 
typically involved an assessment of the developmental maturation of different processes 
in isolation of other processes. Hence, we conducted a systemic evaluation of the 
developmental changes in tissue L-carnitine levels, tissue Octn expression, liver Bbh 
expression and activity, heart Cpt1 and Cpt2 expression and activity, and heart high 
energy phosphate compounds at different postnatal ages simultaneously in the same 
animal with consideration of the known maturation of L-carnitine biosynthesis for the 
rat (257). 
 
8.3 Materials and Methods 
Animals and Chemicals. Female Sprague-Dawley rats ordered at different 
gestation stages were obtained from Charles River Canada (St. Constant, PQ) and were 
housed singly in a temperature and humidity controlled facility (22°C ± 2°C) on a 12-
hour light: dark cycle (0700 h – 1900 h). All rats were allowed a 7-day acclimatization 
period and had free access to food (Prolab® RMH 3000, Purina, Inc., Richmond, IN) 
and water throughout the study. The dams were closely monitored near parturition to 
identify the exact time of birth. The dam was considered the experimental unit and blood 
and tissues were pooled from 5 pups from each dam to carry out the various analyses. 
Rat pups at postnatal day (PD) 4, 8, 11 and 20 were anaesthetized with isoflurane and 
blood (200 – 500 uL depending on age) was collected by intracardiac puncture. The rats 
were immediately sacrificed and heart, intestine, kidney, and liver were rapidly excised 
and flash-frozen in liquid nitrogen with storage at -80°C until analysis. All procedures 
were conducted in accordance with the Canadian Council of Animal Care guidelines for 
the care and use of laboratory animals and were approved by the Animal Research 
Ethics Board of the University of Saskatchewan. 
RNeasy Midi kits were obtained from Qiagen Inc. (Mississauga, ON). The 
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QuantiTect SYBR Green RT-PCR kit was from Applied Biosystems (Foster City, CA). 
The Advanced Protein Assay kit was obtained from Fluka (Buchs, Switzerland). L-
Carnitine and other chemicals not otherwise specified were obtained from Sigma-
Aldrich (St. Louis, MO) and were the highest purity grade available. 
L-Carnitine Analysis in Serum and Heart. Serum and heart L-carnitine was 
quantified by HPLC-UV with pre-column derivatization according to Feng et al (258). 
Briefly, the pooled heart samples were homogenized with phosphate buffer (50 mM, pH 
7.4) in a ratio of 50 mg tissue:250 µL buffer. The homogenate was centrifuged at 
2500×g for 10 min at 4°C. The supernatant or serum (20 μL) sample was precipitated 
using acetonitrile and methanol (9:1 v/v). A 300 mg mixture of Na2HPO4 and Ag2O (9:1 
wt/wt) and 300 mg of KH2PO4 were added followed by a 1 h vortex-mixing. 
Derivatization reagent (40 mg/mL ρ-bromophenacyl bromide with 50 μL 40% 
tetrabutylammonium hydroxide solution) was added into the organic extract. The 
reaction mixture was incubated at 60°C for 2 h followed by centrifugation at 12,000×g 
for 15 min. L-Carnitine was analyzed using a Hewlett Packard 1050 HPLC system with 
Diode Array Detector, Quaternary Pump and Autosampler. Samples (10 μL) were 
injected onto a CN (cyano) column (HyperClone 5 µm, 250 × 4.6 mm, Phenomenex, 
Torrance, CA) with detection wavelength set at 260 nm. The mobile phase (90% 
acetonitrile/10 mM citric-phosphate buffer, pH 3) was delivered at a flow rate of 1 
mL/min. The standard curve range was linear (r2 >0.99) between 2.5-40 μmol/L. Intra- 
and interassay accuracy and precision ranged from 6%-14%.  
Heart Carnitine Palmitoyltransferase (Cpt) Enzyme Activities. Heart Cpt 
enzyme activities were measured using the spectrophotometric method described by 
Bieber et al. (259). Briefly, frozen heart tissue was homogenized in 10% (wt/v) 
homogenization buffer (20 mM HEPES, 140 mM KCl, 10 mM EDTA and 5 mM MgCl2, 
pH 7.4) supplemented with 3 mg nagarse using Polytron homogenizer (Brinkmann 
Instruments, Rexdale, Canada). The homogenate was then centrifuged at 500×g for 10 
min at 4°C. The supernatant was collected in new tubes and centrifuged at 9000×g for 
35 min at 4°C. The pellet was then washed with the homogenization buffer without 
nagarse and centrifuged at 9000×g for 35 min at 4°C. The washed pellet was 
resuspended in 200 μL homogenization buffer without nagarse. Protein concentrations 
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were measured using the Advanced Protein Assay kit with bovine serum albumin as 
standard. The optimal protein concentration and reaction time to give linear product 
formation were initially determined. To determine total Cpt activity 20 µg protein was 
assayed in 200 µL ml reaction buffer containing 20 mM HEPES, 1 mM EGTA, 220 mM 
sucrose, 40 mM KCl, 0.1 mM 5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB), 1.3 mg/mL 
BSA, and 40 μM palmitoyl-CoA, pH 7.4. The reactions were initiated by adding 1 mM 
L-carnitine and read at 412 nm after 5 min incubation at 37ºC using Synergy HT Multi-
Mode Microplate Reader (Biotek instrument, USA). Cpt2 activity was determined using 
the same reaction conditions as total Cpt except 10µL Cpt1 inhibitior, malonyl-CoA, 
was added into 200 μL of the reaction mixtures to obtain a final concentration of 10 μM. 
Cpt1 activity was calculated by subtracting the Cpt2 activity from the total Cpt activity. 
The Cpt activity was calculated as amount of CoASH released per min per mg protein, 
which is based on the 5-thio-2-nitrobenzoate formation from CoASH-DNTB reaction. 
The extinction coefficient for 5-thio-2-nitrobenzoate was 13.6 mM/cm and was used to 
calculate enzyme activity (Alhomida, 2001; Yu et al., 2001).  
Liver γ-Butyrobetaine Hydroxylase (Bbh) Enzyme Activity. The liver tissue was 
homogenized in homogenization buffer consisting of 300 mM sucrose, 1 mM EGTA, 
and 50 mM Tris, pH 7.5 using 1:4 mass to volume ratio. The homogenate was then 
centrifuged at 13,000×g for 30 min at 4°C. The supernatant was collected and 
centrifuged at 100,000×g for 1h at 4°C. 300 μL of the supernatant representing the 
cytosolic fraction containing Bbh was then transferred into a dialysis tubing cellulose 
membrane (molecular weight cutoff of 12,000Da, D9777, Sigma, USA), and submerged 
in 5 L dialysis buffer (75 mM KCl, 0.1mM DTT and 0.5mM EDTA in sodium phosphate 
buffer, pH 7.4) overnight in 4°C. The dialyzed sample (20 μL) was tested for L-carnitine 
residue and the remaining dialysate was stored at -80°C for Bbh testing. The optimal 
protein concentration, substrate concentration and reaction time to give linear product 
formation was determined for each age group. For determination of Bbh activity in rat 
pup liver, 1mL reaction buffer consisting of 0.2 mM γ-butyrobetaine, 20 mM potassium 
chloride, 3 mM 2-oxoglutarate, 10 mM sodium ascorbate, 0.4 mg/mL catalase in 20 mM 
potassium phosphate buffer pH 7.0 was prepared. The reaction was initiated by adding 2 
µL ferrous ammonium sulfate (133) (final concentration: 0.25 mM) and 20 µL dialyzed 
 60
enzyme into 78 µL reaction buffer and incubated for 25 min at 37°C using a 
Boekel/Grant Orbital and Reciprocating Water Bath (Model ORS200, Expotech, USA). 
The reaction was then terminated by adding 10X volume of acetonitrile:methanol (9:1). 
The mixture was centrifuged at 13,000×g for 2 min and the supernatant was used for L-
carnitine analysis by HPLC.  
Total mRNA Isolation and Quantitative RT-PCR Analysis.  Total mRNA was 
extracted from different tissues using RNeasy Midi Kits (Qiagen Inc., Mississauga, ON) 
according to manufacturer instructions. RNA purity and quantity was determined 
spectrophotometrically by measurement at 260 nm and the OD260/OD280 ratio, 
respectively, with Synergy HT Multi-Mode Microplate Reader (Biotek instrument, 
USA). Total RNA was stored at -80°C until analysis. Gene sequences were obtained 
from the National Center for Biotechnology Information GeneBank (260) and specific 
primers were designed using Primer3 software (Whitehead Institute for Medical 
Research. Primer 3) (261) (Table 8.1). Quantitative RT-PCR (QRT-PCR) analysis was 
carried out using a QuantiTect SYBR Green RT-PCR kit and an Applied Biosystems 
7300 Real-Time PCR system. The QRT-PCR protocol was carried out according to 
manufacturer’s instructions. The protocol consisted of reverse transcription (1 cycle at 
48°C, 30 minutes), PCR initial activation step (1 cycle at 95°C, 15 minutes), three-step 
thermal-cycling (40 cycles; denaturing at 94°C, 15 seconds, annealing at 60°C, 30 
seconds, and primer extension at 60°C for 30 seconds), and a melt curve analysis from 
65°C-95°C at 0.5°C/second.  
Validation of Primers. Quantitative RT-PCR assays were initially optimized to 
give PCR efficiency between 1.9-2.1 (as determined by a 3-point standard curving using 
serial dilutions of control RNA with a slope range of -2.9 to -3.5) and a single melt-peak 
corresponding to the appropriate PCR product as verified by 2% agarose gel 
electrophoresis. In addition, the amplification efficiency of each target and β-actin was 
determined by constructing a standard curve from the crossing point (CT) value and 
RNA concentration. The target genes and β-actin were then amplified using the same 
diluted samples. The ΔCT values were calculated (i.e. the difference between the target 
gene CT and β-actin CT). The slope from log RNA concentration versus ΔCT was close to 
zero (<0.1). Only primers giving PCR amplification close to 100% and the relative 
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efficiencies between the target and β-actin that were approximately equal were used in 
our experiment.  
 
Table 8.1. Primer sequences for quantitative RT-PCR of rat enzymes and transporters 
involved in L-carnitine homoestasis.  
Primers 
Gene 
Accession 
Number Forward Reverse 
β-actin NM_031144 agcgtggctacagcttcacc tgccacaggattccataccc 
Octn1 NM_022270 catggctgtgcagactgg gcaccatgtagccgatgg 
Octn2 NM_019269 ggcgcaaccacagtatcc ggggctttccagtcatcc 
Octn3 NM_019723 gacaccgtgaacctgagc ccatccaggcagttctcc 
Cpt1b NM_013200   cagccatgccaccaagatc aagggccgcacagaatcc 
Cpt2 NM_012930 gctccgaggcgtttctca tggccgttgccagatagc 
Bbh NM_022629 acgatggggcagagtcc ctggcctcctgagaaaagc 
Octn1, organic cation/carnitine transporter 1; Cpt, carnitine palmitoyltransferase; 
Bbh, γ-butyrobetaine hydroxylase. 
 
Statistical Analysis. All data are reported as mean ± SEM. One way ANOVA 
with Tukey’s post hoc test were used for the comparisons between ages. A P < 0.05 was 
chosen as the level of statistical significance. Pearson's correlation coefficients were 
computed to quantify the association between heart L-carnitine levels and heart Octn2 
mRNA expression levels.  
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8.4 Results 
To examine the ontogenesis of critical components of the L-carnitine 
homeostasis pathway we conducted an mRNA expression and activity analysis of 
various components of the homeostasis pathway in different tissues of rat pups of 
different postnatal ages. Compared to postnatally day (PD) 4, serum free L-carnitine 
concentrations were significantly higher at PD11 without further significant increases 
thereafter (Figure 8.1A). Heart free L-carnitine levels also increased with postnatal age 
but showed a significant increase between PD11 and PD20 (Figure 8.1B). Heart and 
kidney Octn2 expression increased postnatally although increases in expression after 
postnatal day 11 were not statistically significant (Figure 8.2A and 2B). In the intestine 
Octn1 expression was low at PD4 but increased rapidly to PD8 and remained elevated 
throughout the postnatal period. Generally intestinal Octn2 and Octn3 expression was 
high in the early postnatal period, and expression decreased nonsignificantly through the 
remaining postnatal period (Figure 8.2C). A reasonable correlation (r= 0.462) was 
observed between serum free L-carnitine concentrations and kidney Octn2 mRNA 
expression (P<0.05) in rat pups at different postnatal age groups. In addition, heart free 
L-carnitine concentrations were strongly correlated (r = 0.823) to heart Octn2 mRNA 
expression (P<0.05) in rat pups at different postnatal age groups (Figure 8.3). Liver Bbh 
mRNA expression and activity increased postnatally although increases beyond PD11 
were not statistically significant (Figure 8.4). Heart Cpt1b and Cpt2 mRNA expression 
remained constant in the early postnatal period with significant increases in expression 
occurring only between PD11 and PD20 (Figure 8.5). Despite this increase in mRNA 
expression in the late postnatal period no significant differences in activity were found at 
all examined postnatal ages (Figure 8.6). In addition, heart ATP levels remained constant 
through postnatal development (Figure 8.7). The concentrations of cardiac Cr increased 
significantly during postnatal development (Figure 8.7). Furthermore, our data also 
showed good correlation between ADP and postnatal age in rat pups (Figure 8.7).  
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Figure 8.1. Mean ± SEM Free L-carnitine levels in rat pup serum (A) and heart (B) (n=6) 
at different postnatal ages. Bars with the same letters indicate no significant difference, 
P<0.05.  
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Figure 8.2. Mean ± SEM Organic cation/carnitine transporter (Octn1 – white bar; Octn2 
– light grey bar; Octn3 – dark grey bar) mRNA expression levels in rat pup heart (A), 
kidney (B), and intestine (C) at different postnatal ages (n=6). mRNA expression was 
normalized to ß-actin. Bars with the same letters indicate no significant difference, 
P<0.05.  
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Figure 8.3. A: Correlation between kidney Octn2 mRNA expression levels and serum 
free L-carnitine concentration (r=0.462). B: Correlation between heart Octn2 mRNA 
expression levels and heart free L-carnitine concentration (r=0.823).  
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Figure 8.4. Mean ± SEM liver gamma-butyrobetaine hydroxylase (Bbh) mRNA 
expression level (A) and activity (B) in rat pups at different postnatal age groups (n=6). 
mRNA expression was normalized to ß-actin. Bars with the same letters indicate no 
significant difference, P<0.05. 
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Figure 8.5. Mean ± SEM mRNA expression level of heart carnitine palmitoyltransferase 
1b (Cpt1b) (light grey bar) and carnitine palmitoyltransferase 2 (Cpt2) (black bar) in rat 
pups at different postnatal age groups (n=6). Expression was normalized to ß-actin. Bars 
with the same letters (mRNA expression levels) or same symbol (activity levels) indicate 
no significant difference, P<0.05.  
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Figure 8.6. Mean ± SEM heart carnitine palmitoyltransferase 1 (Cpt1) (light grey bar) 
carnitine palymitoyltransferase 2 (Cpt2) activity in rat pups at different postnatal age 
groups (n=6). Bars with the same symbol (Cpt1) or same letters (Cpt2) indicate no 
significant difference, P<0.05. 
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Figure 8.7. Mean ± SEM heart high energy phosphate substrate concentration in rat pups 
at different postnatal age groups (n=6). Bars with the same letter indicate no significant 
difference, P<0.05.  
 
8.5 Discussion 
During postnatal development, a number of nutrient homeostasis pathways 
undergo ontogenesis to satisfy the nutrient requirements for growth and development. 
The developmental changes in these nutrient homeostasis pathways are usually 
genetically programmed. However, these processes can be affected by exogenous factors 
such as dietary components, environmental compounds and therapeutic drugs. Since we 
are interested in understanding how drug-nutrient transport interactions may impact the 
ontogeny of important nutrient homeostatic processes, we systemically evaluated L-
carnitine homeostasis pathways in the rat, since L-carnitine levels in the body critically 
depend on transporter function in the gastrointestinal tract and the kidney (180). The 
information on the ontogeny of L-carnitine homeostasis pathways can help us to further 
understand the impact of exogenous factors on their maturation and its possible long 
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term consequences.  
In mammals, fatty acid oxidation becomes the main source of energy for many 
tissues with transition to extrauterine life (37, 174). Mitochondrial fatty acid utilization, 
though, requires a sufficient supply of L-carnitine to shuttle long-chain fatty acids across 
the mitochondrial membrane making them available for β-oxidation (183). The maternal 
circulation supplies L-carnitine to the developing fetus. During late gestation, L-
carnitine concentrations significantly increase in fetal tissues and this storage of L-
carnitine assures adequate levels in the immediate postpartum period  (262). These tissue 
stores become quickly depleted due to the immaturity of many of the L-carnitine 
homeostasis mechanisms. In our study, postnatal increases in serum free L-carnitine was 
consistent with levels reported in the literature (125) and these increases correlated with 
maturation of a number of enzymes and transporter systems that critically determine L-
carnitine levels in the body.  
Lower serum free L-carnitine levels in the early postnatal period is, in part, due to 
the limited capacity for endogenous biosynthesis by the young neonate (53, 186, 257). 
As noted in other studies, we found that hepatic γ-Bbh mRNA expression and activity 
was significantly lower at early postnatal development in rat pups (257, 263). Young 
neonates are highly dependent on exogenous sources of L-carnitine, which is usually 
supplied in sufficient amounts by the breast milk during nursing (187). Interestingly, L-
carnitine levels in the milk of nursing rat dams decrease significantly by mid-lactation (1, 
182). Despite the reduced exogenous L-carnitine, serum free L-carnitine levels in rat 
pups increase with advancing age (125, 185). The maturation of hepatic γ-Bbh 
contributes to the postnatal increase in L-carnitine levels in the body. However, our 
study also suggests that maturation of other processes, namely renal reabsorption of L-
carnitine additionally contribute to the postnatal rise in serum L-carnitine. 
Absorption of dietary sources of L-carnitine requires the function of several 
transporter systems expressed at the gastrointestinal epithelial barrier (174). Expression 
of duodenal Octn2 and Octn3 did not change with postnatal development. This is not 
consistent with increases in Octn2 expression noted in the literature (264) but could be 
the result of different rat strains (Sprague Dawley vs. Wistar) or different portion of the 
small intestine (jejunum or ileum vs. duodenum). Both Octn2 and Octn3 mediate active 
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uptake of L-carnitine (198, 265). Lack of changes in mRNA expression with 
development may suggest that the absorptive capacity of L-carnitine by these transporter 
systems remains unchanged. However, without protein expression levels and 
measurements of transport activity with postnatal development, definitive conclusions 
are difficult to make. Interestingly, the mRNA expression level of duodenal Octn1 was 
significantly increased during development. Octn1 is a low affinity, bidirectional L-
carnitine transporter with ubiquitous expression and plays an important role in the tissue 
availability of L-carnitine (189-191). However, whether the postnatal increase in Octn1 
expression in the intestine contributes to an enhanced absorption of L-carnitine from 
dietary sources requires clarification.  
Renal reabsorption of L-carnitine from the urinary filtrate plays a significant role 
in maintenance of L-carnitine levels in the body. Almost 95% of the excreted L-carnitine 
is reabsorbed by transporters expressed in the proximal tubules of the kidney with Octn2  
as the principal transporter involved in this process (179). In our study renal Octn2 
expression increased during postnatal development in the rat, which is consistent with 
the literature (179, 251). The increase in renal Octn2 expression correlated strongly with 
increases in serum L-carnitine levels suggesting that renal Octn2 plays a significant role 
in the postnatal pattern of serum L-carnitine development. Overall our data suggests the 
developmental changes in hepatic γ-Bbh expression, intestinal Octn1 expression, and 
renal Octn2 expression may systemically contribute to the postnatal increase in serum L-
carnitine levels. However, the precise interconnections of these pathways and their 
overall contribution to L-carnitine homeostasis during development is not known and 
further studies are required to clarify their contributions.  
The distribution of L-carnitine in the body is organ dependent with the highest 
concentration of L-carnitine in the heart (266). In our study, heart L-carnitine levels 
increase during postnatal development and these increases were correlated with 
increased expression of Octn2 in the heart. L-Carnitine has a significant role in energy 
production in neonatal cardiac tissue due to its role in fatty oxidation and the reliance of 
neonatal hearts on fatty acids as the primary energy substrate (184). The dramatic 
increase in fatty acid oxidation rates in early heart development after birth has been 
attributed to an increase in L-carnitine levels (184). Although we observed a significant 
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increase in L-carnitine levels in the heart with advancing age of the neonate, cardiac ATP 
levels remained constant through postnatal development. Interestingly, we found that Cr 
and ADP levels were ontogenically regulated during postnatal development.  The 
significance of such developmental changes is not clear and requires investigation.  
We also evaluated heart Cpt enzyme expression and activity due to the pivotal role 
of these enzymes in heart energy production.  The postnatal increase in both Cpt1b and 
Cpt2 mRNA expression at postnatal day 20 are paralleled by the increases in heart L-
carnitine concentrations. Indeed, Cpt1a and Cpt2 mRNA levels were increased by 
carnitine administration in cell culture systems (267). Thus, the significant increase in 
heart L-carnitine levels at postnatal day 20 may account for the transcriptional 
enhancement of both Cpt1b and Cpt2. Despite these transcriptional increases in Cpt 
enzymes, we observed no significant changes in heart Cpt enzyme activity. Cpt enzyme 
activities have been reported to increase with increasing mitochondrial L-carnitine levels 
(268-270).  Unfortunately, L-carnitine levels in the whole heart tissue rather than in the 
mitochondria were measured in our study.  
 In conclusion, several L-carnitine homeostasis pathways underwent significant 
ontogenesis during postnatal development in the rat. However, the exact relationship 
between these pathways and their contribution to L-carnitine homeostasis during 
development is not completely known and further studies are required to clarify their 
contributions.   Such a clarification is necessary to understand the impact of exogenous 
and endogenous factors on L-carnitine status during development. Nonetheless, this 
systematic evaluation of key pathways in the L-carnitine homeostasis pathway provides 
a basis from which we can conduct further evaluations regarding the effects of 
exogenous and endogenous factors on L-carnitine status during postnatal development 
and possible long-term consequences of any disturbance in the normal ontogeny of these 
pathways.  
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9 Drug-Nutrient Transport Interaction during Ontogeny: The Cefepime L-
Carnitine Example  
 
9.1 Abstract 
Our study investigated the potential for an important in vivo drug-nutrient 
transport interaction in developing neonates using the L-carnitine transporter substrates, 
cefepime and L-carnitine, as proof-of-concept. Rat pups were administered cefepime 
(5mg/kg) twice daily by subcutaneous injection according to different dosing schedules 
(postnatal day 1-4, day 1-8, day 8-11, day 8-20 and day 1-20). Cefepime administration 
significantly reduced serum and heart free L-carnitine levels in groups which started 
treatment early and were of short duration (day 1-4, day 1-8 and day 8-11) (P<0.05). 
Severe degenerative changes in ventricular myocardium were also found in these groups. 
Cefepime treatment also altered the ontogeny of several key mechanisms in the L-
carnitine homeostasis pathway. The qualitative and quantitative changes in levels of γ-
butyrobetaine hydroxylase mRNA and activity, intestinal organic cation/carnitine 
transporter (Octn) mRNA, and renal Octn2 mRNA depended on time and duration of 
cefepime exposure. Despite lower levels of heart L-carnitine in earlier postnatal groups, 
levels of carnitine palmitoyltransferase mRNA and acitivity, heart Octn2 mRNA and 
ATP levels in all treatment groups remained unchanged with cefepime exposure. 
However, changes in other high energy phosphate substrates (ADP, AMP and CrP) were 
noted and reductions in the CrP/ATP ratio were found in rat pups with normal serum L-
carnitine levels. In summary, our data suggest a significant in vivo drug-nutrient 
transport interaction in the developing neonates which can lead to detrimental 
consequences depending on the time and duration of the exposure. In addition, specific 
windows of susceptibility towards a drug nutrient transport interaction may exist during 
postnatal development.   
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9.2 Introduction 
 Nutrient homeostasis pathways and processes governing drug pharmacokinetics 
in neonates undergo ontogenesis. When a drug and nutrient share the same mechanism, a 
significant drug-nutrient interaction during postnatal development could affect the 
ontogeny of these pathways. Neonatal illness often requires a pharmacological 
intervention to reduce the burden of disease-associated morbidity and mortality. 
However, most investigations into drug-nutrient interactions examine the influence of 
nutrients on drug pharmacokinetics and/or pharmcodynamics (239, 271-273).  Despite a 
general acknowledgement that drug use may impact the normal development of the 
physiological system, limited research has examined the long-term consequences of 
pharmacological interventions on the developing neonate, particularly when drugs 
influence nutrient availability in the body (274). 
Early postnatal life represents a period of significant susceptibility to nutritional 
alterations that may affect maturing biochemical and physiological processes with long 
term consequences on individual health (59, 275). Developing individuals can adapt to 
nutritional changes to favor survival (276-277). These nutritional adaptations can be 
subtle or obvious, reversible or irreversible, and transient or permanent depending on 
factors such as the stage of physiological development, duration of nutritional alteration 
and whether the alteration occurs during a critical window of susceptibility (278-279).  
Many nutrients require transporter systems to make them available to the 
physiological system and cellular processes (83, 280-281). During postnatal 
development, nutrient transporters undergo significant ontogenesis that reflects a 
developmental need for nutrients required for growth and metabolism. A number of 
these nutrient transporter systems also mediate drug transfer across epithelial barriers 
and cell membranes (282-283). A requirement for the same transporter system could 
result in potential reversible interactions between a drug and a nutrient that may alter 
nutrient absorption and disposition in the developing individual. At present, no research 
is available on the potential risk of drug-nutrient transporter interactions that cause 
nutritional alterations in the neonates. Yet the magnitude and significance of a putative 
drug-nutrient transporter interaction in a neonatal patient could vary depending on the 
size and duration of a drug exposure and the timing of that exposure during postnatal 
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development. Such factors may lead to different adaptive strategies to optimize nutrient 
homeostasis in a neonate and may consequently lead to significant changes in neonatal 
development especially when the nutrient affected is critical for neonatal development. 
An important question, then, is whether pharmacological interventions in the neonate 
can result in a significant drug-nutrient transporter interaction that alters the maturing 
biochemical and physiological processes involved in drug absorption/disposition 
processes and nutrient homeostasis. 
In a proof-of-concept investigation, we used the conditionally essential nutrient, 
L-carnitine, and the β-lactam antibiotic, cefepime, both known to be substrates for 
carnitine transporters expressed at epithelial barriers and cellular membranes. 
Maintenance of L-carnitine levels is important for normal mitochondrial and endothelial 
functions, crucial for normal neonatal growth and development (245, 257). During 
postnatal life, the major pathways involved in L-carnitine homeostasis undergo 
significant ontogenesis (164, 251, 257). The organic cation/carnitine transporter 2 
(Octn2) is particularly important in the maintenance of L-carnitine homeostasis (55, 179, 
189). The substrate specificity of Octns also includes a variety of therapeutically used 
cationic drugs such as the β-lactam antibiotics (219, 284) . Both in vitro and in vivo 
research has identified significant competitive interactions between such drugs and L-
carnitine (1, 219).  
In acknowledgement of the paucity of information regarding drug-nutrient 
interactions during early postnatal life we used the known L-carnitine and cefepime 
competitive transporter interaction to identify possible alterations in the ontogeny of L-
carnitine homeostasis pathways. We also examined whether the consequences of a drug-
nutrient transporter interaction depends on the timing and duration of drug exposure 
time relative to postnatal maturation. The overall purpose of our study was to provide 
the first experimental evidence of metabolic programming as a result of a significant 
drug-nutrient transporter interaction during postnatal development.  
 
9.3 Materials and Methods 
Animals, Diet, and Chemicals.  Female Sprague-Dawley rats ordered at 
gestation day 16 were obtained from Charles River Canada (St. Constant, PQ) and were 
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housed singly in a temperature and humidity controlled facility (22°C ± 2°C) on a 12-
hour light: dark cycle (0700 h – 1900 h). All rats had free access to food and water 
throughout the study and were allowed a 7-day acclimatization period. All procedures 
were conducted in accordance with the Canadian Council of Animal Care guidelines for 
the care and use of laboratory animals and were approved by the Animal Care and 
Supply Committee of the University of Saskatchewan. Throughout the acclimatization 
period and during the study, rats had available ad libitum a rat diet (Prolab® RMH 3000, 
Purina, Inc., Richmond, IN) (protein % = 22.5; fat, ether extr. % = 4.5; fat, acid hydr. % 
= 6.4; crude fiber % = 4.0; ash % = 6.1; calcium % = 1.0; phosphorous % = 0.75) 
meeting the nutritional requirements for lactating Sprague-Dawley rats. 
Cefepime was purchased from the Royal University Hospital at the University of 
Saskatchewan (Saskatoon, SK). RNeasy Midi kits were obtained from Qiagen Inc. 
(Mississauga, ON). The Advanced Protein Assay kit was obtained from Fluka (Sigma-
Aldrich, MO), QuantiTect SYBR Green RT-PCR kit was purchased from Applied 
Biosystem (Foster City, CA). L-carnitine and other chemicals not otherwise specified 
were obtained from Sigma-Aldrich (St. Louis, MO). 
Chronic Cefepime Administration in Rat Pups.  Cefepime (5 mg) or saline 
(control) was subcutaneously administered to rat pups (n=6 dams per dosing schedule) 
twice daily using the following schedules: 1) postnatal day 1 to day 4; 2) postnatal day 1 
to day 8; 3) postnatal day 1 to day 20; 4) postnatal day 8 to day 11; and 5) postnatal day 
8 to day 20. These dosing schedules considered short-term and long-term cefepime 
treatment and developmental maturation of L-carnitine biosynthesis pathways in rat 
pups (postnatal day 8) (Galland et al., 1999; Huhn et al., 1981). Total body weights were 
recorded daily. At the end of each dosing schedule, blood, heart, intestine, kidney and 
liver were collected. All tissues were snap frozen in liquid nitrogen and stored at -80 ºC. 
Blood and tissues were pooled from 5 pups from each mother such that the dam was 
considered the experimental unit.  
Free L-Carnitine Analysis in Serum and Heart. Serum and heart free L-
carnitine was quantified by HPLC-UV with pre-column derivatization according to Feng 
et al (258). Briefly, the pooled heart samples were homogenized with phosphate buffer 
(50 mM, pH 7.4) in a ratio of 50 mg tissue: 250 µL buffer. The homogenate was 
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centrifuged at 2500×g for 10 min at 4°C. The supernatant or serum (20 μL) sample was 
precipitated using 9:1 acetonitrile: methanol in a 1:9 v/v. A 300 mg mixture of Na2HPO4 
and Ag2O (9:1 wt/wt) and 300 mg of KH2PO4 were added followed by 1 h vortex-
mixing. Derivatization reagent (40 mg/mL ρ-bromophenacyl bromide with 50 μL 40% 
tetrabutylammonium hydroxide solution) was added into the organic extract. The 
reaction mixture was incubated at 60°C for 2 h followed by centrifugation at 12,000×g 
for 15 min. L-Carnitine was analyzed using a Hewlett Packard 1050 HPLC system with 
Diode Array Detector, Quaternary Pump and Autosampler. Samples (10 μL) were 
injected onto a CN (cyano) column (HyperClone 5 µm, 250 × 4.6 mm, Phenomenex, 
Torrance, CA) with detection wavelength set at 260 nm. The mobile phase (90% 
acetonitrile/10% mM citric-phosphate buffer, pH 3) was delivered at a flow rate of 1 
mL/min. The standard curve range was linear (r2 >0.99) between 2.5-40 μmol/L. Intra- 
and interassay accuracy and precision ranged from 6%-14%. 
Total mRNA Isolation and Quantitative RT-PCR Analysis. Total mRNA was 
extracted from different tissues using RNeasy Midi Kits according to manufacturer 
instructions. RNA purity and quantity was determined spectrophotometrically by 
measurement at 260 nm and the OD260/OD280 ratio, respectively, using a Synergy HT 
Multi-Mode Microplate Reader (Biotek instrument, USA). Total RNA was stored at -
80°C until analysis. Gene sequences were obtained from the National Center for 
Biotechnology Information GeneBank (260) and specific primers were designed using 
Primer3 software (261) (Table 9.1). Quantitative RT-PCR (QRT-PCR) analysis was 
carried out using a QuantiTect SYBR Green RT-PCR kit and an Applied Biosystems 
7300 Real-Time PCR system. The QRT-PCR protocol was carried out according to 
manufacturer’s instructions. The protocol consisted of reverse transcription (1 cycle at 
48°C, 30 minutes), PCR initial activation step (1 cycle at 95°C, 15 minutes), three-step 
thermal-cycling (40 cycles; denaturing at 94°C, 15 seconds, annealing at 60°C, 30 
seconds, and primer extension at 60°C for 30 seconds), and a melt curve analysis from 
65°C-95°C at 0.5°C/second. 
Validation of the 2-ΔΔCT Method. Real-time PCR assays were initially optimized 
to give PCR efficiency between 1.9-2.1 (as determined by a 3-point standard curving 
using serial dilutions of control RNA with a slope range of -2.9 to -3.5) and a single 
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melt-peak corresponding to the appropriate PCR product as verified by 2% agarose gel 
electrophoresis. The reactions were further optimized for usage of the 2-ΔΔCT method 
using β-actin as an internal standard. The amplification efficiency of each target and β-
actin was determined by constructing a standard curve from crossing point values (CT) 
and RNA concentration. The target genes and β-actin were then amplified using the 
same diluted samples. The ΔCT were calculated (i.e. the difference between the target 
gene CT and β-actin CT). Only primers giving PCR amplification close to 100% and the 
relative efficiencies between the target and β-actin that were approximately equal were 
used in our experiment (i.e. the slope from log RNA concentration versus ΔCT were 
<0.1). Fold differences in mRNA expression between control and treated samples were 
then calculated. 
 
Table 9.1. Primer sequences for quantitative RT-PCR of all the selected targets 
Primers 
Gene 
Accession 
Number Forward Reverse 
Β-actin NM_031144 Agcgtggctacagcttcacc Tgccacaggattccataccc 
Octn1 NM_022270 Catggctgtgcagactgg Gcaccatgtagccgatgg 
Octn2 NM_019269 Ggcgcaaccacagtatcc Ggggctttccagtcatcc 
Octn3 NM_019723 Gacaccgtgaacctgagc Ccatccaggcagttctcc 
Cpt1b NM_013200   Cagccatgccaccaagatc Aagggccgcacagaatcc 
Cpt2 NM_012930 Gctccgaggcgtttctca Tggccgttgccagatagc 
Bbh NM_022629 Acgatggggcagagtcc Ctggcctcctgagaaaagc 
Octn, organic cation/carnitine transporter 1; Cpt, carnitine palmitoyltransferase 1b; 
Bbh, γ-butyrobetaine hydroxylase. 
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Liver γ-Butyrobetaine Hydroxylase (Bbh) Enzyme Activity. Liver tissue was 
homogenized in homogenization buffer consisting of 300 mM sucrose, 1 mM EGTA, 
and 50 mM Tris, pH 7.5 using 1:4 mass to volume ratio. The homogenate was then 
centrifuged at 13,000×g for 30 min at 4°C. The supernatant was collected and 
centrifuged at 100,000×g for 1h at 4°C. 300 μL of the supernatant representing the 
cytosolic fraction containing Bbh was then transferred into a dialysis tubing cellulose 
membrane (molecular weight cutoff of 12,000Da, D9777, Sigma, USA), and submerged 
in 5 L dialysis buffer (75mM KCl, 0.1mM DTT and 0.5mM EDTA in sodium phosphate 
buffer, pH 7.4) overnight in 4°C. The dialyzed sample (20 μL) was tested for L-carnitine 
residue and the remaining dialysate was stored at -80°C for Bbh testing. The optimal 
protein concentration, substrate concentration and reaction time to give linear product 
formation was determined for each age group. For determination of Bbh activity in rat 
pup liver, 1 mL reaction buffer consisting of 0.2 mM γ-butyrobetaine, 20 mM potassium 
chloride, 3 mM 2-oxoglutarate, 10 mM sodium ascorbate, 0.4 mg/mL catalase in 20 mM 
potassium phosphate buffer pH 7.0 was prepared. The reaction was initiated by adding 2 
µL ferrous ammonium sulfate (133) (final concentration: 0.25 mM) and 20 µL enzyme 
into 78 µL reaction buffer and incubated for 25 min at 37°C using a Boekel/Grant 
Orbital and Reciprocating Water Bath (Model ORS200, Expotech, USA). The reaction 
was then terminated by adding 10X volume of acetonitrile: methanol (9:1). The mixture 
was centrifuged at 13,000×g for 2 min and the supernatant was used for L-carnitine 
analysis by HPLC. 
Heart Carnitine Palmitoyltransferase (Cpt) Enzyme Activities. Heart Cpt 
enzyme activities were measured using the spectrophotometric method described by 
Bieber et al (259). Briefly, frozen heart tissue was homogenized in 10% (wt/v) 
homogenization buffer (20 mM HEPES, 140 mM KCl, 10 mM EDTA and 5 mM MgCl2, 
pH 7.4) supplemented with 3 mg nagarse using Polytron homogenizer (Brinkmann 
Instruments, Rexdale, Canada). The homogenate was then centrifuged at 500×g for 10 
min at 4°C. The supernatant was collected in new tubes and centrifuged at 9000×g for 
35 min at 4°C. The pellet was then washed with the homogenization buffer without 
nagarse and centrifuged at 9000×g for 35 min at 4°C. The washed pellet was 
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resuspended in 200 μL isolation buffer without nagarse. Protein concentrations were 
measured using the Advanced Protein Assay kit with bovine serum albumin as standards. 
The optimal protein concentration and reaction time to give linear product formation 
were initially determined. To determine total Cpt activity 20 µg protein was assayed in 
200 µL ml reaction buffer containing 20 mM HEPES, 1 mM EGTA, 220 mM sucrose, 
40 mM KCl, 0.1 mM 5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB), 1.3 mg/mL BSA, 
and 40 μM palmitoyl-CoA, pH 7.4. The reactions were initiated by adding 1 mM L-
carnitine and read at 412 nm after 5 min incubation at 37ºC using Synergy HT Multi-
Mode Microplate Reader (Biotek instrument, USA). Cpt2 activity was determined using 
the same reaction conditions as total Cpt except 10µL Cpt1 inhibitior, malonyl-CoA, 
was added into 200 μL of the reaction mixtures to obtain a final concentration of 10 μM. 
Cpt1 activity was calculated by subtracting the Cpt2 activity from the total Cpt activity. 
The Cpt activity was calculated as amount of CoASH released per min per mg protein, 
which is based on the 5-thio-2-nitrobenzoate formation from CoASH-DNTB reaction. 
The extinction coefficient for 5-thio-2-nitrobenzoate was 13.6 mM/cm (Alhomida, 2001; 
Yu et al., 2001). 
Heart High Energy Phosphate Substrate Determination. The heart high energy 
phosphate substrate levels including creatine (Cr), creatine phosphate (CrP), ATP, ADP 
and AMP were measured with HPLC-UV method as described by  Olkowski et al., (285). 
The heart samples were homogenized in 0.7 M ice cold perchloric acid (MW 100.46) 
with a final concentration 100 mg/ml. The homogenate was centrifuged at 12,000 rpm 
for 5 minutes. The supernatant was collected and neutralized with 2M potassium 
hydroxide to bring pH near to 7.0. The supernatant was then filtered through 0.45 µm 
filter (Nonsterile Syringe Filter Nylon, Chromatographic Specialties Inc. Brockville, 
Ontario, Canada) and 10 µL was injected into a 3μ Luna C-18 (Phenomenex, Torrance, 
CA) column using gradient flow conditions. Two mobile phase components used 
included 20 mM potassium phosphate buffer (pH 7.0) and 100% methanol. The gradient 
was 100% phosphate buffer from 0–6.5 min, 100% methanol from 6.5–12.5 min, and 
100% phosphate buffer from 12.5 to 25 min for column re-equilibration, which was 
sufficient to achieve stable baseline conditions. The high energy phosphate substrates 
including CrP, Cr, ATP, ADP and AMP were monitored at 210 nm. The standard curve 
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range was from 6.25-100 µg/mL and the limit of detection was 0.078125 µg/mL for ATP 
and 0.3125 µg/mL for ADP and AMP. Intra- and interassay accuracy and precision 
ranged from 4.2% to 14.5%.  
Histopathology of the Heart.  Heart tissue collected in formalin was embedded 
in paraffin. The tissue was then sectioned into 5µm thick and stained with hematoxylin 
and eosin. The histological preparations of hearts (six replications per slide) were 
subjected to detailed microscopic evaluation.  For semi-qualitative analysis, the 
observed lesions were graded according to a priori established standards, taking into 
consideration histopathological features characteristic of cell degeneration such as 
cytoplasmic eosinophilia, chromatin condensation and nuclear pyknosis, spongy 
degeneration of the cytoplasm, cytoplasmic vacuolization, and cariorhexis. The 
assessment of the degree of myocardial changes was based on arbitrarily set criteria as 
follows:  1) ‘No visible lesions’ was assigned when all structures of the myocardial 
tissue appeared morphologically normal, 2) ‘Mild lesions’ was assigned when changes 
were predominantly focal or multifocal, but limited to a very small area of myocardium, 
3)  ‘Moderate lesions’ was assigned when changes were focal, but affecting a large area 
of myocardium, predominantly prominent multifocal, or smaller scale locally extensive, 
an 4)  ‘Severe lesions’ was assigned when changes were multifocal and affecting larger 
areas of the ventricular myocardium, or were predominantly locally extensive.   In order 
to ensure unbiased evaluation, two pathologists examined slides with a double blind 
approach (i.e. neither identity of the subjects nor treatments applied were known to the 
scientists who conducted the evaluation). 
Statistical Analysis. All data are reported as mean ± SEM. All experimental data 
were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). The interactions 
between treatment and duration time for all the selected parameters were assessed by 
2x2 factorial ANOVA using General Linear Model (GLM) multivariate.  Multiple 
comparisons for all the parameters at different ages were analyzed using one way 
ANOVA with Fisher's least significant difference (LSD) as post hoc test. The effects of 
cefepime on rat pups in each duration period were analyzed by one way ANOVA. In 
addition, Pearson's correlation coefficients were computed to quantify the association 
between all the processes involved in maintaining L-carnitine homeostasis (serum free 
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L-carnitine levels) during development. Data used for this purpose include serum L-
carnitine levels, mRNA expression level of kidney Octn2, intestinal Octns, and Bbh 
mRNA expression and activity in control rats from postnatal day 4, day 8, day 11 and 
day 20. 
 
9.4 Results 
Body Weight Gain. Cefepime caused no differences in total body weight gain or 
growth pattern regardless of dosing schedule (P>0.05) (data not shown).  However, 
cefepime did cause changes in various molecular, biochemical and histological markers 
depending upon timing and/or duration of cefepime administration relative to postnatal 
age.  
L-Carnitine Levels. Cefepime caused significant decreases in serum L-carnitine 
levels when rat pups were treated from day 1-4, day 1-8 and day 8-11 (P<0.05) with no 
differences in the other dosing schedule groups (P>0.05) (Figure 9.1A). Cefepime 
caused significant decreases in heart L-carnitine levels when rat pups were treated from 
day 1-8 and day 8-11 (P<0.05) with reduced L-carnitine levels from day 1-4 (P=0.07) 
and no differences in the other groups (P>0.05) (Figure 9.1B).  
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Figure 9.1. Mean ± SEM free L-carnitine levels in serum (A) and heart (B) from rat pups 
treated with saline (white bar) or 5 mg cefepime (black bar) twice a day by subcutaneous 
injection according to different dosing schedules (n=6). Means were compared by one 
way ANOVA with LSD as post hoc analysis; *α= 0.05. 
 81
mRNA Expression Levels of  L-Carnitine Transporters. Cefepime treatment 
caused no difference in heart Octn2 expression (P>0.05) (Table 9.2). Kidney Octn2 
mRNA expression levels were significantly upregulated in treatment groups from day 1-
4, day 8-20 and day1-20 (P<0.05) with no difference in the other groups (P>0.05) (Table 
9.2). The mRNA expression of Octn2 was significantly upregulated in the intestine after 
cefepime treatment from day 8-11 (P<0.05) with no differences in other treatment 
groups (Table 9.2). Cefepime treatment caused significant increase in intestinal Octn1 
mRNA expression levels in treatment groups day 8-11 and day 1-20 (P<0.05) (Table 9.2). 
The mRNA expression levels were also enhanced by cefepime exposure in treatment 
groups day 1-8 and day 1-20 (Table 9.2). 
 
Table 9.2. Mean ± SEM fold differences relative to control in mRNA expression level of 
L-carnitine transporters (Octns) in kidney, heart and intestine, liver Bbh and heart Cpts 
from rat pups treated with 5 mg cefepime or saline (control) twice daily by subcutaneous 
injection according to different dosing schedules (n=6).  
 Day 1-4 Day 1-8 Day 8-11 Day 8-20 Day 1-20 
Kidney Octn2 1.27±0.10* 1.17±0.15 0.98±0.14 2.24±0.37* 1.24±0.05*
Intestinal Octn1 0.99±0.09 0.90±0.09 1.89±0.33* 0.84±0.08 1.80±0.16*
Intestinal Octn2 1.18±0.28 1.06±0.16 1.22±0.10* 1.09±0.17 0.76±0.21 
Intestinal Octn3 1.39±0.50 1.84±0.26* 1.02±0.17 2.21±0.89 1.51±0.12*
Heart Octn2 0.99±0.03 0.88±0.13 0.95±0.14 1.09±0.12 0.92±0.10 
Liver Bbh 1.15±0.56 0.90±0.26 0.89±0.20 0.73±0.22 0.90±0.33 
Heart Cpt1b 1.02±0.17 1.03±0.15 1.34±0.22 1.00±0.13 0.83±0.09 
Heart Cpt2 1.19±0.12 0.97±0.07 1.32±0.16 1.15±0.18 1.10±0.09 
Expression was normalized to ß-actin and fold difference was determined using the 
comparative CT method for relative quantitation. Means between control and cefepime 
treatment were compared using unpaired t-test; *α= 0.05. 
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Liver Bbh and Heart Cpt Enzyme Expression and Activity. Cefepime caused no 
changes in Bbh mRNA expression levels in all treatment groups (P>0.05) (Table 9.2). 
However, Bbh enzyme activities were significantly upregulated in rat pups treated from 
day 8-20 (P<0.05). In addition, Bbh enzyme activities were higher in rat pups treated 
from day 8-11 though the changes were not statistically significant (P=0.06) (Figure 
9.2A). Cefepime caused significant increases in heart Cpt1b mRNA expression levels 
(Table 9.2) and Cpt2 activities in rat pups treated from day 1-20 (P<0.05) with no effect 
on other treatment groups (Figure 9.2B and 9.2C).  
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Figure 9.2. Mean ± SEM activities of liver Bbh (A), heart Cpt1 (B) and heart Cpt2 (C) in 
rat pups treated with saline (white bar) or 5 mg cefepime (black bar) by twice daily 
subcutaneous injection according to different dosing schedules (n=6). Means were 
compared using one way ANOVA with LSD as post hoc analysis; *α= 0.05.  
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Heart High Energy Phosphate Substrate Levels. Heart high energy phosphate 
substrate profiles in rat pups including ATP, ADP, AMP, creatine and creatine phosphate 
were measured (Figure 9.3). Creatine phosphate concentration in the rat hearts was 
reduced by cefepime treatment from postnatal day 8-20 and day 1-20 (P<0.05). ADP 
levels were significantly increased in treatment group postnatal day 1-8 (P<0.05) with 
some increase in day 8-20 (P=0.08) and day 1-20 (P=0.08). In addition, AMP levels 
were significantly increased in treatment group postnatal day 1-8 but decreased in 
treatment group day 1-20 (P<0.05). The ratio between CrP and ATP (CrP/ATP ratio) 
were significantly reduced in treatment group postnatal day 8-20 and day 1-20 (P<0.05). 
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Figure 9.3. Heart high energy phosphate substrate profiles in rat pups treated with saline 
(white bar) or 5 mg cefepime (dark grey bar) twice daily by subcutaneous injection 
according to different dosing schedules (n=6). A) creatine phosphate; B) creatine; C) 
ATP; D) ADP; E) AMP; F)CrP/ATP ratio. Means were compared with one way ANOVA 
with LSD as post hoc analysis; *α= 0.05. 
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Histological Analysis.  The heart specimens from both control and treated 
animals showed some pathological changes indicative of myocardial tissue degeneration. 
However, the lesions were more severe in myocardium of rat pups treated with cefepime 
from day 1-4, day 1-8 and day 8-11 with similar lesions in rat pups treated from day 8-
20 and day 1-20 (Table 9.3). Representative examples of severe changes are shown in 
Figure 9.4.  Noteworthy are early degenerative changes marked by cytoplasmic 
eosinophilia and nuclear pyknosis (black arrows). The affected cardiomyocytes had a 
distinct dull dark pink appearance, and had lost their typical striation pattern.  Some 
cardiac cells showed aggregation of the nuclei. A more advanced pathological process in 
the cardiomyocytes was evidenced by cariorhexis (blue arrows). Many cells showed 
spongy degeneration of the cytoplasm, and in some instances cytoplasmic vacuolization 
was prominent (red arrows). The myocardial syncytium was punctuated by clear spaces 
between the myofibers and interstitial edema was present in some areas. Cardiomyocyte 
dropout was evident in more severely affected areas (green arrows) (Figure 9.4).        
Correlation Analysis. Most of the L-carnitine homeostasis pathways and high 
energy phosphate substrates were ontogenically regulated (P<0.05) except liver Bbh 
mRNA expression, heart CrP levels and heart Cpt2 activities in control animals (P>0.05) 
(Table 9.4). Cefepime treatment changed the maturation patterns of intestinal Octn2 and 
Octn3 mRNA expression levels, concentrations of CrP, ATP and AMP, and Cpt1 
activities (P>0.05) (Table 9.4).   
 Interactions between Treatment and Duration Time. There were significant 
interactions between treatment and duration times on the serum L-carnitine levels, liver 
Bbh activities and heart AMP levels (P<0.05). 
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Table 9.3. Mean ± SEM scores of cardiac lesions in rat pups treated with saline (Control) 
or 5 mg cefepime (Treated) by twice daily subcutaneous injection according to different 
dosing schedules (n=6).  
 Day 1-4 Day 1-8 Day 8-11 Day 8-20 Day 1-20 
Control 1.7±0.5 2.2±0.3 1.2±0.4 1.3±0.4 1.0±0.5 
Treated 2.5±0.3 2.8±0.2 2.2±0.3 1.2±0.4 0.3±0.3 
P value 0.240 0.132 0.093 0.937 0.394 
Means between control and cefepime treatment were compared using Mann Whitney 
test; *α= 0.05.  The histopathological score scheme used in this study was: No visible 
lesion: 0; Mild lesion: 1; Moderate lesion: 2; and Severe lesion: 3.  
 
 
Figure 9.4. Representative histopathological features of the mural ventricular 
myocardium of rat pup heart (the specimen is from rat pup treated with cefepime from 
day 1-8).  The significance of the arrows and arrowheads is described in the results 
section of the text (original magnification 400x). 
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Table 9.4. Pearson's correlation coefficients between postnatal ages and all parameters 
assessed in rat pups treated with saline (Control) or 5mg cefepime (Treated) by twice 
daily subcutaneous injection (rat pups were from day 4, day 8, day 11 (n=6 for each age) 
and day 20 (n=12).   
Control Animals Treated Animals 
Parameters 
Pearson Correlation 
Coefficient P value 
Pearson Correlation 
Coefficient P value 
Serum L-carnitine 0.642 0.000 0.861 P<0.0001
Heart L-carnitine 0.840 P<0.0001 0.846 P<0.0001
Kidney Octn2 mRNA 0.369 0.045 0.665 P<0.0001
Heart Octn2 mRNA 0.827 P<0.0001 0.879 P<0.0001
Intestinal Octn1 mRNA 0.305 0.101 0.370 0.044 
Intestinal Octn2 mRNA -0.465 0.010 0.083 0.663 
Intestinal Octn3 mRNA 0.803 P<0.0001 0.098 0.608 
Liver Bbh activities 0.417 0.022 0.707 P<0.0001
Liver Bbh mRNA 0.034 0.857 0.387 0.035 
CrP 0.248 0.186 -0.168 0.375 
Cr 0.956 P<0.0001 0.956 P<0.0001
ATP  0.421 0.021 0.358 0.052 
ADP 0.533 0.002 0.419 0.021 
AMP 0.415 0.023 0.093 0.627 
Cpt1 activities 0.564 0.001 0.268 0.152 
Cpt2 activities  0.086 0.653 0.603 0.000 
Heart Cpt1b mRNA 0.692 P<0.0001 0.382 0.037 
Heart Cpt2 mRNA 0.838 P<0.0001 0.901 P<0.0001
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9.5 Discussion 
Neonates can be exposed to drugs therapeutically and through secondary 
exposure (eg. via breast milk). When drug exposures are intentional, dosage regimens 
consider the developmental changes in drug pharmacokinetic processes in pediatric 
patients with dosage adjustments made according to maturation of enzymes and 
transporters involved in drug absorption and disposition (286). Some of these 
pharmacokinetic processes that undergo developmental maturation are also utilized by 
various nutrients in the body. In particular, a variety of transporters have been identified 
as having substrate specificities that include both nutrients and therapeutically used 
drugs  (282).  Thus, co-administration of a drug may cause a functional interaction with 
the transporters responsible for nutrient absorption and/or disposition. Knowing that the 
body may adapt strategies to maintain optimal nutrient homeostasis in the face of 
nutritional imbalance (287-288), such an interaction has the potential to change nutrient 
homeostasis pathways in developing neonates.  If the interaction occurs during a 
susceptible window of vulnerability the interaction may result in metabolic 
programming of the nutrient homeostasis pathway(s), the consequences of which may 
impact an individual’s risk for development of disease (33).  
The present study used the conditionally essential nutrient, L-carnitine, and a 
known inhibitor of L-carnitine transport, cefepime, to examine possible alterations in the 
ontogeny of L-carnitine homeostasis pathways. This study demonstrated that cefepime 
administration altered L-carnitine homeostasis pathways in neonatal rats. Of particular 
note was the dependence upon duration and timing of exposure relative to postnatal 
development on the qualitative and quantitative changes observed with cefepime 
exposure. Serum and heart free L-carnitine levels were reduced in groups which started 
treatment early and lasted shorter (day 1-4, day 1-8 and day 8-11).  In contrast, L-
carnitine levels remained within developmentally normal levels when rat neonates were 
treated with cefepime until weaning (day 1-20, and day 8-20) (Figure 9.1). Since L-
carnitine is an obligatory nutrient for neonatal development, reduced levels early in 
postnatal development as a result of the cefepime-L-carnitine interaction may pose a 
detrimental risk to the neonates. The literature has drawn an association between 
reductions in L-carnitine levels and development of cardiac hypertrophy and eventually 
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cardiomyopathy (289). In our study, histopathological examinations revealed severe 
degenerative changes in ventricular myocardium in the groups with reduced L-carnitine 
levels. Although minor histopathological changes were identified in groups with normal 
free L-carnitine blood levels and rats pups treated with saline, these changes were likely 
attributed to the stress of twice daily injections. The severe degenerative changes in the 
younger neonates with reduced L-carnitine levels may eventually lead to compromised 
heart function and a predisposition to cardiovascular disease in later life. 
When alterations in nutrient availability occur, the body may have a variety of 
adaptive responses to maintain nutrient homeostasis. L-Carnitine homeostasis is 
maintained primarily through endogenous biosynthesis in the liver, exogenous dietary 
sources, and renal reabsorption of filtered L-carnitine (180).  Transporters mediate both 
the gastrointestinal absorption and active reabsorption of L-carnitine from the urinary 
filtrate and such transporters account for more than 75% of body L-carnitine (174). In 
the adult, renal L-carnitine transport systems are known to rapidly adapt to dietary L-
carnitine levels through modifications in L-carnitine reabsorption efficiency at the 
kidneys (290).  Our results suggest that neonates also have the capacity to adjust their 
renal L-carnitine reabsorption by changing Octn2 expression levels, the principle 
transporter involved in the active reabsorption of L-carnitine from the urinary filtrate 
(179). Renal Octn2 mRNA expression was highly upregualted in the rat pups 
demonstrating normal L-carnitine levels despite cefepime treatment (day 8-20 and day 
1-20) (Table 9.2). Since Octn2 accounts for more than 95% of L-carnitine reabsorption 
from the filtrate (179), the increase in Octn2 expression may significantly contribute to 
the maintenance of L-carnitine levels in these two groups despite competitive 
interactions with cefepime at renal Octn2.  
Duration of treatment also seemed to influence the extent to which renal Octn2 
expression increased with cefepime treatment. Limited or no changes in expression was 
observed with short-term cefepime treatment. Although renal Octn2 mRNA expression 
was also increased in treatment group postnatal day 1-4, the enhanced expression was 
not adequate to assure sufficient reabsorption of L-carnitine in the presence of a 
competitive interaction with cefepime since serum L-carnitine levels were reduced.  
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In addition to renal Octn2, cefepime also influenced intestinal Octn expression, 
but the qualitative and quantitative changes varied depending on the treatment schedules. 
Alterations in intestinal Octn expression may be the result of an adaptive response to 
altered L-carnitine levels following a competitive interaction with cefepime. Intestinal 
transporters are known to undergo adaptive regulation according to nutrient status (291-
293) . Although a competitive interaction at gastrointestinal L-carnitine transporters in 
rat pups is unlikely following subcutaneous administration, a competitive interaction a 
renal reabsorption mechanisms may lead to reduced L-carnitine levels and a need to 
alter intestinal L-carnitine transporters in response to altered L-carnitine status. 
Interestingly, cefepime administration did not influence heart Octn2 expression in any of 
the postnatal groups evaluated. These data suggest that regulation of heart Octn2 
expression is refractory to the interaction between cefepime and L-carnitine unlike 
Octn2 expression in the kidney and intestine.  
Endogenous biosynthesis of L-carnitine, particularly by the liver, accounts for 
25% of L-carnitine in the adult. However, immaturity of hepatic γ-butyrobetaine 
hydroxylase (Bbh) activity at birth limits the ability of neonates to biosynthesize L-
carnitine. In the rat, Bbh activity reaches adult capacity by postnatal day 8 (257). 
Interestingly, our study demonstrated that hepatic Bbh activity was affected only when 
cefepime treatment was instituted after Bbh maturation (i.e. day 8). Enhancements in 
Bbh activity in treatment groups postnatal day 8-20 (P<0.05) and day 8-11 (P=0.06) may 
be an adaptive response to compensate for the loss of L-carnitine in the body via 
competitive interactions at renal Octn2. Cefepime exposure did not alter Bbh maturation 
when treatment was initiated in early postnatal life. These observations may suggest that 
the maturation of hepatic Bbh activity is genetically programmed and may not be 
influenced by either internal (i.e. L-carnitine concentration) or external factors (i.e. 
cefepime exposure). This phenomenon has been noted for other nutrient homeostasis 
pathways, such as in the case of age related changes in monosaccharide uptake rate, 
which undergoes genetically programmed maturation and is only slightly influenced by 
dietary manipulations (294).  
L-Carnitine plays an obligate role in energy production as it facilitates the 
transport of long chain fatty acids across the mitochondrial membrane making them 
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available for β-oxidation (174, 295). Tissues with low L-carnitine levels often have low 
fatty acid oxidation rates (296). Despite reductions in serum and heart L-carnitine levels 
in some treatment groups in our study, Cpt activity and heart Octn2 expression was not 
altered and cefepime exposure did not influence ATP levels in rat pup hearts. However, 
alterations in other high energy phosphate substrates including ADP, AMP and CrP were 
observed depending on the treatment schedules. Unfortunately, the specific 
interrelationships between the changes in these high energy phosphate substrates are 
difficult to rationalize in our study. However, we did identify significant decreases in 
CrP and the CrP/ATP ratios in treatment groups with normal L-carnitine levels (Day 8-
20 and day 1-20).  These findings are significant because both the loss of creatine 
phosphate and the reduction in the ratio of CrP/ATP has been associated with several 
pathological conditions in animals (297).  Moreover, the reduction of CrP/ATP ratios has 
been used as a predictor of mortality for patients with dilated cardiomyopathy (298), 
which is a typical symptom of L-carnitine deficiency (206). The decreased CrP levels 
and CrP/ATP ratios may be early signs of heart dysfunction in these cefepime treated 
animals despite the fact that serum and heart L-carnitine levels were maintained in the 
normal range.  
For many physiological and biochemical processes, considerable maturation of 
these processes continues throughout neonatal development (163). In the rat, many 
components involved in the L-carnitine homeostasis pathway undergo significant 
ontogeny in the period from birth to weaning (Chapter 8). In this study, treatment of rat 
pups with cefepime, a known inhibitor of L-carnitine transport, altered various L-
carnitine homeostasis mechanisms during postnatal development. The qualitative and 
quantitative changes in these pathways depended upon when during postnatal 
development the neonate was exposed to the drug, as well as to the duration of the 
exposure. However, despite compensatory changes in renal and intestinal L-carnitine 
transport systems, rat pups treated at postnatal day 1-4, 1-8 and 8-11 could not maintain 
serum and heart L-carnitine concentrations at levels associated with their untreated 
counterparts. As well, these pups showed more severe histopathological changes in the 
heart relative to their untreated counterparts and to older treated pups. These data 
suggest that although young neonates have the ability to mount an adaptive response to 
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exogenous factors that influence nutrient status, this adaptive response may not be 
sufficient depending upon the magnitude of the environmental insult. Our data also 
generally showed that neonates exposed to cefepime later in postnatal development or 
throughout the postnatal period seemed to mount an adaptive response that was 
sufficient to maintain serum and tissue L-carnitine levels and prevent pathological 
changes in the heart.  
In conclusion, our study, which was premised on the known competitive 
interaction between cefepime and L-carnitine at L-carnitine transporter systems, 
demonstrated that cefepime administration to neonatal rat pups caused significant 
alterations in the ontogenesis of several mechanisms involved in the L-carnitine 
homeostasis pathway. These alterations likely represented adaptive responses to 
cefepime-induced alteration in L-carnitine status. The qualitative and quantitative 
changes in these L-carnitine homeostasis pathways seemed to depend upon duration and 
timing of exposure relative to postnatal maturation, but whether these changes are 
permanent are unknown. Future studies are planned to assess the potential for metabolic 
programming of L-carnitine homeostasis mechanisms following a cefepime-L-carnitine 
transport interaction and the long-term consequences of this interaction on the risk for 
disease later in life. Nonetheless, our findings could have major implications with 
respect to drug treatment of paediatric patients, particularly young neonates, and 
highlights a potential need for nutritional interventions during drug therapy in this 
population.  
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10 Lipopolysaccharide and Lipoteichoic Acid Differentially Alter Glucose, Fatty 
Acid and Carnitine Transporter Expression in MCF12A Cells 
 
10.1 Abstract  
We investigated whether gram-positive (Lipotechoic acid, LTA) and gram-
negative (Lipopolysaccharide, LPS) bacterial inflammatory stimuli differentially affect 
glucose, fatty acid and carnitine transporter expression in human mammary epithelial 
cells. MCF12A cells were incubated with 1μg/mL LPS or LTA for 6 or 12 hours and 
expression of tumor necrosis factor-α (TNF-α), organic cation/carnitine transporters 
(OCTN1, OCTN2), facilitated glucose transporters (GLUT1, GLUT8) sodium 
dependent glucose transporter 1 (SGLT1), fatty acid transporters (FATP1, FATP4), and 
fatty acid binding protein 3 (FABP3) was measured using Quantitative RT-PCR. We 
quantified high-energy phosphate substrates (ATP, ADP, AMP) by HPLC and oxygen 
consumption rates using the Hansatech oxygen electrode. LPS decreased expression of 
OCTN1, OCTN2, FATP1, and FABP3, but increased GLUT1, GLUT8 and SGLT1 
expression after 6 hours. Transporter expression returned to control levels or exceeded 
control (OCTN2, GLUT1, FATP1, FABP3) after 12 hours. LTA caused limited changes 
with 6 hour exposure but significantly downregulated GLUT1, GLUT8 and SGLT1 and 
upregulated OCTN1, FATP1 and FABP3 expression after 12 hours. ATP, ADP, and AMP 
levels were unaltered; however, LTA significantly decreased oxygen consumption rates 
after 12 hours. LPS and LTA exposure caused qualitative and quantitative differences in 
the time course and expression of glucose, fatty acid, and L-carnitine transporters in 
MCF12A cells. Whether changes in transporter expression levels lead to differences in 
substrate availability to support cellular energy metabolism and/or synthesis of milk 
constituents warrants further investigation. The time-dependent and reciprocal regulation 
of glucose transporters relative to carnitine and fatty acid transporters also warrant 
investigation. 
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10.2 Introduction 
Mastitis is a common condition of breastfeeding mothers (137, 299-300) with 
reported incidence rates of up to 33% in the United States (Barbosa-Cesnik et al., 2003; 
Betzold, 2007). Infective mastitis represents an important cause of inflammation of the 
mammary gland (301) and typically follows from infections with Escherichia coli 
(gram-negative) and Staphylococcus aureus (gram positive) (302-303). These pathogens 
elicit different pathophysiological outcomes in the mammary gland. Infection induced 
by Escherichia coli is usually acute with extensive damage, but usually resolves within a 
few days (304). On the other hand, Staphylococcus aureus infections may result in a less 
severe, but chronic and persistent condition (141).  
Much research into infective mastitis has focused on the immunological factors 
that lead to pathogenesis and recovery of the mammary gland from infection. 
Interestingly, investigations involving other epithelial barriers are uncovering a role for 
insufficient epithelial cell energy metabolism resulting from decreased availability and 
utilization of preferred energy substrates as an underlying cause for the pathogenesis of 
chronic inflammation (305-306). Carbohydrate and lipid are the principal fuels for 
cellular energy production (307) and these energy substrates gain access to the epithelial 
cells via transporter systems (76).  
During lactation, enhanced ATP generation is necessary to satisfy the energy 
requirements for milk synthesis and secretion in the mammary gland (308). Principally, 
glucose and, in part, fatty acids are the major energy substrates for ATP production (113, 
308-310). In the lactating mammary gland, transporters play a decisive role in making 
available the substrates that support mammary epithelial cell energy metabolism, 
synthetic functions, and various milk components (i.e. lactose, fat, micronutrients) (2, 76, 
311). The lactating mammary gland expresses a variety of transporters (76, 83, 95, 234), 
but our understanding of the influence of exogenous and endogenous factors on their 
function is limited. 
As the principal substrate for ATP generation and synthesis of various milk 
components, the lactating mammary gland requires the transport of free glucose into the 
epithelium (312). Two different types of glucose transporter families mediate glucose 
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uptake and transfer across epithelial barriers: facilitative glucose transporters (GLUTs) 
and sodium dependent glucose transporters (SGLTs) (75, 85). Both GLUT1 and SGLT1 
are expressed in lactating human mammary epithelial cells (84, 313) with GLUT1 
accounting for a significant portion of mammary gland glucose transport (309, 313). In 
addition, GLUT8 was also identified in lactating bovine mammary gland as a high-
affinity glucose transporter with moderate expression (85, 314). Free fatty acid 
availability in the lactating mammary epithelium depends on both de novo biosynthesis 
and uptake from maternal circulation (116). Fatty acid uptake pathways include the fatty 
acid binding proteins (FABPs) located in the plasma membrane, fatty acid translocators 
and fatty acid transport proteins (FATPs) (86, 315). FABP3 is the most abundant isoform 
in the bovine mammary gland (316), and though limited information is available on the 
expression of FATPs in the human mammary gland, the human term placenta expresses 
both FATP1 and FATP4 (317). In addition to glucose and fatty acids in ATP generation 
in epithelial barriers, L-carnitine has critical importance in fatty acid oxidation (318). 
The lactating mammary gland expresses two members of the organic cation/carnitine 
transporter family, OCTN1 and OCTN2, which contribute to the transport of L-carnitine 
into the epithelial cell (1, 83).  
Clearly, changes in such transporter levels with inflammation may affect energy 
substrate availability to the lactating mammary gland. Investigations undertaken with 
other organ systems or cell types have uncovered intriguing data that suggests 
inflammation alters transporter expression profiles thereby modulating substrate 
availability to these tissues (147-148, 319-325). Some studies even correlate 
inflammation-mediated alteration in transporter expression and activity to organ 
dysfunction. For example, inflammation downregulates renal tubule glucose transporters, 
which leads to glucosuria and acute renal failure (148).  In the intestine, inflammation 
decreases L-carnitine transport with reductions in fatty acid oxidation and concomitant 
loss of mucosal cell number, compromised barrier function, and mucosal ulceration 
(326-327).  Such data suggests inflammatory stimuli may alter the expression of such 
energy substrate transporters in the mammary gland, which, in turn, may affect substrate 
availability, cellular metabolism, and biosynthetic capacity in the mammary epithelium.  
In this study, we investigated the influence of inflammatory stimuli on the 
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expression of critical energy substrate transporters of human mammary epithelial cells 
(GLUT1 and 4, SGLT1, FATP1 and 4, FABP3 and OCTN1 and 2). We used 
lipopolysaccharide (LPS) and lipoteichoic acid (LTA) as two widely applied model 
bacterial challenges of mammalian cells (131) to explore the possible differential effects 
of gram positive and gram negative bacterial stimuli on mRNA expression levels of 
these transporters. Since the origin of the infectious stimulus is known to cause different 
pathophysiological outcomes in the mammary gland, this comparison was necessary to 
support future investigations into whether differential changes in transporter expression 
profiles could contribute to the different clinical presentations of mastitis caused by 
gram negative and gram positive pathogens. Finally, quantification of high energy 
phosphate substrates (ATP, ADP, and AMP) and oxygen consumption rates accompanied 
the expression analysis to provide functional measures of the consequences of altered 
transporter expression profiles on cellular energy metabolism. 
 
10.3 Materials and Methods 
Chemicals, Reagents and Supplies. Falcon tissue culture flasks (T-75), bottle-
top filters (0.2 μm), and sterile polystyrene 12-cell culture dishes were purchased from 
VWR (Mississauga, ON, Canada). ATP, ADP, and AMP were purchased from Sigma-
Aldrich Ltd. (Oakville, ON, Canada). CellTiter-Glo® Luminescent Cell Viability Assay 
kit was obtained from Promega (Promega, WI, USA). All other chemicals and solvents 
were of the highest analytical grade. All water solutions were made from high quality 
water processed by steam distillation followed by particle absorption, ionic exchange 
and bacterial filtration by a Milli-Q Synthesis Water System (Millipore, MA, USA). 
Cell Culture and LPS/LTA Treatment. The human mammary epithelial cell line 
(MCF12A) was purchased from American Type Culture Collection (ATCC, Rockville, 
MD) at passage 52. The cells were cultured, as specified by ATCC, in a 1:1 mixture of 
Dulbecco's modified Eagle's medium and Ham's F12 medium with 5% horse serum, 
supplemented with 20 ng/mL human epidermal growth factor, 100 ng/mL cholera toxin, 
0.01 mg/mL bovine insulin and 500 ng/mL hydrocortisone. The cells were maintained 
under an atmosphere of 95% air-5% CO2 at 37°C. Media was changed every 2–3 days. 
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MCF12A cells were grown in T-75 cell culture flasks and passaged once before 
LPS/LTA challenge experiments (passage 54). Three experiments on different occasions 
were conducted using the same cell source. Cells were plated in triplicate on 12-well cell 
culture plates and grown to 70-80% confluence. Optimal LPS/LTA dose and exposure 
times were experimentally determined according to cell viability and cytokine TNF-α 
mRNA expression levels. Cells treated with 1 µg/mL LPS and LTA for 6 and 12 hours 
were used in the quantitative RT-PCR assay experiments. Cells treated with 1 µg/mL 
LPS and LTA for 24 hours were used for cellular measurements of high energy 
phosphate compounds and oxygen consumption rate. Cell viability was assessed in 96-
well plate format by using Promega CellTiter-Glo® Luminescent Cell Viability Assay kit 
following the manufacturer’s instruction.  All the experiments were performed in 
triplicate under three different occasions.  
Total mRNA Isolation and Quantitative RT-PCR Analysis. Total mRNA was 
extracted from MCF12A cells using RNeasy Midi Kits (Qiagen Inc., Mississauga, ON) 
according to manufacturer instructions. RNA purity and quantity was determined 
spectrophotometrically by measurement at 260 nm and the OD260/OD280 ratio, 
respectively, with a UV/VIS spectrophotometer (8453E, Agilent Technologies, Palo Alto, 
CA). Total RNA was stored at -80°C until analysis. Gene sequences for each transporter 
were obtained from the National Center for Biotechnology Information GeneBank (260)  
and specific primers were designed using Primer3 software (261) (Table 10.1). 
Quantitative RT-PCR (QRT-PCR) analysis was carried out using a QuantiTect SYBR 
Green RT-PCR kit (Applied Biosystems, Foster City, CA) and an Applied Biosystems 
7300 Real-Time PCR system. The QRT-PCR protocol was carried out according to 
manufacturer’s instructions. The protocol consisted of reverse transcription (1 cycle at 
48°C, 30 minutes), PCR initial activation step (1 cycle at 95°C, 15 minutes), three-step 
thermal-cycling (50 cycles; denaturing at 94°C, 15 seconds, annealing at 60°C, 30 
seconds, and primer extension at 60°C for 30 seconds), and a melt curve analysis from 
65°C-95°C at 0.5°C/second.  
Validation of the 2-ΔΔCT Method. Real-time PCR assays were initially optimized 
to give PCR efficiency between 1.9-2.1 (as determined by a 3-point standard curving 
using serial dilutions of control RNA with a slope range of -2.9 to -3.5) and a single 
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melt-peak corresponding to the appropriate PCR product as verified by 2% agarose gel 
electrophoresis. The reactions were further optimized for usage of the 2-ΔΔCT method 
using β-actin as an internal standard. The amplification efficiency of each target and β-
actin was determined by constructing a standard curve from CT and RNA concentration. 
The target genes and β-actin were then amplified using same diluted samples. The ΔCT 
were calculated (i.e. the difference between the target gene CT and β-actin CT). The 
slope from log RNA concentration versus The ΔCT was close to zero (<0.1). Only 
primers giving PCR amplification close to 100% and the relative efficiencies between 
the target and β-actin that were approximately equal were used in our experiment. Fold 
differences in mRNA expression between control and treated samples were then 
calculated. 
High Energy Phosphate Compound Measurement. High-energy phosphate 
substrate levels including ATP, ADP and AMP were measured with HPLC-UV method 
as described by Olkowski et al., (285). Briefly, MCF12A cells were quickly washed with 
1 mL PBS twice after a 24 h exposure to LPS, LTA, or vehicle. To each well, 0.35 mL of 
0.7 M ice cold perchloric acid (MW 100.46) was added and cells were detached from the 
plate by using a cell scrubber. The mixture was then homogenized and centrifuged at 
12,000 rpm in an Eppendorf microcentrifuge (Model 5417 C, Brinkman instruments, 
Westbury, NY, USA) for 5 minutes. The supernatant was collected and neutralized with 
2 M potassium hydroxide to bring the pH to 7.0. The supernatant was then filtered 
through 0.45 µm filter (ChromSpec, Brockville, Ontario, Canada) and 10 µL was 
injected onto a HPLC analytical column (150×4.5 mm, 3 μ Luna ODS3, Phenomenex, 
Torrance, CA) using a gradient system. The mobile phase was 20 mM KH2PO4/K2HPO4 
buffer adjusted to pH 7.0 and methanol with the gradient set at 100% phosphate buffer 
from 0 to 6.5 min, 100% methanol from 6.5–12.5 min, and 100% phosphate buffer from 
12.5 to 25 min for column re-equilibration. The mobile phase was delivered at a rate of 1 
mL/min and detection was performed at 210 nm. The HPLC system consisted of Agilent 
1200 series quaternary pump (G1311A), standard and preparative autosampler 
(G1329A), and diode array and multiple wavelength detector (G1315D) (Agilent, USA). 
Calibration curves were constructed from known concentrations of 0.625 to 20 
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µg/mL for ATP, 1.56 to 50µg/mL for ADP and 3.125 to 100 µg/mL for AMP standard 
solution in blank cell homogenate. The calibration standards were diluted with PBS to 
achieve calibration standards in a total volume of 1 mL. Three quality control (QC) 
samples at 16, 4 and 1 µg/mL for ATP, 40, 10 and 2 µg/mL for ADP and 80, 20 and 5 
µg/mL for AMP were prepared independent of those used for the calibration curves. The 
mixtures were extracted using the same method as the samples. Concentration of the 
high energy phosphate substrates were calculated by interpolation from the linear 
calibration curve using external standards. Intra- and interday accuracy and precision 
was <15% for all analytes. 
Oxygen Consumption Rate. After 24 h LPS/LTA treatment, cell viability was 
assessed by Trypan blue exclusion and MCF12A cells were re-suspended in freshly 
prepared growth media at 5 x 106 cells/mL. The oxygen consumption rates were 
measured at 37°C using the Hansatech oxygen electrode (Hansatech Instruments Ltd, 
UK) with cell free media as blank. Oxygen consumption rates were obtained by 
measuring the oxygen concentration in a closed chamber over time and finding the slope 
that resulted in a linear plot. Oxygen consumption rates were expressed as 
nmole/min/106cells.  
Statistics. All data are reported as Mean ± SEM. All experimental data were 
analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). The mRNA expression levels 
of various transporters after LPS or LTA treatment were compared to control using 
unpaired t-test. Multiple comparisons for fold difference caused by LPS or LTA with 
different incubation time for each target gene were analyzed using one way ANOVA 
with Tukey's Multiple Comparison Test. Means of ATP, ADP, AMP concentrations and 
oxygen consumption rate in MCF12A cells treated with LPS or LTA were compared 
separately with control using paired t-test. Significance level was set at α = 0.05. 
 
10.4 Results 
To determine a noncytotoxic concentration of LPS and LTA, MCF12A cells were 
incubated with increasing concentrations of LPS/LTA for 24 hours. LPS caused a 
concentration-dependent decrease in MCF12A viability, while Lipoteichoic acid (LTA) 
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had limited effects (Figure 10.1). Cell viability remained >95 % at 1 μg/mL LPS and 
LTA, and this concentration was used for all remaining experiments. TNF-α mRNA 
expression levels were assessed to ensure that 1 μg/mL LPS and LTA was sufficient to 
elicit an immune response in MCF12A cells. LPS stimulated a rapid increase in TNF-α 
expression with expression levels highest at 6 h and declined by 12 h exposure (Table 
10.2). On the other hand, LTA induced a delayed response with TNF-α expression levels 
significantly higher than control only after 12 h duration of exposure (Table 10.2).  
Both LPS and LTA caused time-dependent changes in mRNA expression levels 
of selected transporters (Table 10.2). LPS significantly downregulated the mRNA 
expression of OCTN1, OCTN2, FATP1, and FABP3 relative to control, but upregulated 
GLUT1, GLUT8 and SGLT1 in MCF12A cells after 6 hours of incubation (P<0.05). 
Transporter expression generally returned to control levels or exceeded control (OCTN2, 
GLUT1, FATP1, and FABP3) after 12 hour incubation (P<0.05). Incubation with LPS 
for 6 or 12 h had minimal effect on the expression levels of FATP4. LTA caused limited 
changes in transporter expression after 6 hours of incubation except for slight decreases 
in GLUT1, GLUT8 and SGLT1 expression. After 12 hours of exposure, LTA 
significantly downregulated the mRNA expression levels of GLUT1, GLUT8 and 
SGLT1 but upregulated OCTN1, FATP1 and FABP3 expression (P<0.05).  
Furthermore, the fold differences in transporter mRNA expression levels caused 
by LPS or LTA treatment were compared (Table 10.2). After 6 hours of incubation, the 
LPS-induced changes in OCTN1, GLUT1, GLUT8, SGLT1 and FATP1 expression 
levels were significantly different from LTA (P<0.05). At 12 h, the FD in OCTN2, 
GLUT1 and GLUT8 expression caused by LPS were significantly different from LTA 
treatment (P<0.05).  
To determine whether altered transporter expression levels with LPS and LTA 
treatment altered energy balance in MCF12A cells, the concentration of high energy 
phosphate substrates, ATP, ADP and AMP, and the oxygen consumption rates (OCR) in 
MCF12A cells after 24 hours LPS or LTA exposure were measured. Both LPS and LTA 
failed to change ATP, ADP, and AMP levels in the MCF12A cells. However, LTA caused 
a significant decrease in OCR in MCF12A cells (P<0.05) (Figure 10.2).  
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Table 10.1. Primer sequences for quantitative RT-PCR of L-carnitine, glucose, and fatty 
acid transporters in MCF12A cells.  
Primer Sequences 
Gene 
Accession 
Number Forward Reverse 
OCTN1 NM_003059 ggcgcaacaacagtgtcc ctgaactcccagccatcc 
OCTN2 AB015050 Gtcacggctgccttttcc ggatggctgtcaggatgg 
GLUT1 NM_006516 accgcaacgaggagaacc ccacagcgatgaggatgg 
GLUT8 NM_014580 Cactcagcttcggcttcg acggagcacagcaagagg 
SGLT1 NM_000343 gcgctaaggccctgatctt ggcagtagaggcctccttca 
FATP1 NM_198580 cactcggtgtgggttttgct tgtgtgtttttagggtgagaatgtc 
FABP3 NM_004102 Gtgtgggaatcacgatgg ctgtgctcacacgacagc 
FATP4 NM_005094 Catgcggcccaacga cgattcccacgatgtttcct 
TNFα NM_000594 Cggtgcttgttcctcagc  cttgtcactcggggttcg 
FABP, Fatty Acid Binding Protein; FATP, Fatty Acid Transport Protein; GLUT, 
Sodium-Independent Glucose Transporter; OCTN, Organic Cation/Carnitine 
Transporter; SGLT, Sodium-Dependent Glucose Transporter 1; TNFα, Tissue 
Necrosis Factor-Alpha.  
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Table 10.2. Mean ± SEM fold difference relative to control in mRNA expression levels 
of various transporters in MCF12A cells incubated with 1 μg/mL lipopolysaccharide 
(LPS) or Lipotechoic Acid (LTA) for 6 or 12 hours (n=3).  
 LPS  LTA 
Target Gene 
 6 h 12 h  6 h 12 h 
TNF-alpha  1.54 ± 0.12a* 1.17 ± 0.19ac  0.83 ± 0.09bc 1.70 ± 0.08aξ 
OCTN1  0.50 ± 0.09a* 1.18 ± 0.12bc  0.82 ± 0.06ac 1.11 ± 0.04bc 
OCTN2  0.59 ± 0.09a* 1.95 ± 0.23b*  0.80 ± 0.04aξ 1.11 ± 0.02aξ 
GLUT1  1.72 ± 0.13a* 1.60 ± 0.10a*  0.85 ± 0.04b 0.70 ± 0.05bξ 
GLUT8  1.69 ± 0.07a* 1.16 ± 0.09b  0.79 ± 0.08c 0.74 ± 0.05cξ 
SGLT1  1.44 ± 0.13a* 1.03 ± 0.11ac  0.84 ± 0.07bc 0.76 ± 0.05bcξ
FATP1  0.60 ± 0.15a 1.37 ± 0.04b*  0.99 ± 0.02c 1.26 ± 0.06bcξ
FABP3  0.80 ± 0.13a 1.10 ± 0.06ac  0.94 ± 0.01ac 1.21 ± 0.08bcξ
FATP4  0.99 ± 0.02a 1.14 ± 0.02a*  1.07 ± 0.13a 1.22 ± 0.01aξ 
Expression was normalized to ß-actin and fold difference were determined using the 
comparative CT for relative quantitation. Multiple comparisons for fold difference 
caused by LPS or LTA with different incubation time for each target gene were analyzed 
using one way ANOVA with Tukey's Multiple Comparison Test. Significance level was 
set at α = 0.05. 
Means with the different letters are significantly different from each other. Means with 
*, ξ are significantly different from the control. α = 0.05. 
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Figure 10.1. Concentration-dependent cell viability of the human immortalized 
mammary epithelial cell line, MCF12A, to LPS and LTA. MCF12A cells were incubated 
with different concentrations of LPS ( ) /LTA ( ) for 24 hours and cell viability 
determined using Promega CellTiter-Glo® Luminescent Cell Viability Assay kit.  
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Figure 10.2. Mean (+ SEM) concentrations of ATP, ADP, AMP and oxygen consumption 
rate in MCF12A cells incubated with vehicle (open bar), 1 μg/mL LPS (light grey bar) or 
1 μg/mL LTA (dark grey bar) for 24 hours. Means (n=3) were compared with control 
using paired t-Test, *α = 0.05   
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10.5 Discussion  
A possible factor contributing to the pathogenesis of mastitis may involve the 
ability of different inflammatory stimuli to alter transporter expression and, hence, 
substrate availability to lactating mammary epithelial cells. In the present study, we 
tested the effects of LTA and LPS on glucose, fatty acid and L-carnitine transporter 
expression levels in the human mammary epithelial cell line, MCF12A, as these 
transporters make available critical substrates that support energy requirements, 
biosynthetic capacity and milk composition of various nutrients. Our data suggests 
inflammatory stimuli alter glucose, fatty acid and L-carnitine transporter expression and 
cellular metabolism in MCF12A cells. Furthermore, LPS and LTA exposure showed 
qualitative and quantitative differences in the time course of the innate immune response 
(as assessed through TNFα expression) and in the expression of glucose, fatty acid, and 
L-carnitine transporters in mammary epithelial cells. 
Since gram positive and gram negative bacteria evoke a different innate immune 
response (137), these differential inflammatory responses may cause dissimilar 
outcomes on transporter expression. Lipopolysaccharide (LPS) (gram negative) and 
Lipoteichoic Acid (LTA) (gram positive) are strong inducers of cytokine release and are 
widely used to model bacterial challenges of mammalian cells. This provided a 
compelling reason for their use in the present study. Furthermore, the human MCF-12A 
cell line is an immortalized mammary epithelial cell line with phenotypic characteristics 
of mammary epithelial cells in vivo (328). MCF12A cells also have been used to 
examine LPS and cytokine-mediated effects on cell function and gene expression (329-
331). Given these characteristics, optimization experiments were conducted with 
MCF12A cells to determine the appropriate physiological concentrations of LPS and 
LTA that induced TNF-α expression, as a major cytokine of the innate immune response 
(332-333), without loss of MCF12A cell viability. As expected, concentration-dependent 
cytotoxicity was observed with LPS but not LTA (137). However, in MCF12A cells LPS 
and LTA induced a time-dependent increase in TNFα expression where expression was 
highest early following LPS administration, while LTA caused a delayed increase in 
TNFα expression (Table 10.2). This was not consistent with Strandberg et al, 2005 who 
reported that LPS and LTA stimulation of primary bovine mammary epithelial cells 
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resulted in rapid stimulation of TNFα expression in the first 2-4 h of challenge, but LPS 
maintained a sustained response while TNFα expression returned to control levels by 8-
16 h following LTA challenge (137). Species differences, differences in the 
concentration of LPS/LTA employed, and cell source (primary versus immortalized) 
may explain differences in response to LPS and LTA in vitro challenge. Nonetheless, the 
source of the bacterial stimulus influenced the nature of the innate immune response 
elicited in MCF12A cells, which compelled us to investigate further whether LPS and 
LTA challenge might lead to differences in the expression profiles of glucose, fatty acid 
and L-carnitine transporters.  
Both LPS and LTA altered glucose, fatty acid and L-carnitine transporter 
expression in MCF12A cells. Major changes in expression seemed to correspond to the 
exposure time at which TNFα expression levels were highest. However, the extent and 
direction of change in transporter expression was different between LPS and LTA 
suggesting that TNFα alone may not be the principal cytokine regulator of transporter 
expression. Many cytokines are produced within the mammary gland by mammary 
epithelial cells and inflammatory cells present or recruited to the gland (334). Cytokines 
may have differential and/or overlapping effects on transporter expression and may 
involve different levels of regulation, i.e. transcriptional or post-transcriptional. 
Although LPS and LTA are considered strong inducers of inflammatory cytokines (335), 
LPS and LTA could regulate transporter expression through mechanisms that do not 
involve cytokine release and autocrine regulation. 
With regards to the qualitative and quantitative differences in transporter 
expression levels, most significant is the differential effects of LPS and LTA on glucose 
transporter expression, where downregulation is observed with LTA but upregulation 
with LPS. In particular, GLUT1, the principal glucose uptake transporter of the 
mammary epithelium (336-337), was persistently upregulated following LPS challenge, 
but downregulated by LTA exposure. GLUT8 and SGLT1 expression returned to control 
levels with more prolonged exposure (12 h) to LPS and the expression of these 
transporters remained persistently low with LTA challenge. These expression changes 
are important to note because glucose functions both as the main energy fuel and 
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biosynthetic precursor (i.e. for lactose, short-chain fatty acids) in the lactating mammary 
gland (312). Several studies have identified the ability of inflammation to alter glucose 
transporter expression with concomitant changes in glucose transport rates (147-148, 
324-325). Although the functional outcomes of such expression changes in the 
mammary epithelium require further investigation, our expression data suggests that 
chronic LPS and LTA exposure increases and decreases, respectively, the capacity for 
glucose uptake in the mammary epithelium. Alterations in glucose availability could 
significantly impact the metabolically active lactating mammary epithelial cell. Whether 
this contributes to the pathogenesis of mastitis warrants further investigation.   
Interestingly, LPS and LTA challenge caused reciprocal changes in the 
expression of transporters critically involved in fatty acid uptake and/or oxidation 
relative to their effects on glucose transporter expression. Short-term exposure (6 h) of 
LPS resulted in the reduced expression of FATP1, FABP3, OCTN1 and OCTN2 (while 
the glucose transporters exhibited increased expression), with expression either 
recovering with more prolonged exposure (12 h) or, in the case of OCTN2, FATP1, and 
FATP4, exceeding expression levels relative to control. With LTA OCTN2, FATP1, 
FATP4, and FABP3 were significantly upregulated with more prolonged exposure (12 h) 
while the glucose transporters were significantly downregulated. Altered expression of 
fatty acid and L-carnitine transporters could result in altered substrate availability (338) 
with concomittant changes in the extent to which fatty acid oxidation contributes to ATP 
generation in the mammary epithelium and the availability of fatty acids and L-carnitine 
in the mammary epithelial cell and breast milk. Recently, our laboratory showed that L-
carnitine milk levels directly correlated with the mRNA expression of L-carnitine 
transporters in the lactating mammary gland (1), supporting the notion that substrate 
availability is influenced by the magnitude of expression of transporters in the mammary 
epithelium. 
A reciprocal interaction between glucose and fatty acid utilization for cellular 
metabolism is well described in the literature (339-341). Different cell types tend to have 
a preference for a particular energy substrate to meet its energy requirements (i.e. 
glucose versus fatty acid). However, decreased cellular availability of one type of energy 
substrate can result in an increased usage in the other major energy substrate to maintain 
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ATP generation in the cell (342-343). Although fatty acid oxidation may contribute only 
~ 10% of oxidative metabolism in the mammary gland (308), changes in the balance 
between glucose and fatty acid oxidation may have negative consequences on overall 
cell function. The reciprocal changes in transporter expression profiles may suggest that 
with acute LPS exposure epithelial cells may rely almost completely on glucose 
oxidation, while LTA challenged mammary epithelial cells may enhance utilization of 
fatty acids to maintain cellular energy requirements. In either case, altered glucose 
availability may pose a problem to the lactating mammary epithelial cell as glucose is 
both a preferred energy source and biosynthetic precursor. Interestingly, we found 
significant decreases in oxygen consumption rates when MCF12A cells were exposed to 
LTA but not LPS.  Unlike glucose metabolism, ATP production from fatty acids 
metabolism is oxygen-dependent (307). Hence, enhanced fatty acid oxidation due to 
increased substrate availability should result in higher oxygen consumption rates. We 
found no differences in ATP, ADP and AMP levels in cells exposed to LTA and LPS. 
Why LTA challenge results in decreased oxygen consumption rates with changes in 
transporter expression profiles that are consistent with greater fatty acid utilization 
requires further investigation.  
With short-term LPS exposure (6 h) upregulation of glucose transporters and 
downregulation of L-carnitine and fatty acid transporters suggests that cellular energy 
requirements more heavily rely on glucose oxidation. Expression of FATP1 and FATP4, 
which are responsible for the transport of fatty acids across the plasma membrane, is 
known to be affected by endotoxaemia (344), with decreased expression reported in 
various tissues including heart, brain and kidney in patients with sepsis (344). With more 
prolonged exposure (12 h), GLUT1 remained upregulated but GLUT8, SGLT1, OCTN1, 
FABP3, and FATP4 returned to normal levels, while OCTN2 and FATP1 were 
upregulated. Proinflammatory cytokines including TNF-α can increase ATP turnover, 
requiring a higher rate of ATP synthesis to maintain the cellular ATP pool (345). When a 
higher rate of ATP synthesis is required, fatty acid rather than glucose oxidation is 
preferred (307). Indeed, fatty acid oxidation is normally considered as the preferred 
substrate for ATP production during certain inflammatory conditions such as sepsis 
(346). This may explain why OCTN2 and FATP1 expression increased with prolonged 
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LPS challenge and why fatty acid and L-carnitine transporter expression was higher in 
LTA challenged cells. Such shifts in fuel substrate availability and usage may be 
necessary biochemical adaptations for cells under stress to ensure steady state ATP 
levels.  
In conclusion, our data indicate that inflammatory stimuli alter glucose, fatty 
acid and L-carnitine transporter expression in mammary epithelial cells. Furthermore, 
LPS and LTA exposure showed qualitative and quantitative differences in the time 
course and expression of glucose, fatty acid, and L-carnitine transporters in these cells. 
Whether changes in transporter expression levels lead to differences in substrate 
availability (i.e. glucose, fatty acid, L-carnitine) to support cellular energy metabolism 
and/or cellular synthesis of milk constituents (i.e. lactose, milk fat) is not known and 
warrants further investigation. The time-dependent changes in transporter expression 
and the reciprocal regulation of glucose transporters relative to the L-carnitine and fatty 
acid transporters also warrant investigation. Since the lactating mammary gland is a 
complex, heterogenous tissue where critical factors such as limitations in substrate 
availability (i.e. glucose, fatty acid, L-carnitine), immune cell contribution to the 
inflammatory response, and differences in transporter expression with stage of lactation 
are not represented in in vitro systems, in vivo investigations are necessary complements 
to future proposed in vitro studies.  
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11.1 Abstract:  
Glucose, fatty acids, and L-carnitine are important substrates that support 
mammary epithelial cell metabolism, biosynthetic capacity, and milk yield and 
composition. Our study investigated the effects of LPS-induced inflammation on the 
expression of several glucose, fatty acid, and L-carnitine transporters in the lactating rat 
mammary gland at different lactation stages. Day 4, 11, and 18 lactating rats 
(n=3/treatment) were administered LPS (1 mg/kg) or saline by intraperitoneal (IP) 
injection. Fold differences in the mRNA expression of glucose transporters Glut1, Glut8 
and Sglt1, fatty acid transporters Fatp1, Fatp4 and Fabp3, and L-carnitine transporters 
Octn1, Octn2, and Octn3, were determined using the Comparative CT method. The 
mRNA expression levels of all transporters evaluated, except Fatp4 and Octn2, were 
markedly higher in mammary gland at lactation day 11 compared to lactation day 4. LPS 
caused a marked decrease in transporter mRNA expression at each lactation stage except 
for Octn3 and Fatp1, which were markedly increased with LPS administration at 
lactation day 4, and Sglt1, which was slightly increased at day 11 of lactation. Our 
results suggest LPS-induced inflammation generally downregulates glucose, fatty acid 
and L-carnitine transporter expression. Whether such changes lead to reductions in 
transporter substrate availability to the lactating mammary epithelial cell requires 
investigation since decreases in the availability of these nutrients may significantly 
impact mammary epithelial function and milk quality and yield. 
 
 
Keywords: Inflammation, nutrient transporter, mammary gland, rat 
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During lactation mammary epithelial metabolic activities increase dramatically to 
meet the energy requirement for milk synthesis and secretion in the mammary gland. 
Although glucose contributes significantly to the energy requirement of the lactating 
mammary gland (113), both glucose and fatty acids are in demand as precursor 
molecules to facilitate production of high amounts of lactose, oligosaccharides and 
triglycerides in the milk (84, 115). L-Carnitine is an obligate nutrient required for 
efficient utilization of fatty acids as energy substrates in the developing neonate (183). 
Consequently, mammary gland availability of glucose, fatty acids and L-carnitine is 
essential for milk production and composition due to their crucial roles as energy 
substrates and/or as milk nutrients or nutrient precursors (112).  
Transporters are responsible for the movement of glucose, fatty acids and L-
carnitine across the cell membranes of the polarized mammary epithelial barrier.  
Glucose uptake is mediated by facilitative glucose transporters (Gluts) and secondary 
active Na+/glucose transporters (Sglts) (75). Fatty acid binding proteins (Fabps), fatty 
acid translocators and fatty acid transport proteins (Fatps) mediate fatty acid uptake into 
mammary epithelial cells (86). The organic cation/carnitine (Octn) transporters are 
responsible for L-carnitine transfer across the epithelium (1, 183).  
Inflammatory states are known to alter transporter expression and function in 
various organs (347). Limited information is available concerning the effects of 
inflammation on glucose, fatty acid and L-carnitine transporter expression in the 
lactating mammary gland. Recent studies also show quantitative and qualitative 
differences in transporter expression between early, middle and late lactation stages (1, 
95), and the influence of inflammation on transporter expression could depend on 
lactation stage. Such differences could have significant implications with respect to milk 
production and composition, clinical outcomes and therapeutic interventions.  
This study represents an initial investigation into the role of inflammatory states 
on glucose, fatty acid and L-carnitine transporter expression and function at the lactating 
mammary gland as these transporters make available critical substrates that support the 
energy requirements, biosynthetic capacity and milk composition of the mammary gland. 
In this study we challenged lactating rats with lipopolyscaccharide (LPS) at early 
(lactation day 4), mid (lactation day 11) and late (lactation day 18) lactation stages to 
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determine the effect of LPS on mRNA expression of glucose, fatty acid, and L-carnitine 
transporters and whether such effects depend upon lactation stage.  
Female Sprague-Dawley rats at gestation day 16 were obtained from Charles River 
Canada (St. Constant, PQ) (n=3 for each lactation stage) and were housed singly in a 
temperature and humidity controlled facility (22°C ± 2°C) on a 12-hour light: dark cycle. 
All rats had free access to food and water. Animal use and procedures were approved by 
the Animal Care and Supply Committee of the University of Saskatchewan. 
Lipopolysaccharide (LPS) (Escherichia coli O111:B4 serotype) and other chemicals 
were obtained from Sigma-Aldrich (St. Louis, MO). 
Lactating rats received 1 mg/kg (250 μL/kg body weight) of LPS or saline 
(n=3/treatment) via intraperitoneal (IP) injection and pups were not returned to the dams. 
Dams were humanely killed at 8 hours post-treatment and mammary glands were rapidly 
excised, snap-frozen in liquid nitrogen, and stored at -80ºC until analysis. Total mRNA 
was extracted from mammary gland using RNeasy Mini Kits (Qiagen Inc., Mississauga, 
ON) according to manufacturer instructions. RNA purity and quantity was determined 
spectrophotometrically (UV/VIS spectrophotometer 8453E, Agilent Technologies, Palo 
Alto, CA) by measurement at 260 nm and the OD260/OD280, respectively. Gene 
sequences were obtained from the National Center for Biotechnology Information 
GeneBank and specific primers were designed using Primer3 software (Table 11.1). 
Quantitative RT-PCR (QRT-PCR) analysis was carried out using a QuantiTect SYBR 
Green RT-PCR kit (Applied Biosystems, Foster City, CA) and an Applied Biosystems 
7300 Real-Time PCR system. The QRT-PCR protocol was carried out according to 
manufacturer’s instructions.  
QRT-PCR assays were initially optimized to give PCR efficiency between 1.9-2.1 
and a single melt-peak corresponding to the appropriate PCR product as verified by 2% 
agarose gel electrophoresis. The reactions were further optimized for usage of the 
Comparative CT method (2-ΔΔCT method). The amplification efficiency of each target and 
β-actin (internal standard) was determined by constructing a standard curve from CT 
values and RNA concentration. The ΔCT were calculated (i.e. the difference between the 
target gene CT and β-actin CT) and plotted against the log RNA concentration. Only 
primers giving PCR amplification close to 100% and the relative efficiencies between 
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the target and β-actin that were approximately equal (slope <0.1) were used in our 
experiment. Fold differences were then calculated using the 2-ΔΔCT method. 
Table 11.2 identifies the effects of LPS on mRNA expression levels of glucose, 
fatty acid and L-carnitine transporters at lactation day 4 and 11 and the difference in 
their expression levels in untreated dams between lactation day 4 and 11. Dams at 
lactation day 18 reached humane intervention points prior to the end of the exposure 
period requiring their euthanasia. Consequently, no results are available for this lactation 
stage. The mRNA expression levels of all transporters, except Fatp4 and Octn2, were 
markedly higher in mammary gland at lactation day 11 compared to day 4 (Table 11.2). 
LPS administration generally resulted in a marked decrease in transporter expression at 
each lactation stage except for Octn3 and Fatp1, which were markedly increased with 
LPS administration at lactation day 4, and Sglt1, which was slightly increased at day 11 
of lactation (Table 11.2). Our results show that LPS-induced inflammation generally 
downregulates the mRNA expression of glucose, fatty acid and L-carnitine transporters 
in both early and mid lactation stages. If changes in expression result in corresponding 
changes in transporter activity, our results may suggest altered availability of these 
substrates to the lactating mammary epithelium. Any decrease in the availability of 
glucose, fatty acids, and L-carnitine may significantly impact mammary epithelial 
function, biosynthetic capacity, and milk quality and yield. 
Glucose transporters previously identified in rodent lactating mammary gland 
include Glut1, Glut12 and Sglt1 (97, 348). In our study we detected Glut8, a glucose 
transporter often expressed in tissues under insulin regulation (314), at mRNA 
expression levels lower than the major facilitative glucose transporter, Glut1. Its exact 
role in the mammary gland, particularly in coordination with Glut1 and Sglt1, is not 
known. We also observed an increase in glucose transporter expression from early to 
mid lactation, which is consistent with the literature (85, 97-98). The mammary 
epithelium relies solely on the maternal circulation to meet its glucose needs (76, 115). 
As well, regulation of glucose transport in the mammary gland plays a key role in the 
maintenance of glucose homeostasis in lactation (309). Hence, the increase in glucose 
transporter expression likely explains the increase in glucose uptake by the mammary 
gland with the advance of lactation (309) to support the increasing need for lactose 
 115
synthesis, ATP generation, and other synthetic capacities. In our study, LPS-induced 
inflammation decreased glucose transporter expression (with the exception of a small 
increase in Sglt1 expression at mid lactation), which could have significant 
consequences on mammary epithelial function and milk yield and quality. 
The lactating mammary gland is capable of synthesizing fatty acids and 
triglycerides de novo (76, 115). The de novo synthesis of fatty acids and triglycerides 
depends on extraction of short-chain volatile fatty acids and free fatty acids, respectively, 
from the blood and the latter process is dependent upon the fatty acid transport proteins 
examined and the extent of extraction changes with stage of lactation (349). The exact 
underlying mechanism of fatty acid uptake from maternal circulation is not known but 
likely involves fatty acid binding proteins and fatty acid transporters (86). We detected 
Fatp1, Fatp4 and Fabp3 expression in the lactating rat mammary gland. Fatp1 and Fabp3 
increased markedly with lactation stage suggesting an important role for these proteins 
in making available free fatty acids to the lactating mammary epithelium. In our study 
Octn1 and Octn3 mRNA expression increased with lactation stage though no statistical 
significance was observed. However, Octn2 expression was similar between early and 
mid lactation stage, which is not consistent with our previous report where we found 
Octn2 expression was highest at early lactation and decreased 2-fold in mid-lactation (1). 
Differences in experimental design (milk was allowed to accumulate for 8 hours in the 
current study versus 4 hours in the previous study) and limited sample size likely 
contributed to the differences.  
As with the glucose transporters, LPS-induced inflammation generally caused 
downregulation of fatty acid and L-carnitine transporters irrespective of lactation stage 
with one exception – at early lactation, LPS administration markedly increased Fatp1 
and Octn3 expression. In our previous study, immunohistochemical analysis revealed 
Octn3 expression in the interstitial space and not the mammary epithelium of the rat 
lactating mammary gland (1). Octn3 is expressed in the peroxisome and plays a critical 
role in peroxisomal β-oxidation (202). Upregulation of Fatp1 and Octn3 might suggest 
enhanced peroxisomal β-oxidation as an important response of the lactating mammary 
gland to inflammation in early lactation. This finding warrants further investigation. 
In summary, LPS-induced inflammation downregulated the mRNA expression of 
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glucose, fatty acid and L-carnitine transporters in rat mammary gland at early and mid-
lactation stages. Whether such downregulation is associated with changes in mammary 
epithelial cell availability of these substrates requires investigation. Furthermore, the 
reduction in milk yield and quality associated with inflammatory states such as mastitis 
could be, in part, due to downregulation of glucose, fatty acids and L-carnitine 
transporters and this warrants investigation.   
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Table 11.1. Primer sequences for quantitative RT-PCR of transporters in rat lactating 
mammary gland.  
Primers 
Gene Accession Number 
Forward Reverse 
Product Size 
Octn1 NM_022270 catggctgtgcagactgg gcaccatgtagccgatgg 209 
Octn2 NM_019269 ggcgcaaccacagtatcc ggggctttccagtcatcc 244 
Octn3 NM_019723 gacaccgtgaacctgagc ccatccaggcagttctcc 188 
Glut1 NM_138827 agctgccctggatgtccta gagaagccagccacagcaa 151 
Glut8 NM_053494 cgcagagcctgctgatgtt cggtagccacacccttgatg 152 
Sglt1 NM_013033 gatgcacccatccagtcc cagccccacaaagtgacc 222 
Fatp1 NM_053580 aggagtggaggggaaagc tgtagccgggtcttctgg 180 
Fabp3 NM_024162 aggagtggaggggaaagc tgtagccgggtcttctgg 231 
Fatp4 XM_231115 tggatgagctgggctacc gttgctagtggggcttgc 200 
Fatp, Fatty acid transport protein; Fabp, Fatty acid binding protein; Glut, Na+-
Independent glucose transporter; Octn, Organic cation/carnitine transporter; Sglt, Na+-
Dependent glucose transporter. 
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Table 11.2. Fold differences in mRNA expression of LPS treated relative to saline 
administration of glucose, fatty acid and carnitine transporters in Sprague-Dawley dams 
at lactation day 4 and 11. Fold differences between lactation day 11 and day 4 of saline 
administered dams are also presented.  
Lactation 
Day 
Glut1 Glut8 Sglt1 Fatp1 Fabp3 Fatp4 Octn1 Octn2 Octn3
L4 0.27 1.01 0.39 5.23 0.11 0.57 0.74 0.39 1.77 
L11 0.10 0.29 1.51 0.15 0.03 0.60 0.37 0.24 0.45 
Between 
L4 & L11* 
10.6 5.02 2.63 5.49 4.55 1.11 5.07 0.95 3.13 
Fold differences were calculated according to the 2-ΔΔCT method. *Control (saline 
administered) dams 
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Table 11.3. Mean ± SEM mRNA expression levels of glucose, fatty acid and carnitine 
transporters in whole mammary gland tissue from Sprague-Dawley dams treated with 
saline (Control) or 1 mg/kg body weight LPS (Treated) at lactation day 4 and day 11 
(n=3/treatment; rats on lactation day 4 are different from lactation day 11).  
Expression was normalized to ß-actin. Means between control and treated dams within a 
lactation stage, or between the control dams at L4 and L11, were compared using 
unpaired t-test.  
a Significantly different from control at lactation day 4 for a given transporter, P<0.05.  
* Significantly different from control within a lactation stage, P<0.05.  
 
 
 Lactation Day 4 Lactation Day11 
Transporters  Control Treated Control Treated 
Glut1  0.51±0.13 0.15±0.02* 6.52±0.28a 0.38±0.19* 
Glut8  0.40±0.05 0.33±0.01 2.47±0.68a 0.45±0.08* 
Sglt1  3.72±1.91 1.46±0.73 8.76±2.07 15.44±4.41 
Fatp1  0.14±0.06 0.88±0.24* 1.05±0.44 0.14±0.08 
Fabp3  1.07±0.04 0.15±0.10* 5.55±1.31a 0.16±0.05* 
Fatp4  4.18±1.73 2.10±0.52 5.23±2.80 5.30±2.92 
Octn1  0.09±0.03 0.11±0.07 0.56±0.26 0.24±0.14 
Octn2  0.56±0.06 0.22±0.05* 0.53±0.09 0.12±0.01* 
Octn3  0.03±0.01 0.05±0.01 0.13±0.05 0.04±0.01 
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12 General Conclusions and Future Directions 
12.1 General Conclusions 
Exclusive breastfeeding for the first six months of life is highly recommended by 
a number of health organizations including Health Canada and WHO (5). However, 
maternal medications used to treat disease in mothers during breastfeeding raise 
significant safety concerns. Most research in this area has focused on identifying the 
amount and mechanism of drug transfer into breast milk and the exposure risk to the 
nursing neonate (102, 152, 156, 223).  However, limited information is available on the 
potential effect of maternal disease and medications on nutrient transporters in the 
mammary gland and the nursing neonate. Limited research recognizes the potential for 
disease/drug-nutrient transporter interactions in the lactating mammary gland and the 
potential of such interactions to affect the levels of specific nutrients and drugs in the 
breast milk. Similarly, it is generally poorly acknowledged that disease- or drug-nutrient 
transport interactions can occur in the nursing neonate when the drug is delivered via 
breast milk. Moreover, it should be understood that the expression levels of transporters 
in the mammary gland and neonate change with stage of lactation and age of the 
neonate, respectively, and that these interactions may have different effects depending 
on the timing and duration of drug administration and or development of disease. My 
dissertation research offers important advancements in our understanding of the possible 
interactions between maternal inflammatory disease or drug use and nutrient transport in 
the nursing mother-neonate dyad. The competitive interaction between the conditionally 
essential nutrient, L-carnitine, and the beta-lactam antibiotic, cefepime, were used as 
proof-of-concept in the lactating dam-neonate rat model. 
Numerous transporters are expressed in the lactating mammary gland that 
function to transport nutrients, bioactive molecules and drugs into the breast milk. 
Substrate specificity of such transporters can include endogenous molecules and drugs. 
Consequently, a drug and nutrient competing for the same transporter may result in 
reduced nutrient transport to breast milk. In my study, we identified a significant 
interaction between a critical nutrient, L-carnitine, and a drug, cefepime, which 
competes for the same nutrient transporter in the lactating mammary gland.  The results 
indicated that cefepime reduced L-carnitine transfer into rat milk, but most significantly, 
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this interaction occurred only during early lactation. This study demonstrated that both 
L-carnitine and cefepime levels in rat milk were found to be higher during early 
lactation stage compared to mid lactation stage and these levels seemed to correlate with 
the higher expression levels of Octn2, a major L-carnitine uptake transporter in the rat 
lactating mammary gland, in early lactation. The ability of a drug to affect the milk 
composition of a critical nutrient via competitive inhibition of a transporter and the 
dependence of lactation stage on the significance of the interaction represent highly 
novel outcomes of my dissertation research. My work suggests that in addition to the 
amount of drug transfer into milk, the influence of the drug on mammary gland function 
(i.e. nutrient transporter function) is an additional critical determinant of neonatal 
exposure risk when nursing mothers require pharmacological interventions. Furthermore, 
assessment of the possible risk must take into consideration the stage of lactation when 
drug therapy is instituted as the potential for significant drug-nutrient transporter 
interactions may change with lactation stage.  
In addition to a potential for drug-nutrient transport interactions in the lactating 
mammary gland, carrier-mediated transport of drugs into breast milk requires additional 
considerations as drug levels in the milk can change with lactation stage. My dissertation 
work showed that the milk-to-serum ratio of cefepime changed considerably with 
lactation stage. Since the milk-to-serum ratio is an important determinant of neonatal 
exposure indices, any change in the ratio with lactation stage may significantly impact 
the magnitude of infant exposure risks following maternal medication use during 
breastfeeding and the assessment of risk. The risk to the neonate is further compounded 
by the immature drug elimination mechanisms of early postnatal life. The results of my 
pharmacokinetic study provided experimental evidence for age-related changes in the 
elimination capacity of cefepime.  The higher milk levels of cefepime at earlier lactation 
stage (high M/S ratio) coupled with the lower capacity to eliminate cefepime at earlier 
postnatal life resulted in considerably higher values for the exposure indices used to 
assess neonatal risk to drugs present in the breast milk. My dissertation work clearly 
identifies the importance of considering both lactation stage and the developmental stage 
of the neonate when assessing the exposure risk via breast milk drug exposures. 
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As with the lactating mammary gland, when transporters are shared by a drug 
and nutrient a possibility exists of a drug-nutrient interaction when neonatal patients 
require drug therapy. Such processes also undergo ontogenesis during postnatal life. 
Thus, the magnitude and significance of drug-nutrient transport interaction in the 
neonatal population could vary depending on timing and/or duration of exposure relative 
to postnatal maturation. In my study, I identified that cefepime exposure during early 
life affected L-carnitine homeostasis mechanisms in rat pups, which did indeed depend 
on the time and duration of the exposure. Neonates demonstrated a capacity to adapt to 
alterations in nutrient availability by altering the ontogenesis of several L-carnitine 
homeostasis mechanisms. However, these adaptations were not sufficient in young 
neonates as evidenced by severe histopathological changes in cardiac ventricular tissue. 
These findings could have major implications with respect to drug treatment of neonates 
highlighting a potential need for nutritional interventions during drug therapy in this 
population.  
Inflammation of the mammary gland is a very common condition during 
breastfeeding. Presently with the majority of research being focused on the 
immunological factors that lead to pathogenesis and recovery of the mammary gland 
from infection, I investigated the effects of different inflammatory stimuli on the 
expression of energy substrate transporters in mammary gland. Alterations in energy 
substrate availability and utilization may explain, in part, the pathogenesis of mastitis 
and of other diseases in which epithelial barrier integrity is a critical underlying factor in 
the disease process. In vitro studies with a human mammary gland cell line showed that 
two widely used inflammatory stimuli, one gram-negative and one gram-positive, 
altered the expression of glucose, fatty acid and L-carnitine transporters in a time-
dependent manner.  The extent and direction of change in transporter expression was 
found to be different between the two bacterial stimuli. However, whether such 
differences contribute to the different pathological manifestations of mastitis caused by 
gram-negative and gram-positive bacterial stimuli was not investigated and requires 
further studies.  Interestingly, the research demonstrated reciprocal regulation of glucose 
transporters relative to the L-carnitine and fatty acid transporters.  This may suggest that 
with gram-negative inflammatory stimuli mammary epithelial cells may rely almost 
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completely on glucose oxidation (upregulated glucose transporters), while gram-positive 
bacterial stimuli challenged mammary epithelial cells may enhance utilization of fatty 
acids to maintain cellular energy requirements (upregulated fatty acid transporters).  
Additionally, my in vivo study indentified that a gram-negative bacterial inflammatory 
stimulus markedly reduced expression of glucose, fatty acid and L-carnitine transporters 
in rat mammary gland at early and mid lactation stages.  However, knowledge of 
whether changes in transporter expression levels lead to differences in substrate 
availability (i.e. glucose, fatty acid, L-carnitine) to support cellular energy metabolism 
and/or cellular synthesis of milk constituents (i.e. lactose, milk fat) was not obtained and 
thus further investigations are needed to explore this possibility. Nonetheless, these 
studies provide experimental evidence to support my novel hypothesis that inflammation 
may affect epithelial barrier function through alterations in the expression of energy 
substrate transporters.  
Collectively, the results of my research provided experimental evidence for 
significant disease- or drug-nutrient transport interactions in the nursing mother-neonate 
dyad. In a practical sense, my research offers invaluable information to health care 
professionals in their pharmacological management of the nursing mother-neonate dyad. 
My research may one day point to a need for dietary modification or supplementation 
when medications are administered to the nursing mother-neonate dyad to minimize the 
risk for unfavourable outcomes following a significant drug-nutrient transport 
interaction. Moreover, the results of my research identify the possible risks associated 
with maternal disease that may consequently alter mammary gland function and milk 
composition. Additional research in this area may lead to the identification of improved 
nutritional intervention strategies for mothers with certain diseases, such as 
inflammation, who still wish to breastfeed, but do not wish to place their nursing child at 
risk.  
Although drug administration to the nursing mother or the neonate is necessary 
to reduce the morbidity and mortality associated with disease, drug use is not without its 
own risks, particularly in the nursing mother-neonate dyad. My research represents the 
acknowledgement of one possible significant risk factor associated with drug use in this 
population. My dissertation research has made some considerable first steps towards an 
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understanding of this risk, but much more research is needed into this novel area of 
investigation.  
 
12.2 Future Directions 
My work provided experimental support of a significant in vivo drug-nutrient 
transport interaction in the nursing mother-neonate dyad. Identification of this 
interaction leads to a number of possible additional investigations. In the neonate, my 
work suggested that the interaction resulted in changes in nutrient homeostasis pathways 
depending on timing and duration of drug exposure relative to postnatal age. However, 
whether these changes are permanent or transient are unknown. Future studies are 
needed to investigate the potential for metabolic programming of nutrient homeostasis 
pathways following a drug-nutrient transport interaction and the possible long-term 
consequences of such interactions on the risk for adult onset disease. 
 In the lactating mother, future studies could investigate other relevant drug-
nutrient transport interactions at the lactating mammary gland and the health 
consequences of such interactions on the breastfeeding mother-infant dyad. Furthermore, 
studies are needed to determine whether alterations in the milk levels of specific 
nutrients resulting from a drug-nutrient transport interaction at the lactating mammary 
gland can significantly impact nutrient availability and the ontogenesis of nutrient 
homeostasis pathways in the nursing neonate. Such studies are critically important in 
determining whether nutritional interventions are required to overcome nutrient 
deficiencies in the breastfeeding mother-infant dyad imposed by an interacting maternal 
medication and/or disease. 
Maternal disease-nutrient transporter interactions were also identified in the 
mammary gland at transcriptional levels. Future studies are needed to investigate 
whether changes in energy substrate transporter expression levels eventually lead to 
alterations in cellular energy metabolism with consequent effects on milk yield and 
quality. Although the focus of my work was on the mammary gland, disease-nutrient 
transporter interactions can also occur in other epithelial barriers. Future investigations 
into whether changes in energy substrate transporter expression profiles could contribute 
to diseases associated with other epithelial barriers are warranted.  
 125
REFERENCES: 
1. Ling, B., and Alcorn, J. (2008) Acute administration of cefepime lowers L-
carnitine concentrations in early lactation stage rat milk, J Nutr 138, 1317-1322. 
2. Neville, M. C. (1999) Physiology of lactation, Clin Perinatol 26, 251-279. 
3. Neville, M. C. (2001) Anatomy and physiology of lactation, Pediatr Clin North 
Am 48, 13-34. 
4. Thiesen, A., Wild, G., Keelan, M., Clandinin, M. T., McBurney, M., Van Aerde, J., 
and Thomson, A. B. (2000) Ontogeny of intestinal nutrient transport, Can J 
Physiol Pharmacol 78, 513-527. 
5. WHO (2005) The World Health Assembly held its fifty-eighth session from 16 to 
25 May this year, East Mediterr Health J 11, 256-257. 
6. Howard, C. R., and Lawrence, R. A. (2001) Xenobiotics and breastfeeding, 
Pediatr Clin North Am 48, 485-504. 
7. Banta-Wright, S. A. (1997) Minimizing infant exposure to and risks from 
medications while breastfeeding, J Perinat Neonatal Nurs 11, 71-84. 
8. McNamara, P. J., and Abbassi, M. (2004) Neonatal exposure to drugs in breast 
milk, Pharm Res 21, 555-566. 
9. Merewood, A., Brooks, D., Bauchner, H., MacAuley, L., and Mehta, S. D. (2006) 
Maternal birthplace and breastfeeding initiation among term and preterm infants: 
a statewide assessment for Massachusetts, Pediatrics 118, e1048-1054. 
10. Hauck, Y. L., Fenwick, J., Dhaliwal, S. S., and Butt, J. (2010) A Western 
Australian Survey of Breastfeeding Initiation, Prevalence and Early Cessation 
Patterns, Matern Child Health J. In Press.  
11. Millar, W. J., Maclean, H. . (2005) Breastfeeding practices, In Health Reports, pp 
23-31, Statistics Canada. 
12. Lonnerdal, B. (2000) Breast milk: a truly functional food, Nutrition 16, 509-511. 
13. Feldman, R., and Eidelman, A. I. (2003) Direct and indirect effects of breast milk 
 126
on the neurobehavioral and cognitive development of premature infants, Dev 
Psychobiol 43, 109-119. 
14. Hale, T. W. (2003) Medications in breastfeeding mothers of preterm infants, 
Pediatr Ann 32, 337-347. 
15. Newman, J. (1995) How breast milk protects newborns, Sci Am 273, 76-79. 
16. Georgeson, J. C., and Filteau, S. M. (2000) Physiology, immunology, and disease 
transmission in human breast milk, AIDS Patient Care STDS 14, 533-539. 
17. Losonsky, G. A., and Ogra, P. L. (1981) Maternal-neonatal interactions and 
human breast milk, Prog Clin Biol Res 70, 171-182. 
18. Dewey, K. G., Cohen, R. J., and Brown, K. H. (2004) Exclusive breast-feeding 
for 6 months, with iron supplementation, maintains adequate micronutrient status 
among term, low-birthweight, breast-fed infants in Honduras, J Nutr 134, 1091-
1098. 
19. Schack-Nielsen, L., Larnkjaer, A., and Michaelsen, K. F. (2005) Long term 
effects of breastfeeding on the infant and mother, Adv Exp Med Biol 569, 16-23. 
20. Chua, S., Arulkumaran, S., Lim, I., Selamat, N., and Ratnam, S. S. (1994) 
Influence of breastfeeding and nipple stimulation on postpartum uterine activity, 
Br J Obstet Gynaecol 101, 804-805. 
21. Heinig, M. J., and Dewey, K. G. (1997) Health effects of breast feeding for 
mothers: a critical review, Nutr Res Rev 10, 35-56. 
22. Labbok, M. H. (2001) Effects of breastfeeding on the mother, Pediatr Clin North 
Am 48, 143-158. 
23. Davies, H. A., Clark, J. D., Dalton, K. J., and Edwards, O. M. (1989) Insulin 
requirements of diabetic women who breast feed, BMJ 298, 1357-1358. 
24. Ball, T. M., and Bennett, D. M. (2001) The economic impact of breastfeeding, 
Pediatr Clin North Am 48, 253-262. 
25. Tuttle, C. R., and Dewey, K. G. (1996) Potential cost savings for Medi-Cal, 
AFDC, food stamps, and WIC programs associated with increasing breast-
 127
feeding among low-income Hmong women in California, J Am Diet Assoc 96, 
885-890. 
26. Ball, T. M., and Wright, A. L. (1999) Health care costs of formula-feeding in the 
first year of life, Pediatrics 103, 870-876. 
27. Bennett, P. N. (1996) Use of the monographs on drugs, In Drugs and Human 
Lactation (Bennett, P. N., Ed.) 2 ed., pp 67-74, Elsevier, Amsterdam. 
28. Kimberly, G. L. (2007) Lactation and drugs, Paediatrics and Child Health 17, 
68-71. 
29. Ito, S., and Alcorn, J. (2003) Xenobiotic transporter expression and function in 
the human mammary gland, Adv Drug Deliv Rev 55, 653-665. 
30. Alcorn, J., and McNamara, P. J. (2002) Ontogeny of hepatic and renal systemic 
clearance pathways in infants: part II, Clin Pharmacokinet 41, 1077-1094. 
31. Alcorn, J., and McNamara, P. J. (2002) Ontogeny of hepatic and renal systemic 
clearance pathways in infants: part I, Clin Pharmacokinet 41, 959-998. 
32. Hines, R. N. (2007) Ontogeny of human hepatic cytochromes P450, J Biochem 
Mol Toxicol 21, 169-175. 
33. Srinivasan, M., Laychock, S. G., Hill, D. J., and Patel, M. S. (2003) Neonatal 
nutrition: metabolic programming of pancreatic islets and obesity, Exp Biol Med 
(Maywood) 228, 15-23. 
34. Ollivier-Bousquet, M., Devinoy, E. (2005) Physiology of lactation: Old questions, 
new approaches, Livestock Production Science 98, 163-173. 
35. Fleishaker, J. C., and McNamara, P. J. (1988) Effect of altered serum protein 
binding on propranolol distribution into milk in the lactating rabbit, J Pharmacol 
Exp Ther 244, 925-928. 
36. Holness, M. J., Priestman, D. A., and Sugden, M. C. (1998) Impact of protein 
restriction on the regulation of cardiac carnitine palmitoyltransferase by malonyl-
CoA, J Mol Cell Cardiol 30, 1381-1390. 
37. Lavrentyev, E. N., He, D., and Cook, G. A. (2004) Expression of genes 
 128
participating in regulation of fatty acid and glucose utilization and energy 
metabolism in developing rat hearts, Am J Physiol Heart Circ Physiol 287, 
H2035-2042. 
38. Cuthbertson, W. F. (1999) Evolution of infant nutrition, Br J Nutr 81, 359-371. 
39. Picciano, M. F. (2001) Nutrient composition of human milk, Pediatr Clin North 
Am 48, 53-67. 
40. Lawrence, R. A., Lawrence, R.M. (2005) Breastfeeding: A guide for the medical 
profession, Mosby, MO, USA. 
41. Koletzko, B., Rodriguez-Palmero, M., Demmelmair, H., Fidler, N., Jensen, R., 
and Sauerwald, T. (2001) Physiological aspects of human milk lipids, Early Hum 
Dev 65 Suppl, S3-S18. 
42. Bitman, J., Wood, L., Hamosh, M., Hamosh, P., and Mehta, N. R. (1983) 
Comparison of the lipid composition of breast milk from mothers of term and 
preterm infants, Am J Clin Nutr 38, 300-312. 
43. Harzer, G., Haug, M., Dieterich, I., and Gentner, P. R. (1983) Changing patterns 
of human milk lipids in the course of the lactation and during the day, Am J Clin 
Nutr 37, 612-621. 
44. Hambraeus, L., Lonnerdal, B., Forsum, E., and Gebre-Medhin, M. (1978) 
Nitrogen and protein components of human milk, Acta Paediatr Scand 67, 561-
565. 
45. Lonnerdal, B. (2003) Nutritional and physiologic significance of human milk 
proteins, Am J Clin Nutr 77, 1537S-1543S. 
46. Lopez Alvarez, M. J. (2007) Proteins in human milk, Breastfeed Rev 15, 5-16. 
47. Sugawara, M., Sato, N., Nakano, T., Idota, T., and Nakajima, I. (1995) Profile of 
nucleotides and nucleosides of human milk, J Nutr Sci Vitaminol (Tokyo) 41, 
409-418. 
48. McArdle, H. J., and Ashworth, C. J. (1999) Micronutrients in fetal growth and 
development, Br Med Bull 55, 499-510. 
 129
49. Ashworth, C. J., and Antipatis, C. (2001) Micronutrient programming of 
development throughout gestation, Reproduction 122, 527-535. 
50. Dalmiya, N., and Schultink, W. (2003) Combating hidden hunger: the role of 
international agencies, Food Nutr Bull 24, S69-77. 
51. Latham, M. C. (2003) Hidden hunger and the role of public-private partnership, 
Food Nutr Bull 24, S67-68. 
52. Kendler, B. S. (2006) Supplemental conditionally essential nutrients in 
cardiovascular disease therapy, J Cardiovasc Nurs 21, 9-16. 
53. Novak, M., Wieser, P. B., Buch, M., and Hahn, P. (1979) Acetylcarnitine and free 
carnitine in body fluids before and after birth, Pediatr Res 13, 10-15. 
54. Rebouche, C. J., and Seim, H. (1998) Carnitine metabolism and its regulation in 
microorganisms and mammals, Annu Rev Nutr 18, 39-61. 
55. Tang, N. L., Hui, J., Law, L. K., To, K. F., Cheung, K. L., Magnus, H. N., Yuen, P. 
M., and Fok, T. F. (2000) Primary carnitine deficiency in the Chinese, Chin Med 
J (Engl) 113, 376-380. 
56. Picciano, M. F. (1998) Human milk: nutritional aspects of a dynamic food, Biol 
Neonate 74, 84-93. 
57. Smit, E. N., Martini, I. A., Kemperman, R. F., Schaafsma, A., Muskiet, F. A., and 
Boersma, E. R. (2003) Fatty acids in formulae for term infants: compliance of 
present recommendations with the actual human milk fatty acid composition of 
geographically different populations, Acta Paediatr 92, 790-796. 
58. Erney, R. M., Malone, W. T., Skelding, M. B., Marcon, A. A., Kleman-Leyer, K. 
M., O'Ryan, M. L., Ruiz-Palacios, G., Hilty, M. D., Pickering, L. K., and Prieto, P. 
A. (2000) Variability of human milk neutral oligosaccharides in a diverse 
population, J Pediatr Gastroenterol Nutr 30, 181-192. 
59. Patel, M. S., and Srinivasan, M. (2002) Metabolic programming: causes and 
consequences, J Biol Chem 277, 1629-1632. 
60. Solomon, G. M., and Weiss, P. M. (2002) Chemical contaminants in breast milk: 
 130
time trends and regional variability, Environ Health Perspect 110, A339-347. 
61. Wright, K. S., Quinn, T. J., and Carey, G. B. (2002) Infant acceptance of breast 
milk after maternal exercise, Pediatrics 109, 585-589. 
62. Gluckman, P. D., Hanson, M. A., and Spencer, H. G. (2005) Predictive adaptive 
responses and human evolution, Trends Ecol Evol 20, 527-533. 
63. Barja-Fidalgo, C., Souza, E. P., Silva, S. V., Rodrigues, A. L., Anjos-Valotta, E. 
A., Sannomyia, P., DeFreitas, M. S., and Moura, A. S. (2003) Impairment of 
inflammatory response in adult rats submitted to maternal undernutrition during 
early lactation: role of insulin and glucocorticoid, Inflamm Res 52, 470-476. 
64. Armitage, J. A., Khan, I. Y., Taylor, P. D., Nathanielsz, P. W., and Poston, L. 
(2004) Developmental programming of the metabolic syndrome by maternal 
nutritional imbalance: how strong is the evidence from experimental models in 
mammals?, J Physiol 561, 355-377. 
65. Nishina, H., Green, L. R., McGarrigle, H. H., Noakes, D. E., Poston, L., and 
Hanson, M. A. (2003) Effect of nutritional restriction in early pregnancy on 
isolated femoral artery function in mid-gestation fetal sheep, J Physiol 553, 637-
647. 
66. Barker, D. J. (1997) The fetal origins of coronary heart disease, Eur Heart J 18, 
883-884. 
67. Barker, D. J., and Martyn, C. N. (1997) The fetal origins of hypertension, Adv 
Nephrol Necker Hosp 26, 65-72. 
68. Butte, N. F. (2009) Impact of infant feeding practices on childhood obesity, J 
Nutr 139, 412S-416S. 
69. Frankel, S., Gunnell, D. J., Peters, T. J., Maynard, M., and Davey Smith, G. 
(1998) Childhood energy intake and adult mortality from cancer: the Boyd Orr 
Cohort Study, BMJ 316, 499-504. 
70. Forsyth, J. S., Willatts, P., Agostoni, C., Bissenden, J., Casaer, P., and Boehm, G. 
(2003) Long chain polyunsaturated fatty acid supplementation in infant formula 
 131
and blood pressure in later childhood: follow up of a randomised controlled trial, 
BMJ 326, 953. 
71. Hofman, P. L., Regan, F., and Cutfield, W. S. (2006) Prematurity--another 
example of perinatal metabolic programming?, Horm Res 66, 33-39. 
72. Cole, C. R., and Lifshitz, F. (2008) Zinc nutrition and growth retardation, Pediatr 
Endocrinol Rev 5, 889-896. 
73. Hiilesmaa, V. K., Teramo, K., Granstrom, M. L., and Bardy, A. H. (1983) Serum 
folate concentrations during pregnancy in women with epilepsy: relation to 
antiepileptic drug concentrations, number of seizures, and fetal outcome, Br Med 
J (Clin Res Ed) 287, 577-579. 
74. Metcalfe, N. B., and Monaghan, P. (2001) Compensation for a bad start: grow 
now, pay later?, Trends Ecol Evol 16, 254-260. 
75. McManaman, J. L., and Neville, M. C. (2003) Mammary physiology and milk 
secretion, Adv Drug Deliv Rev 55, 629-641. 
76. Shennan, D. B., and Peaker, M. (2000) Transport of milk constituents by the 
mammary gland, Physiol Rev 80, 925-951. 
77. Mather, I. H., and Keenan, T. W. (1998) The cell biology of milk secretion: 
historical notes. Introduction, J Mammary Gland Biol Neoplasia 3, 227-232. 
78. Nguyen, D. A., and Neville, M. C. (1998) Tight junction regulation in the 
mammary gland, J Mammary Gland Biol Neoplasia 3, 233-246. 
79. Linzell, J. L., and Peaker, M. (1971) Intracellular concentrations of sodium, 
potassium and chloride in the lactating mammary gland and their relation to the 
secretory mechanism, J Physiol 216, 683-700. 
80. Linzell, J. L., and Peaker, M. (1971) Mechanism of milk secretion, Physiol Rev 
51, 564-597. 
81. Mather, I. H., and Keenan, T. W. (1998) Origin and secretion of milk lipids, J 
Mammary Gland Biol Neoplasia 3, 259-273. 
82. Monks, J., and Neville, M. C. (2001) Vesicular transport of soluble substances 
 132
into mouse milk, Adv Exp Med Biol 501, 257-263. 
83. Alcorn, J., Lu, X., Moscow, J. A., and McNamara, P. J. (2002) Transporter gene 
expression in lactating and nonlactating human mammary epithelial cells using 
real-time reverse transcription-polymerase chain reaction, J Pharmacol Exp Ther 
303, 487-496. 
84. Obermeier, S., Huselweh, B., Tinel, H., Kinne, R. H., and Kunz, C. (2000) 
Expression of glucose transporters in lactating human mammary gland epithelial 
cells, Eur J Nutr 39, 194-200. 
85. Zhao, F. Q., and Keating, A. F. (2007) Functional properties and genomics of 
glucose transporters, Curr Genomics 8, 113-128. 
86. Barber, M. C., Clegg, R. A., Travers, M. T., and Vernon, R. G. (1997) Lipid 
metabolism in the lactating mammary gland, Biochim Biophys Acta 1347, 101-
126. 
87. Kronfeld, D. S. (1982) Major metabolic determinants of milk volume, mammary 
efficiency, and spontaneous ketosis in dairy cows, J Dairy Sci 65, 2204-2212. 
88. Zhao, F. Q., Moseley, W. M., Tucker, H. A., and Kennelly, J. J. (1996) Regulation 
of glucose transporter gene expression in mammary gland, muscle, and fat of 
lactating cows by administration of bovine growth hormone and bovine growth 
hormone-releasing factor, J Anim Sci 74, 183-189. 
89. Groneberg, D. A., Doring, F., Theis, S., Nickolaus, M., Fischer, A., and Daniel, H. 
(2002) Peptide transport in the mammary gland: expression and distribution of 
PEPT2 mRNA and protein, Am J Physiol Endocrinol Metab 282, E1172-1179. 
90. Kelleher, S. L., and Lonnerdal, B. (2005) Molecular regulation of milk trace 
mineral homeostasis, Mol Aspects Med 26, 328-339. 
91. King, J. C. (2002) Enhanced zinc utilization during lactation may reduce 
maternal and infant zinc depletion, Am J Clin Nutr 75, 2-3. 
92. Lonnerdal, B. (2007) Trace element transport in the mammary gland, Annu Rev 
Nutr 27, 165-177. 
 133
93. Friesema, E. C., Jansen, J., Jachtenberg, J. W., Visser, W. E., Kester, M. H., and 
Visser, T. J. (2008) Effective cellular uptake and efflux of thyroid hormone by 
human monocarboxylate transporter 10, Mol Endocrinol 22, 1357-1369. 
94. van Herwaarden, A. E., Wagenaar, E., Merino, G., Jonker, J. W., Rosing, H., 
Beijnen, J. H., and Schinkel, A. H. (2007) Multidrug transporter ABCG2/breast 
cancer resistance protein secretes riboflavin (vitamin B2) into milk, Mol Cell 
Biol 27, 1247-1253. 
95. Gilchrist, S. E., and Alcorn, J. (2009) Lactation stage-dependent expression of 
transporters in rat whole mammary gland and primary mammary epithelial 
organoids, Fundam Clin Pharmacol. In Press. 
96. Laspiur, J. P., Burton, J. L., Weber, P. S., Kirkwood, R. N., and Trottier, N. L. 
(2004) Short communication: amino acid transporters in porcine mammary gland 
during lactation, J Dairy Sci 87, 3235-3237. 
97. Macheda, M. L., Williams, E. D., Best, J. D., Wlodek, M. E., and Rogers, S. 
(2003) Expression and localisation of GLUT1 and GLUT12 glucose transporters 
in the pregnant and lactating rat mammary gland, Cell Tissue Res 311, 91-97. 
98. Nemeth, B. A., Tsang, S. W., Geske, R. S., and Haney, P. M. (2000) Golgi 
targeting of the GLUT1 glucose transporter in lactating mouse mammary gland, 
Pediatr Res 47, 444-450. 
99. Leong, W. I., and Lonnerdal, B. (2005) Iron transporters in rat mammary gland: 
effects of different stages of lactation and maternal iron status, Am J Clin Nutr 81, 
445-453. 
100. Ezekiel, E., and Morgan, E. H. (1963) Milk iron and its metabolism in the 
lactating rat, J Physiol 165, 336-347. 
101. Kelleher, S. L., and Lonnerdal, B. (2006) Mammary gland copper transport is 
stimulated by prolactin through alterations in Ctr1 and Atp7A localization, Am J 
Physiol Regul Integr Comp Physiol 291, R1181-1191. 
102. Ito, S., and Lee, A. (2003) Drug excretion into breast milk--overview, Adv Drug 
Deliv Rev 55, 617-627. 
 134
103. Koepsell, H. (1998) Organic cation transporters in intestine, kidney, liver, and 
brain, Annu Rev Physiol 60, 243-266. 
104. Kwok, B., Yamauchi, A., Rajesan, R., Chan, L., Dhillon, U., Gao, W., Xu, H., 
Wang, B., Takahashi, S., Semple, J., Tamai, I., Nezu, J., Tsuji, A., Harper, P., and 
Ito, S. (2006) Carnitine/xenobiotics transporters in the human mammary gland 
epithelia, MCF12A, Am J Physiol Regul Integr Comp Physiol 290, R793-802. 
105. Peaker, M. (2002) The mammary gland in mammalian evolution: a brief 
commentary on some of the concepts, J Mammary Gland Biol Neoplasia 7, 347-
353. 
106. Goldman, A. S. (2002) Evolution of the mammary gland defense system and the 
ontogeny of the immune system, J Mammary Gland Biol Neoplasia 7, 277-289. 
107. Oftedal, O. T. (2002) The mammary gland and its origin during synapsid 
evolution, J Mammary Gland Biol Neoplasia 7, 225-252. 
108. Neville, M. C., Morton, J., and Umemura, S. (2001) Lactogenesis. The transition 
from pregnancy to lactation, Pediatr Clin North Am 48, 35-52. 
109. Neville, M. C., McFadden, T. B., and Forsyth, I. (2002) Hormonal regulation of 
mammary differentiation and milk secretion, J Mammary Gland Biol Neoplasia 
7, 49-66. 
110. Adriance, M. C., Inman, J. L., Petersen, O. W., and Bissell, M. J. (2005) 
Myoepithelial cells: good fences make good neighbors, Breast Cancer Res 7, 
190-197. 
111. Haslam, S. Z. (1988) Cell to cell interactions and normal mammary gland 
function, J Dairy Sci 71, 2843-2854. 
112. Williamson, D. H. (1980) Integration of metabolism in tissues of the lactating rat, 
FEBS Lett 117 Suppl, K93-105. 
113. Kuhn, N. J. (1978) Glucose as a fuel for the mammary gland, Biochem Soc Trans 
6, 539-543. 
114. Scott, R. A., Beuman, D. E., and Clark, J. H. (1976) Cellular gluconeogenesis by 
 135
lactating bovine mammary tissue, J Dairy Sci 59, 50-56. 
115. Neville, M. C., and Picciano, M. F. (1997) Regulation of milk lipid secretion and 
composition, Annu Rev Nutr 17, 159-183. 
116. Ringseis, R., Dathe, C., Muschick, A., Brandsch, C., and Eder, K. (2007) 
Oxidized fat reduces milk triacylglycerol concentrations by inhibiting gene 
expression of lipoprotein lipase and fatty acid transporters in the mammary gland 
of rats, J Nutr 137, 2056-2061. 
117. Neville, M. C., and Walsh, C. T. (1995) Effects of xenobiotics on milk secretion 
and composition, Am J Clin Nutr 61, 687S-694S. 
118. Dickey, R. P. (1979) Drugs affecting lactation, Semin Perinatol 3, 279-286. 
119. Dickey, R. P., and Stone, S. C. (1975) Drugs that affect the breast and lactation, 
Clin Obstet Gynecol 18, 95-111. 
120. Martel, P., Houdebine, L. M., Teyssot, B., and Djiane, J. (1983) Effects of 
phorbol esters on multiplication and differentiation of mammary cells, Biol Cell 
49, 119-126. 
121. Stull, M. A., Pai, V., Vomachka, A. J., Marshall, A. M., Jacob, G. A., and 
Horseman, N. D. (2007) Mammary gland homeostasis employs serotonergic 
regulation of epithelial tight junctions, Proc Natl Acad Sci U S A 104, 16708-
16713. 
122. Taketani, Y., and Oka, T. (1983) Epidermal growth factor stimulates cell 
proliferation and inhibits functional differentiation of mouse mammary epithelial 
cells in culture, Endocrinology 113, 871-877. 
123. Vilaro, S., Vinas, O., Remesar, X., and Herrera, E. (1987) Effects of chronic 
ethanol consumption on lactational performance in rat: mammary gland and milk 
composition and pups' growth and metabolism, Pharmacol Biochem Behav 27, 
333-339. 
124. Brass, E. P., Mayer, M. D., Mulford, D. J., Stickler, T. K., and Hoppel, C. L. 
(2003) Impact on carnitine homeostasis of short-term treatment with the pivalate 
 136
prodrug cefditoren pivoxil, Clin Pharmacol Ther 73, 338-347. 
125. Peschechera, A., Scalibastri, M., Russo, F., Giarrizzo, M. G., Carminati, P., 
Giannessi, F., Arduini, A., and Ricciolini, R. (2005) Carnitine depletion in rat 
pups from mothers given mildronate: a model of carnitine deficiency in late fetal 
and neonatal life, Life Sci 77, 3078-3091. 
126. Sadler, L. C., Lane, M., and North, R. (1995) Severe fetal intracranial 
haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of 
pregnancy, Br J Obstet Gynaecol 102, 169-170. 
127. Gregory, J. F., 3rd, Williamson, J., Liao, J. F., Bailey, L. B., and Toth, J. P. (1998) 
Kinetic model of folate metabolism in nonpregnant women consuming 
[2H2]folic acid: isotopic labeling of urinary folate and the catabolite para-
acetamidobenzoylglutamate indicates slow, intake-dependent, turnover of folate 
pools, J Nutr 128, 1896-1906. 
128. Miller, L. T. (1986) Do oral contraceptive agents affect nutrient requirements--
vitamin B-6?, J Nutr 116, 1344-1345. 
129. Miller, L. T., Johnson, A., Benson, E. M., and Woodring, M. J. (1975) Effect of 
oral contraceptives and pyridoxine on the metabolism of vitamin B6 and on 
plasma tryptophan and alpha-amino nitrogen, Am J Clin Nutr 28, 846-853. 
130. Lawrence, V. A., Loewenstein, J. E., and Eichner, E. R. (1984) Aspirin and folate 
binding: in vivo and in vitro studies of serum binding and urinary excretion of 
endogenous folate, J Lab Clin Med 103, 944-948. 
131. Metz, J., Zalusky, R., and Herbert, V. (1968) Folic acid binding by serum and 
milk, Am J Clin Nutr 21, 289-297. 
132. Michalczyk, A., Varigos, G., Catto-Smith, A., Blomeley, R. C., and Ackland, M. 
L. (2003) Analysis of zinc transporter, hZnT4 ( Slc30A4), gene expression in a 
mammary gland disorder leading to reduced zinc secretion into milk, Hum Genet 
113, 202-210. 
133. Mayer-Davis, E. J., Rifas-Shiman, S. L., Zhou, L., Hu, F. B., Colditz, G. A., and 
Gillman, M. W. (2006) Breast-feeding and risk for childhood obesity: does 
 137
maternal diabetes or obesity status matter?, Diabetes Care 29, 2231-2237. 
134. Guilbert, T. W., Stern, D. A., Morgan, W. J., Martinez, F. D., and Wright, A. L. 
(2007) Effect of breastfeeding on lung function in childhood and modulation by 
maternal asthma and atopy, Am J Respir Crit Care Med 176, 843-848. 
135. Johnson, P. R., Jr., and Roloff, J. S. (1982) Vitamin B12 deficiency in an infant 
strictly breast-fed by a mother with latent pernicious anemia, J Pediatr 100, 917-
919. 
136. McPhee, A. J., Davidson, G. P., Leahy, M., and Beare, T. (1988) Vitamin B12 
deficiency in a breast fed infant, Arch Dis Child 63, 921-923. 
137. Strandberg, Y., Gray, C., Vuocolo, T., Donaldson, L., Broadway, M., and Tellam, 
R. (2005) Lipopolysaccharide and lipoteichoic acid induce different innate 
immune responses in bovine mammary epithelial cells, Cytokine 31, 72-86. 
138. Barbosa-Cesnik, C., Schwartz, K., and Foxman, B. (2003) Lactation mastitis, 
JAMA 289, 1609-1612. 
139. Wockel, A., Abou-Dakn, M., Beggel, A., and Arck, P. (2008) Inflammatory 
breast diseases during lactation: health effects on the newborn-a literature review, 
Mediators Inflamm 2008, 298760. 
140. Smith, K. L., and Hogan, J. S. (1993) Environmental mastitis, Vet Clin North Am 
Food Anim Pract 9, 489-498. 
141. Sutra, L., and Poutrel, B. (1994) Virulence factors involved in the pathogenesis 
of bovine intramammary infections due to Staphylococcus aureus, J Med 
Microbiol 40, 79-89. 
142. Auldist, M. J. a. H., I. B. (1998) Effects of mastitis on raw milk and dairy 
products, Aust. J. Dairy Technol. 53, 28-36. 
143. Thomas, L. H., Haider, W., Hill, A. W., and Cook, R. S. (1994) Pathologic 
findings of experimentally induced Streptococcus uberis infection in the 
mammary gland of cows, Am J Vet Res 55, 1723-1728. 
144. Fetherston, C. M., Lai, C. T., Mitoulas, L. R., and Hartmann, P. E. (2006) 
 138
Excretion of lactose in urine as a measure of increased permeability of the 
lactating breast during inflammation, Acta Obstet Gynecol Scand 85, 20-25. 
145. Foster, D. R., Landowski, C. P., Zheng, X., Amidon, G. L., and Welage, L. S. 
(2009) Interferon-gamma increases expression of the di/tri-peptide transporter, h-
PEPT1, and dipeptide transport in cultured human intestinal monolayers, 
Pharmacol Res 59, 215-220. 
146. Vee, M. L., Lecureur, V., Stieger, B., and Fardel, O. (2009) Regulation of drug 
transporter expression in human hepatocytes exposed to the proinflammatory 
cytokines tumor necrosis factor-alpha or interleukin-6, Drug Metab Dispos 37, 
685-693. 
147. Douard, V., and Ferraris, R. P. (2008) Regulation of the fructose transporter 
GLUT5 in health and disease, Am J Physiol Endocrinol Metab 295, E227-237. 
148. Schmidt, C., Hocherl, K., Schweda, F., Kurtz, A., and Bucher, M. (2007) 
Regulation of renal sodium transporters during severe inflammation, J Am Soc 
Nephrol 18, 1072-1083. 
149. Schmith, V. D., and Foss, J. F. (2008) Effects of inflammation on 
pharmacokinetics/pharmacodynamics: increasing recognition of its contribution 
to variability in response, Clin Pharmacol Ther 83, 809-811. 
150. Wilson, J. T. (1983) Determinants and consequences of drug excretion in breast 
milk, Drug Metab Rev 14, 619-652. 
151. Condon, M. (2005) Breast is best, but it could be better: what is in breast milk 
that should not be?, Pediatr Nurs 31, 333-338. 
152. Atkinson, H. C., Begg, E. J., and Darlow, B. A. (1988) Drugs in human milk. 
Clinical pharmacokinetic considerations, Clin Pharmacokinet 14, 217-240. 
153. Misri, S., and Kostaras, X. (2002) Benefits and risks to mother and infant of drug 
treatment for postnatal depression, Drug Saf 25, 903-911. 
154. Berlin, C. M., and Briggs, G. G. (2005) Drugs and chemicals in human milk, 
Semin Fetal Neonatal Med 10, 149-159. 
 139
155. Scheuplein, R., Charnley, G., and Dourson, M. (2002) Differential sensitivity of 
children and adults to chemical toxicity. I. Biological basis, Regul Toxicol 
Pharmacol 35, 429-447. 
156. Ito, S., and Koren, G. (1994) A novel index for expressing exposure of the infant 
to drugs in breast milk, Br J Clin Pharmacol 38, 99-102. 
157. Larsen, L. A., Ito, S., and Koren, G. (2003) Prediction of milk/plasma 
concentration ratio of drugs, Ann Pharmacother 37, 1299-1306. 
158. Fleishaker, J. C., Desai, N., and McNamara, P. J. (1989) Possible effect of 
lactational period on the milk-to-plasma drug concentration ratio in lactating 
women: results of an in vitro evaluation, J Pharm Sci 78, 137-141. 
159. Yoshida, K., Smith, B., Craggs, M., and Kumar, R. C. (1997) Investigation of 
pharmacokinetics and of possible adverse effects in infants exposed to tricyclic 
antidepressants in breast-milk, J Affect Disord 43, 225-237. 
160. Alcorn, J., and McNamara, P. J. (2003) Pharmacokinetics in the newborn, Adv 
Drug Deliv Rev 55, 667-686. 
161. Auerbach, K. G. (1999) Breastfeeding and maternal medication use, J Obstet 
Gynecol Neonatal Nurs 28, 554-563. 
162. Jonker, J. W., Merino, G., Musters, S., van Herwaarden, A. E., Bolscher, E., 
Wagenaar, E., Mesman, E., Dale, T. C., and Schinkel, A. H. (2005) The breast 
cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic 
xenotoxins into milk, Nat Med 11, 127-129. 
163. Pacha, J. (2000) Development of intestinal transport function in mammals, 
Physiol Rev 80, 1633-1667. 
164. Garcia-Delgado, M., Peral, M. J., Duran, J. M., Garcia-Miranda, P., Calonge, M. 
L., and Ilundain, A. A. (2009) Ontogeny of Na(+)/L-carnitine transporter and of 
gamma-trimethylaminobutyraldehyde dehydrogenase and gamma-butyrobetaine 
hydroxylase genes expression in rat kidney, Mech Ageing Dev 130, 227-233. 
165. Miyamoto, K., Hase, K., Taketani, Y., Minami, H., Oka, T., Nakabou, Y., and 
 140
Hagihira, H. (1992) Developmental changes in intestinal glucose transporter 
mRNA levels, Biochem Biophys Res Commun 183, 626-631. 
166. Nagamatsu, S., Sawa, H., Nakamichi, Y., Katahira, H., and Inoue, N. (1994) 
Developmental expression of GLUT3 glucose transporter in the rat brain, FEBS 
Lett 346, 161-164. 
167. Toloza, E. M., and Diamond, J. (1992) Ontogenetic development of nutrient 
transporters in rat intestine, Am J Physiol 263, G593-604. 
168. Shu, R., David, E. S., and Ferraris, R. P. (1997) Dietary fructose enhances 
intestinal fructose transport and GLUT5 expression in weaning rats, Am J 
Physiol 272, G446-453. 
169. Brasitus, T. A., Dudeja, P. K., Bolt, M. J., Sitrin, M. D., and Baum, C. (1989) 
Dietary triacylglycerol modulates sodium-dependent D-glucose transport, 
fluidity and fatty acid composition of rat small intestinal brush-border membrane, 
Biochim Biophys Acta 979, 177-186. 
170. Pinto, N., Halachmi, N., Verjee, Z., Woodland, C., Klein, J., and Koren, G. (2005) 
Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin 
renal clearance, Pediatr Res 58, 1284-1289. 
171. Maka, D. A., and Murphy, L. K. (2000) Drug-nutrient interactions: a review, 
AACN Clin Issues 11, 580-589. 
172. Alonso-Aperte, E., and Varela-Moreiras, G. (2000) Drugs-nutrient interactions: a 
potential problem during adolescence, Eur J Clin Nutr 54 Suppl 1, S69-74. 
173. Pronsky, Z. M. (2000) Powers and Moore's food medication interactions, 11th ed 
ed., Birchrunville, PA. 
174. Arenas, J., Rubio, J. C., Martin, M. A., and Campos, Y. (1998) Biological roles 
of L-carnitine in perinatal metabolism, Early Hum Dev 53 Suppl, S43-50. 
175. Degrace, P., Demizieux, L., Gresti, J., Tsoko, M., Andre, A., Demaison, L., and 
Clouet, P. (2004) Fatty acid oxidation and related gene expression in heart 
depleted of carnitine by mildronate treatment in the rat, Mol Cell Biochem 258, 
 141
171-182. 
176. Azuero, R., Debata, C., Quinn, M., McDonough, K., Thomson, J., and Penn, D. 
(2004) Dobutamine alters carnitine metabolism in the neonatal piglet heart, Can 
J Physiol Pharmacol 82, 493-501. 
177. Kido, Y., Tamai, I., Ohnari, A., Sai, Y., Kagami, T., Nezu, J., Nikaido, H., 
Hashimoto, N., Asano, M., and Tsuji, A. (2001) Functional relevance of carnitine 
transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine 
across the blood-brain barrier, J Neurochem 79, 959-969. 
178. Tamai, I., Ohashi, R., Nezu, J., Yabuuchi, H., Oku, A., Shimane, M., Sai, Y., and 
Tsuji, A. (1998) Molecular and functional identification of sodium ion-dependent, 
high affinity human carnitine transporter OCTN2, J Biol Chem 273, 20378-
20382. 
179. Tamai, I., China, K., Sai, Y., Kobayashi, D., Nezu, J., Kawahara, E., and Tsuji, A. 
(2001) Na(+)-coupled transport of L-carnitine via high-affinity carnitine 
transporter OCTN2 and its subcellular localization in kidney, Biochim Biophys 
Acta 1512, 273-284. 
180. Vaz, F. M., and Wanders, R. J. (2002) Carnitine biosynthesis in mammals, 
Biochem J 361, 417-429. 
181. Thanka, J., Padmasani, Krishnan, L., and Kuruvilla, S. (2005) Fatty acid 
oxidation disorder as a cause of sudden infant death syndrome (SIDS)--a case 
report, Indian J Pathol Microbiol 48, 485-487. 
182. Robles-Valdes, C., McGarry, J. D., and Foster, D. W. (1976) Maternal-fetal 
carnitine relationship and neonatal ketosis in the rat, J Biol Chem 251, 6007-
6012. 
183. Shennan, D. B., Grant, A., Ramsay, R. R., Burns, C., and Zammit, V. A. (1998) 
Characteristics of L-carnitine transport by lactating rat mammary tissue, Biochim 
Biophys Acta 1393, 49-56. 
184. Onay-Besikci, A., Campbell, F. M., Hopkins, T. A., Dyck, J. R., and Lopaschuk, 
G. D. (2003) Relative importance of malonyl CoA and carnitine in maturation of 
 142
fatty acid oxidation in newborn rabbit heart, Am J Physiol Heart Circ Physiol 
284, H283-289. 
185. Borum, P. R. (1983) Carnitine, Annu Rev Nutr 3, 233-259. 
186. Rovamo, L. M., Salmenpera, L., Arjomaa, P., and Raivio, K. O. (1986) Carnitine 
during prolonged breast feeding, Pediatr Res 20, 806-809. 
187. Melegh, B., Kerner, J., Sandor, A., Vinceller, M., and Kispal, G. (1986) Oral L-
carnitine supplementation in low-birth-weight newborns: a study on neonates 
requiring combined parenteral and enteral nutrition, Acta Paediatr Hung 27, 253-
258. 
188. Ohashi, R., Tamai, I., Inano, A., Katsura, M., Sai, Y., Nezu, J., and Tsuji, A. 
(2002) Studies on functional sites of organic cation/carnitine transporter OCTN2 
(SLC22A5) using a Ser467Cys mutant protein, J Pharmacol Exp Ther 302, 
1286-1294. 
189. Ramsay, R. R., Gandour, R. D., and van der Leij, F. R. (2001) Molecular 
enzymology of carnitine transfer and transport, Biochim Biophys Acta 1546, 21-
43. 
190. Yabuuchi, H., Tamai, I., Nezu, J., Sakamoto, K., Oku, A., Shimane, M., Sai, Y., 
and Tsuji, A. (1999) Novel membrane transporter OCTN1 mediates multispecific, 
bidirectional, and pH-dependent transport of organic cations, J Pharmacol Exp 
Ther 289, 768-773. 
191. Wu, X., George, R. L., Huang, W., Wang, H., Conway, S. J., Leibach, F. H., and 
Ganapathy, V. (2000) Structural and functional characteristics and tissue 
distribution pattern of rat OCTN1, an organic cation transporter, cloned from 
placenta, Biochim Biophys Acta 1466, 315-327. 
192. Tamai, I., Ohashi, R., Nezu, J. I., Sai, Y., Kobayashi, D., Oku, A., Shimane, M., 
and Tsuji, A. (2000) Molecular and functional characterization of organic 
cation/carnitine transporter family in mice, J Biol Chem 275, 40064-40072. 
193. Seth, P., Wu, X., Huang, W., Leibach, F. H., and Ganapathy, V. (1999) Mutations 
in novel organic cation transporter (OCTN2), an organic cation/carnitine 
 143
transporter, with differential effects on the organic cation transport function and 
the carnitine transport function, J Biol Chem 274, 33388-33392. 
194. Wu, X., Huang, W., Prasad, P. D., Seth, P., Rajan, D. P., Leibach, F. H., Chen, J., 
Conway, S. J., and Ganapathy, V. (1999) Functional characteristics and tissue 
distribution pattern of organic cation transporter 2 (OCTN2), an organic 
cation/carnitine transporter, J Pharmacol Exp Ther 290, 1482-1492. 
195. Grube, M., Schwabedissen, H. M., Draber, K., Prager, D., Moritz, K. U., 
Linnemann, K., Fusch, C., Jedlitschky, G., and Kroemer, H. K. (2005) 
Expression, localization, and function of the carnitine transporter octn2 (slc22a5) 
in human placenta, Drug Metab Dispos 33, 31-37. 
196. Kobayashi, D., Tamai, I., Sai, Y., Yoshida, K., Wakayama, T., Kido, Y., Nezu, J., 
Iseki, S., and Tsuji, A. (2007) Transport of carnitine and acetylcarnitine by 
carnitine/organic cation transporter (OCTN) 2 and OCTN3 into epididymal 
spermatozoa, Reproduction 134, 651-658. 
197. Rodriguez, C. M., Labus, J. C., and Hinton, B. T. (2002) Organic cation/carnitine 
transporter, OCTN2, is differentially expressed in the adult rat epididymis, Biol 
Reprod 67, 314-319. 
198. Duran, J. M., Peral, M. J., Calonge, M. L., and Ilundain, A. A. (2005) OCTN3: A 
Na+-independent L-carnitine transporter in enterocytes basolateral membrane, J 
Cell Physiol 202, 929-935. 
199. Taylor, P. M. (2001) Absorbing competition for carnitine, J Physiol 532, 283. 
200. Nakanishi, T., Hatanaka, T., Huang, W., Prasad, P. D., Leibach, F. H., Ganapathy, 
M. E., and Ganapathy, V. (2001) Na+- and Cl--coupled active transport of 
carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in 
HRPE cells and Xenopus oocytes, J Physiol 532, 297-304. 
201. Enomoto, A., Wempe, M. F., Tsuchida, H., Shin, H. J., Cha, S. H., Anzai, N., 
Goto, A., Sakamoto, A., Niwa, T., Kanai, Y., Anders, M. W., and Endou, H. 
(2002) Molecular identification of a novel carnitine transporter specific to human 
testis. Insights into the mechanism of carnitine recognition, J Biol Chem 277, 
 144
36262-36271. 
202. Lamhonwah, A. M., Ackerley, C. A., Tilups, A., Edwards, V. D., Wanders, R. J., 
and Tein, I. (2005) OCTN3 is a mammalian peroxisomal membrane carnitine 
transporter, Biochem Biophys Res Commun 338, 1966-1972. 
203. Seim, H., Eichler, K., Kleber, H.P. (2001) Nutraceuticals in Health and Disease 
Prevention, Marcel Dekker, Inc,, New York. 
204. Wang, Y., Korman, S. H., Ye, J., Gargus, J. J., Gutman, A., Taroni, F., Garavaglia, 
B., and Longo, N. (2001) Phenotype and genotype variation in primary carnitine 
deficiency, Genet Med 3, 387-392. 
205. Spaniol, M., Brooks, H., Auer, L., Zimmermann, A., Solioz, M., Stieger, B., and 
Krahenbuhl, S. (2001) Development and characterization of an animal model of 
carnitine deficiency, Eur J Biochem 268, 1876-1887. 
206. Cederbaum, S. D., Koo-McCoy, S., Tein, I., Hsu, B. Y., Ganguly, A., Vilain, E., 
Dipple, K., Cvitanovic-Sojat, L., and Stanley, C. (2002) Carnitine membrane 
transporter deficiency: a long-term follow up and OCTN2 mutation in the first 
documented case of primary carnitine deficiency, Mol Genet Metab 77, 195-201. 
207. Makhseed, N., Vallance, H. D., Potter, M., Waters, P. J., Wong, L. T., Lillquist, Y., 
Pasquali, M., Amat di San Filippo, C., and Longo, N. (2004) Carnitine 
transporter defect due to a novel mutation in the SLC22A5 gene presenting with 
peripheral neuropathy, J Inherit Metab Dis 27, 778-780. 
208. Ohashi, R., Tamai, I., Yabuuchi, H., Nezu, J. I., Oku, A., Sai, Y., Shimane, M., 
and Tsuji, A. (1999) Na(+)-dependent carnitine transport by organic cation 
transporter (OCTN2): its pharmacological and toxicological relevance, J 
Pharmacol Exp Ther 291, 778-784. 
209. Winter, S. C., Szabo-Aczel, S., Curry, C. J., Hutchinson, H. T., Hogue, R., and 
Shug, A. (1987) Plasma carnitine deficiency. Clinical observations in 51 
pediatric patients, Am J Dis Child 141, 660-665. 
210. Pons, R., and De Vivo, D. C. (1995) Primary and secondary carnitine deficiency 
syndromes, J Child Neurol 10 Suppl 2, S8-24. 
 145
211. Glenn, D. J., and Gardner, D. G. (2007) Lipids and the heart: neither feast nor 
famine, Hypertension 50, 463-464. 
212. Vockley, J., and Whiteman, D. A. (2002) Defects of mitochondrial beta-oxidation: 
a growing group of disorders, Neuromuscul Disord 12, 235-246. 
213. Oey, N. A., den Boer, M. E., Wijburg, F. A., Vekemans, M., Auge, J., Steiner, C., 
Wanders, R. J., Waterham, H. R., Ruiter, J. P., and Attie-Bitach, T. (2005) Long-
chain fatty acid oxidation during early human development, Pediatr Res 57, 755-
759. 
214. Li, X. X., Kobayashi, K., Horiuchi, M., Jalil, A., Yoshida, G., and Saheki, T. 
(2002) Hyperammonemia in carnitine-deficient adult JVS mice used by 
starvation, Metab Brain Dis 17, 359-366. 
215. Lamhonwah, A. M., Olpin, S. E., Pollitt, R. J., Vianey-Saban, C., Divry, P., 
Guffon, N., Besley, G. T., Onizuka, R., De Meirleir, L. J., Cvitanovic-Sojat, L., 
Baric, I., Dionisi-Vici, C., Fumic, K., Maradin, M., and Tein, I. (2002) Novel 
OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy 
prevents cardiomyopathy, Am J Med Genet 111, 271-284. 
216. Forgue, S. T., Shyu, W. C., Gleason, C. R., Pittman, K. A., and Barbhaiya, R. H. 
(1987) Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in 
rats and monkeys, Antimicrob Agents Chemother 31, 799-804. 
217. Kessler, R. E., Bies, M., Buck, R. E., Chisholm, D. R., Pursiano, T. A., Tsai, Y. 
H., Misiek, M., Price, K. E., and Leitner, F. (1985) Comparison of a new 
cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics, 
Antimicrob Agents Chemother 27, 207-216. 
218. Tune, B. M., and Hsu, C. Y. (1994) Toxicity of cephaloridine to carnitine 
transport and fatty acid metabolism in rabbit renal cortical mitochondria: 
structure-activity relationships, J Pharmacol Exp Ther 270, 873-880. 
219. Ganapathy, M. E., Huang, W., Rajan, D. P., Carter, A. L., Sugawara, M., Iseki, K., 
Leibach, F. H., and Ganapathy, V. (2000) beta-lactam antibiotics as substrates for 
OCTN2, an organic cation/carnitine transporter, J Biol Chem 275, 1699-1707. 
 146
220. Wilson, J. T., Brown, R. D., Hinson, J. L., and Dailey, J. W. (1985) 
Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for 
drugs, Annu Rev Pharmacol Toxicol 25, 667-689. 
221. Bennett, P. (1996) Drugs and Human Lactation, 2nd Edition ed., Elsevier, 
Amsterdam. 
222. Alcorn, J., and McNamara, P. J. (2002) Acyclovir, ganciclovir, and zidovudine 
transfer into rat milk, Antimicrob Agents Chemother 46, 1831-1836. 
223. Lee, K. (2007) Lactation and Drugs, Paediatrics and child health 17, 68-71. 
224. Sanchez, L., Aranda, P., Perez, M. D., and Calvo, M. (1988) Concentration of 
lactoferrin and transferrin throughout lactation in cow's colostrum and milk, Biol 
Chem Hoppe Seyler 369, 1005-1008. 
225. Borgatta, L., Jenny, R. W., Gruss, L., Ong, C., and Barad, D. (1997) Clinical 
significance of methohexital, meperidine, and diazepam in breast milk, J Clin 
Pharmacol 37, 186-192. 
226. Baka, N. E., Bayoumeu, F., Boutroy, M. J., and Laxenaire, M. C. (2002) 
Colostrum morphine concentrations during postcesarean intravenous patient-
controlled analgesia, Anesth Analg 94, 184-187, table of contents. 
227. Ohman, R., Hagg, S., Carleborg, L., and Spigset, O. (1999) Excretion of 
paroxetine into breast milk, J Clin Psychiatry 60, 519-523. 
228. Hagg, S., Granberg, K., and Carleborg, L. (2000) Excretion of fluvoxamine into 
breast milk, Br J Clin Pharmacol 49, 286-288. 
229. Stowe, Z. N., Cohen, L. S., Hostetter, A., Ritchie, J. C., Owens, M. J., and 
Nemeroff, C. B. (2000) Paroxetine in human breast milk and nursing infants, Am 
J Psychiatry 157, 185-189. 
230. Fleishaker, J. C., and McNamara, P. J. (1988) In vivo evaluation in the lactating 
rabbit of a model for xenobiotic distribution into breast milk, J Pharmacol Exp 
Ther 244, 919-924. 
231. RN-BC, K. G. (2005) Lactation and Milk, In A Layman's guide to health, 
 147
medication use, breeding and responsible care of pet rats. 
232. Gerald G. Briggs, R. K. F., Sumner J. Yaffe (2008) Drugs in pregnancy and 
lactation : a reference guide to fetal and neonatal risk, 8th ed., Lippincott 
Williams & Wilkins, Philadelphia; London. 
233. Andersen, L. W., Qvist, T., Hertz, J., and Mogensen, F. (1987) Concentrations of 
thiopentone in mature breast milk and colostrum following an induction dose, 
Acta Anaesthesiol Scand 31, 30-32. 
234. Rudolph, M. C., McManaman, J. L., Phang, T., Russell, T., Kominsky, D. J., 
Serkova, N. J., Stein, T., Anderson, S. M., and Neville, M. C. (2007) Metabolic 
regulation in the lactating mammary gland: a lipid synthesizing machine, Physiol 
Genomics 28, 323-336. 
235. WHO. (2001) Transfer of drugs and other chemicals into human milk, Pediatrics 
108, 776-789. 
236. Kelleher, S. L., and Lonnerdal, B. (2003) Marginal maternal Zn intake in rats 
alters mammary gland Cu transporter levels and milk Cu concentration and 
affects neonatal Cu metabolism, J Nutr 133, 2141-2148. 
237. Murray, M. (2006) Altered CYP expression and function in response to dietary 
factors: potential roles in disease pathogenesis, Curr Drug Metab 7, 67-81. 
238. Tsuji, A. (2002) Transporter-mediated Drug Interactions, Drug Metab 
Pharmacokinet 17, 253-274. 
239. Chan, L. N. (2002) Drug-nutrient interaction in clinical nutrition, Curr Opin Clin 
Nutr Metab Care 5, 327-332. 
240. Santos, C. A., and Boullata, J. I. (2005) An approach to evaluating drug-nutrient 
interactions, Pharmacotherapy 25, 1789-1800. 
241. Girard, J., Ferre, P., Pegorier, J. P., and Duee, P. H. (1992) Adaptations of glucose 
and fatty acid metabolism during perinatal period and suckling-weaning 
transition, Physiol Rev 72, 507-562. 
242. Borum, P. R. (1985) Role of carnitine during development, Can J Physiol 
 148
Pharmacol 63, 571-576. 
243. Zammit, V. A., Ramsay, R. R., Bonomini, M., and Arduini, A. (2009) Carnitine, 
mitochondrial function and therapy, Adv Drug Deliv Rev 61, 1353-1362. 
244. Stanley, C. A. (2004) Carnitine deficiency disorders in children, Ann N Y Acad 
Sci 1033, 42-51. 
245. Sharma, S., Black, S.M. (2009) Carnitine homeostasis, mitochondrial function 
and cardiovascular disease, Drug Discovery Today: Disease Mechanisms In 
Press, Corrected Proof. 
246. Giovannini, M., Agostoni, C., and Salari, P. C. (1991) Is carnitine essential in 
children?, J Int Med Res 19, 88-102. 
247. Rebouche, C. J. (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine 
and acetyl-L-carnitine metabolism, Ann N Y Acad Sci 1033, 30-41. 
248. Rebouche, C. J. (1977) Carnitine movement across muscle cell membranes. 
Studies in isolated rat muscle, Biochim Biophys Acta 471, 145-155. 
249. Duran, J. M., Peral, M. J., Calonge, M. L., and Ilundain, A. A. (2002) Functional 
characterization of intestinal L-carnitine transport, J Membr Biol 185, 65-74. 
250. Lamhonwah, A. M., Skaug, J., Scherer, S. W., and Tein, I. (2003) A third human 
carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's 
disease locus (IBD5), Biochem Biophys Res Commun 301, 98-101. 
251. Alnouti, Y., and Klaassen, C. D. (2006) Tissue distribution and ontogeny of 
sulfotransferase enzymes in mice, Toxicol Sci 93, 242-255. 
252. Bressler, R., and Brendel, K. (1966) The role of carnitine and carnitine 
acyltransferase in biological acetylations and fatty acid synthesis, J Biol Chem 
241, 4092-4097. 
253. Kerner, J., Hoppel, C.L. . (2005) Carnitine palmitoyltransferase-I and regulation 
of mitochondrial fatty acid oxidation, Chemical Monthly 136, 1311–1323. 
254. Price, N., van der Leij, F., Jackson, V., Corstorphine, C., Thomson, R., Sorensen, 
A., and Zammit, V. (2002) A novel brain-expressed protein related to carnitine 
 149
palmitoyltransferase I, Genomics 80, 433-442. 
255. Yu, G. S., Lu, Y. C., and Gulick, T. (1998) Rat carnitine palmitoyltransferase 
Ibeta mRNA splicing isoforms, Biochim Biophys Acta 1393, 166-172. 
256. Woldegiorgis, G., Dai, J., Arvidson, D. (2005) Structure-Function Studies with 
the Mitochondrial Carnitine Palmitoyltransferases I and II, Chemical Monthly 
136, 1325-1340. 
257. Hahn, P. (1981) The development of carnitine synthesis from gamma-
butyrobetaine in the rat, Life Sci 28, 1057-1060. 
258. Feng, Y., Zhang, S., Xu, Y., Zhoum J., Tao, Y., Cai, W. . (2006) Study on 
determination of carnitine in serum by HPLC, Acta Nutrimenta Sin. 28, 177-179. 
259. Bieber, L. L., Abraham, T., and Helmrath, T. (1972) A rapid spectrophotometric 
assay for carnitine palmitoyltransferase, Anal Biochem 50, 509-518. 
260. NCBI. National Center for Biotechnology Information. 
261. Rozen, S., Skaletsky, H.J., . (2000) Primer3 on the WWW for general users and 
for biologist programmers., In Bioinformatics Methods and Protocols: Methods 
in Molecular Biology. (Krawetz, S., Misener, S., Ed.), pp 365–386. 
262. Nakano, C., Takashima, S., and Takeshita, K. (1989) Carnitine concentration 
during the development of human tissues, Early Hum Dev 19, 21-27. 
263. Galland, S., Le Borgne, F., Bouchard, F., Georges, B., Clouet, P., Grand-Jean, F., 
and Demarquoy, J. (1999) Molecular cloning and characterization of the cDNA 
encoding the rat liver gamma-butyrobetaine hydroxylase, Biochim Biophys Acta 
1441, 85-92. 
264. Garcia-Miranda, P., Duran, J. M., Peral, M. J., and Ilundain, A. A. (2005) 
Developmental maturation and segmental distribution of rat small intestinal L-
carnitine uptake, J Membr Biol 206, 9-16. 
265. Kato, Y., Sugiura, M., Sugiura, T., Wakayama, T., Kubo, Y., Kobayashi, D., Sai, 
Y., Tamai, I., Iseki, S., and Tsuji, A. (2006) Organic cation/carnitine transporter 
OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes 
 150
of small intestinal epithelial cells in mouse, Mol Pharmacol 70, 829-837. 
266. Lohninger, A., Pittner, G., Pittner, F. (2005) L-Carnitine: New Aspects of a 
Known Compound – A Brief Survey Chemical Monthly 136, 1255-1268. 
267. Godarova, A., Litzlbauer, E., Brunner, S., Agu, A.C., Lohninger, A., Hofbauer, 
R., . (2005) L-Carnitine Regulates mRNA ExpressionLevels of the Carnitine 
Acyltransferases –CPT1A, CPT2, and CRAT, Chemical Monthly 136, 1349-1363. 
268. Lin, X., and Odle, J. (2003) Changes in kinetics of carnitine palmitoyltransferase 
in liver and skeletal muscle of dogs (Canis familiaris) throughout growth and 
development, J Nutr 133, 1113-1119. 
269. Girard, J., Duee, P. H., Ferre, P., Pegorier, J. P., Escriva, F., and Decaux, J. F. 
(1985) Fatty acid oxidation and ketogenesis during development, Reprod Nutr 
Dev 25, 303-319. 
270. Penas, M., and Benito, M. (1986) Regulation of carnitine palmitoyltransferase 
activity in the liver and brown adipose tissue in the newborn rat: effect of 
starvation and hypothermia, Biochem Biophys Res Commun 135, 589-596. 
271. Bailey, D. G., Malcolm, J., Arnold, O., and Spence, J. D. (1998) Grapefruit juice-
drug interactions, Br J Clin Pharmacol 46, 101-110. 
272. Harris, R. Z., Jang, G. R., and Tsunoda, S. (2003) Dietary effects on drug 
metabolism and transport, Clin Pharmacokinet 42, 1071-1088. 
273. Murry, D. J., Riva, L., and Poplack, D. G. (1998) Impact of nutrition on 
pharmacokinetics of anti-neoplastic agents, Int J Cancer Suppl 11, 48-51. 
274. Genser, D. (2008) Food and drug interaction: consequences for the 
nutrition/health status, Ann Nutr Metab 52 Suppl 1, 29-32. 
275. Gluckman, P. D., Hanson, M. A., Spencer, H. G., and Bateson, P. (2005) 
Environmental influences during development and their later consequences for 
health and disease: implications for the interpretation of empirical studies, Proc 
Biol Sci 272, 671-677. 
276. Gurr, M. I. (1989) Individuals can or do adapt their metabolism to changes in 
 151
diet, Br J Nutr 62, 1-3. 
277. Waterlow, J. C. (1990) Nutritional adaptation in man: general introduction and 
concepts, Am J Clin Nutr 51, 259-263. 
278. Symonds, M. E., Pearce, S., Bispham, J., Gardner, D. S., and Stephenson, T. 
(2004) Timing of nutrient restriction and programming of fetal adipose tissue 
development, Proc Nutr Soc 63, 397-403. 
279. Waterlow, J. C. (1999) The nature and significance of nutritional adaptation, Eur 
J Clin Nutr 53 Suppl 1, S2-5. 
280. Edinger, A. L. (2005) Growth factors regulate cell survival by controlling 
nutrient transporter expression, Biochem Soc Trans 33, 225-227. 
281. Rivas, C. I., Zuniga, F. A., Salas-Burgos, A., Mardones, L., Ormazabal, V., and 
Vera, J. C. (2008) Vitamin C transporters, J Physiol Biochem 64, 357-375. 
282. El-Sheikh, A. A., Masereeuw, R., and Russel, F. G. (2008) Mechanisms of renal 
anionic drug transport, Eur J Pharmacol 585, 245-255. 
283. Kuroda, M., Kusuhara, H., Endou, H., and Sugiyama, Y. (2005) Rapid 
elimination of cefaclor from the cerebrospinal fluid is mediated by a 
benzylpenicillin-sensitive mechanism distinct from organic anion transporter 3, J 
Pharmacol Exp Ther 314, 855-861. 
284. Kano, T., Kato, Y., Ito, K., Ogihara, T., Kubo, Y., and Tsuji, A. (2009) 
Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal 
secretion of cephaloridine in mice, Drug Metab Dispos 37, 1009-1016. 
285. Olkowski, A. A., Nain, S., Wojnarowicz, C., Laarveld, B., Alcorn, J., and Ling, B. 
B. (2007) Comparative study of myocardial high energy phosphate substrate 
content in slow and fast growing chicken and in chickens with heart failure and 
ascites, Comp Biochem Physiol A Mol Integr Physiol 148, 230-238. 
286. Bartelink, I. H., Rademaker, C. M., Schobben, A. F., and van den Anker, J. N. 
(2006) Guidelines on paediatric dosing on the basis of developmental physiology 
and pharmacokinetic considerations, Clin Pharmacokinet 45, 1077-1097. 
 152
287. Brass, E. P., Hoppel, C. L., and Hiatt, W. R. (1994) Effect of intravenous L-
carnitine on carnitine homeostasis and fuel metabolism during exercise in 
humans, Clin Pharmacol Ther 55, 681-692. 
288. Knapp, A. C., Todesco, L., Torok, M., Beier, K., and Krahenbuhl, S. (2008) 
Effect of carnitine deprivation on carnitine homeostasis and energy metabolism 
in mice with systemic carnitine deficiency, Ann Nutr Metab 52, 136-144. 
289. Amat di San Filippo, C., Taylor, M. R., Mestroni, L., Botto, L. D., and Longo, N. 
(2008) Cardiomyopathy and carnitine deficiency, Mol Genet Metab 94, 162-166. 
290. Rebouche, C. J., Lombard, K. A., and Chenard, C. A. (1993) Renal adaptation to 
dietary carnitine in humans, Am J Clin Nutr 58, 660-665. 
291. Dyer, J., Barker, P. J., and Shirazi-Beechey, S. P. (1997) Nutrient regulation of 
the intestinal Na+/glucose co-transporter (SGLT1) gene expression, Biochem 
Biophys Res Commun 230, 624-629. 
292. Dyer, J., Vayro, S., King, T. P., and Shirazi-Beechey, S. P. (2003) Glucose 
sensing in the intestinal epithelium, Eur J Biochem 270, 3377-3388. 
293. Hyatt, S. L., Aulak, K. S., Malandro, M., Kilberg, M. S., and Hatzoglou, M. 
(1997) Adaptive regulation of the cationic amino acid transporter-1 (Cat-1) in 
Fao cells, J Biol Chem 272, 19951-19957. 
294. Vega, Y. M., Puchal, A. A., and Buddington, R. K. (1992) Intestinal amino acid 
and monosaccharide transport in suckling pigs fed milk replacers with different 
sources of carbohydrate, J Nutr 122, 2430-2439. 
295. Stefanovic-Racic, M., Perdomo, G., Mantell, B. S., Sipula, I. J., Brown, N. F., 
and O'Doherty, R. M. (2008) A moderate increase in carnitine 
palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic 
triglyceride levels, Am J Physiol Endocrinol Metab 294, E969-977. 
296. Paulson, D. J. (1998) Carnitine deficiency-induced cardiomyopathy, Mol Cell 
Biochem 180, 33-41. 
297. Weiss, R. G., Bottomley, P. A., Hardy, C. J., and Gerstenblith, G. (1990) Regional 
 153
myocardial metabolism of high-energy phosphates during isometric exercise in 
patients with coronary artery disease, N Engl J Med 323, 1593-1600. 
298. Neubauer, S., Horn, M., Cramer, M., Harre, K., Newell, J. B., Peters, W., Pabst, 
T., Ertl, G., Hahn, D., Ingwall, J. S., and Kochsiek, K. (1997) Myocardial 
phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated 
cardiomyopathy, Circulation 96, 2190-2196. 
299. Amir, L. H. (2007) Medicines and breastfeeding: information is available on safe 
use, Med J Aust 186, 485. 
300. Hughes, L. E. (1989) Management of recurrent infection following surgery for 
periductal mastitis, Br J Clin Pract Suppl 68, 81-85; discussion 87-89. 
301. Betzold, C. M. (2007) An update on the recognition and management of 
lactational breast inflammation, J Midwifery Womens Health 52, 595-605. 
302. DeGraves, F. J., and Anderson, K. L. (1993) Ibuprofen treatment of endotoxin-
induced mastitis in cows, Am J Vet Res 54, 1128-1132. 
303. Jahanfar, S., Ng, C. J., and Teng, C. L. (2009) Antibiotics for mastitis in 
breastfeeding women, Cochrane Database Syst Rev, CD005458. 
304. Smith, K. L., Todhunter, D. A., and Schoenberger, P. S. (1985) Environmental 
mastitis: cause, prevalence, prevention, J Dairy Sci 68, 1531-1553. 
305. Fukushima, K., Sasaki, I., Takahashi, K., Naito, H., and Matsuno, S. (1999) 
Lipopolysaccharide- and proinflammatory cytokine-induced energy production 
in intestinal and colonic epithelial cell lines, Scand J Gastroenterol 34, 291-296. 
306. Roediger, W. E. (1980) The colonic epithelium in ulcerative colitis: an energy-
deficiency disease?, Lancet 2, 712-715. 
307. Leverve, X., Batandier, C., and Fontaine, E. (2007) Choosing the right substrate, 
Novartis Found Symp 280, 108-121; discussion 121-107, 160-104. 
308. Dimenna, G. P., and Emery, R. S. (1980) Factors affecting fatty acid oxidation in 
bovine mammary tissue, Lipids 15, 497-503. 
309. Bell, A. W., and Bauman, D. E. (1997) Adaptations of glucose metabolism 
 154
during pregnancy and lactation, J Mammary Gland Biol Neoplasia 2, 265-278. 
310. Butte, N. F., Hopkinson, J. M., Mehta, N., Moon, J. K., and Smith, E. O. (1999) 
Adjustments in energy expenditure and substrate utilization during late 
pregnancy and lactation, Am J Clin Nutr 69, 299-307. 
311. Demmelmair, H., Sauerwald, T., Fidler, N., Baumheuer, M., and Koletzko, B. 
(2001) Polyunsaturated fatty acid metabolism during lactation, World Rev Nutr 
Diet 88, 184-189. 
312. Akers, R. M. (2002) Lactation and the Mammary Gland, Ames IA: Iowa State. 
313. Komatsu, T., Itoh, F., Kushibiki, S., and Hodate, K. (2005) Changes in gene 
expression of glucose transporters in lactating and nonlactating cows, J Anim Sci 
83, 557-564. 
314. Zhao, F. Q., Miller, P. J., Wall, E. H., Zheng, Y. C., Dong, B., Neville, M. C., and 
McFadden, T. B. (2004) Bovine glucose transporter GLUT8: cloning, expression, 
and developmental regulation in mammary gland, Biochim Biophys Acta 1680, 
103-113. 
315. Glatz, J. F., Luiken, J. J., van Nieuwenhoven, F. A., and Van der Vusse, G. J. 
(1997) Molecular mechanism of cellular uptake and intracellular translocation of 
fatty acids, Prostaglandins Leukot Essent Fatty Acids 57, 3-9. 
316. Bionaz, M., and Loor, J. J. (2008) ACSL1, AGPAT6, FABP3, LPIN1, and 
SLC27A6 are the most abundant isoforms in bovine mammary tissue and their 
expression is affected by stage of lactation, J Nutr 138, 1019-1024. 
317. Larque, E., Demmelmair, H., Klingler, M., De Jonge, S., Bondy, B., and 
Koletzko, B. (2006) Expression pattern of fatty acid transport protein-1 (FATP-1), 
FATP-4 and heart-fatty acid binding protein (H-FABP) genes in human term 
placenta, Early Hum Dev 82, 697-701. 
318. Calvani, M., Reda, E., and Arrigoni-Martelli, E. (2000) Regulation by carnitine 
of myocardial fatty acid and carbohydrate metabolism under normal and 
pathological conditions, Basic Res Cardiol 95, 75-83. 
 155
319. Fernandez-Veledo, S., Valdes, R., Wallenius, V., Casado, F. J., and Pastor-
Anglada, M. (2004) Up-regulation of the high-affinity pyrimidine-preferring 
nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis 
factor-alpha and interleukin-6 in liver parenchymal cells, J Hepatol 41, 538-544. 
320. Podgorska, M., Kocbuch, K., Grden, M., Szutowicz, A., and Pawelczyk, T. (2006) 
Reduced ability to release adenosine by diabetic rat cardiac fibroblasts due to 
altered expression of nucleoside transporters, J Physiol 576, 179-189. 
321. Rodriguez-Mulero, S., Errasti-Murugarren, E., Ballarin, J., Felipe, A., Doucet, A., 
Casado, F. J., and Pastor-Anglada, M. (2005) Expression of concentrative 
nucleoside transporters SLC28 (CNT1, CNT2, and CNT3) along the rat nephron: 
effect of diabetes, Kidney Int 68, 665-672. 
322. Vavricka, S. R., Musch, M. W., Fujiya, M., Kles, K., Chang, L., Eloranta, J. J., 
Kullak-Ublick, G. A., Drabik, K., Merlin, D., and Chang, E. B. (2006) Tumor 
necrosis factor-alpha and interferon-gamma increase PepT1 expression and 
activity in the human colon carcinoma cell line Caco-2/bbe and in mouse 
intestine, Pflugers Arch 452, 71-80. 
323. Johnson, D., Bayele, H., Johnston, K., Tennant, J., Srai, S. K., and Sharp, P. 
(2004) Tumour necrosis factor alpha regulates iron transport and transporter 
expression in human intestinal epithelial cells, FEBS Lett 573, 195-201. 
324. Lertanekawattana, S., Wichatrong, T., Chaisiri, K., Uchikawa, R., and Arizono, N. 
(2005) Expression of cytokines and monosaccharide transporters in the duodenal 
mucosa of patients with gastrointestinal symptoms in rural Thailand, Southeast 
Asian J Trop Med Public Health 36, 923-930. 
325. Plomgaard, P., Bouzakri, K., Krogh-Madsen, R., Mittendorfer, B., Zierath, J. R., 
and Pedersen, B. K. (2005) Tumor necrosis factor-alpha induces skeletal muscle 
insulin resistance in healthy human subjects via inhibition of Akt substrate 160 
phosphorylation, Diabetes 54, 2939-2945. 
326. D'Argenio, G., Calvani, M., Casamassimi, A., Petillo, O., Margarucci, S., Rienzo, 
M., Peluso, I., Calvani, R., Ciccodicola, A., Caporaso, N., and Peluso, G. (2006) 
 156
Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes 
induces carnitine depletion that is reversible by carnitine-loaded liposomes, 
FASEB J 20, 2544-2546. 
327. Shekhawat, P. S., Srinivas, S. R., Matern, D., Bennett, M. J., Boriack, R., George, 
V., Xu, H., Prasad, P. D., Roon, P., and Ganapathy, V. (2007) Spontaneous 
development of intestinal and colonic atrophy and inflammation in the carnitine-
deficient jvs (OCTN2(-/-)) mice, Mol Genet Metab 92, 315-324. 
328. Huynh, H. T., Robitaille, G., and Turner, J. D. (1991) Establishment of bovine 
mammary epithelial cells (MAC-T): an in vitro model for bovine lactation, Exp 
Cell Res 197, 191-199. 
329. Pareek, R., Wellnitz, O., Van Dorp, R., Burton, J., and Kerr, D. (2005) 
Immunorelevant gene expression in LPS-challenged bovine mammary epithelial 
cells, J Appl Genet 46, 171-177. 
330. McClenahan, D. J., Sotos, J. P., and Czuprynski, C. J. (2005) Cytokine response 
of bovine mammary gland epithelial cells to Escherichia coli, coliform culture 
filtrate, or lipopolysaccharide, Am J Vet Res 66, 1590-1597. 
331. Okada, H., Ohtsuka, H., Kon Nai, S., Kirisawa, R., Yokomizo, Y., Yoshino, T., 
and Rosol, T. J. (1999) Effects of lipopolysaccharide on production of 
interleukin-1 and interleukin-6 by bovine mammary epithelial cells in vitro, J Vet 
Med Sci 61, 33-35. 
332. Rainard, P., and Riollet, C. (2003) Mobilization of neutrophils and defense of the 
bovine mammary gland, Reprod Nutr Dev 43, 439-457. 
333. Le, J. M., and Vilcek, J. (1989) Interleukin 6: a multifunctional cytokine 
regulating immune reactions and the acute phase protein response, Lab Invest 61, 
588-602. 
334. Oviedo-Boyso, J., Valdez-Alarcon, J. J., Cajero-Juarez, M., Ochoa-Zarzosa, A., 
Lopez-Meza, J. E., Bravo-Patino, A., and Baizabal-Aguirre, V. M. (2007) Innate 
immune response of bovine mammary gland to pathogenic bacteria responsible 
for mastitis, J Infect 54, 399-409. 
 157
335. Su, S. C., Hua, K. F., Lee, H., Chao, L. K., Tan, S. K., Yang, S. F., and Hsu, H. Y. 
(2006) LTA and LPS mediated activation of protein kinases in the regulation of 
inflammatory cytokines expression in macrophages, Clin Chim Acta 374, 106-
115. 
336. Haney, P. M. (2004) Glucose transport in lactation, Adv Exp Med Biol 554, 253-
261. 
337. Zhao, F. Q., and Keating, A. F. (2007) Expression and regulation of glucose 
transporters in the bovine mammary gland, J Dairy Sci 90 Suppl 1, E76-86. 
338. Scholte, H. R., Rodrigues Pereira, R., de Jonge, P. C., Luyt-Houwen, I. E., 
Hedwig, M., Verduin, M., and Ross, J. D. (1990) Primary carnitine deficiency, J 
Clin Chem Clin Biochem 28, 351-357. 
339. Frayn, K. N. (2003) The glucose-fatty acid cycle: a physiological perspective, 
Biochem Soc Trans 31, 1115-1119. 
340. Wolfe, B. M., Klein, S., Peters, E. J., Schmidt, B. F., and Wolfe, R. R. (1988) 
Effect of elevated free fatty acids on glucose oxidation in normal humans, 
Metabolism 37, 323-329. 
341. Carlson, M. G., Snead, W. L., Hill, J. O., Nurjhan, N., and Campbell, P. J. (1991) 
Glucose regulation of lipid metabolism in humans, Am J Physiol 261, E815-820. 
342. Randle, P. J., Priestman, D. A., Mistry, S. C., and Halsall, A. (1994) Glucose fatty 
acid interactions and the regulation of glucose disposal, J Cell Biochem 55 Suppl, 
1-11. 
343. Fujii, N., Nozawa, T., Igawa, A., Kato, B., Igarashi, N., Nonomura, M., Asanoi, 
H., Tazawa, S., Inoue, M., and Inoue, H. (2004) Saturated glucose uptake 
capacity and impaired fatty acid oxidation in hypertensive hearts before 
development of heart failure, Am J Physiol Heart Circ Physiol 287, H760-766. 
344. Memon, R. A., Feingold, K. R., Moser, A. H., Fuller, J., and Grunfeld, C. (1998) 
Regulation of fatty acid transport protein and fatty acid translocase mRNA levels 
by endotoxin and cytokines, Am J Physiol 274, E210-217. 
 158
345. Berg, S., Sappington, P. L., Guzik, L. J., Delude, R. L., and Fink, M. P. (2003) 
Proinflammatory cytokines increase the rate of glycolysis and adenosine-5'-
triphosphate turnover in cultured rat enterocytes, Crit Care Med 31, 1203-1212. 
346. Eaton, S., Pierro, A. (2005) Carnitine and Fatty Acid Oxidation in Sepsis, 
Chemical Monthly 136, 1483-1492. 
347. Petrovic, V., Teng, S., and Piquette-Miller, M. (2007) Regulation of drug 
transporters during infection and inflammation, Mol Interv 7, 99-111. 
348. Shennan, D. B., and Beechey, R. B. (1995) Mechanisms involved in the uptake 
of D-glucose into the milk producing cells of rat mammary tissue, Biochem 
Biophys Res Commun 211, 986-990. 
349. Bauman, D. E., Davis, C.L., . (1974) Biosynthesis of milk fat, In Lactation 
(Larson, B. L., and Smith, V.R., Ed.), pp 31-75, Academic, New York. 
 
 
 159
APPENDIX A 
 Supplemental Table 1. Primer sequences for quantitative RT-PCR of L-carnitine 
transporters in whole rat lactating mammary gland.  
Primers 
Gene 
Accession 
Number Forward Reverse 
Control 
Tissue 
Octn1 NM_022270 catggctgtgcagactgg gcaccatgtagccgatgg Kidney 
Octn2 NM_019269 ggcgcaaccacagtatcc ggggctttccagtcatcc Kidney 
Octn3 NM_019723 gacaccgtgaacctgagc ccatccaggcagttctcc Testis 
Atb0,+ AF_320226 gtgtgggaatcacgatgg ctgtgctcacacgacagc Lung 
Ct2 BC_100473 cagtccttgcttcgatgg agaagaacacgccgatgc Testis 
Octn1, organic cation/carnitine transporter 1; Octn2, organic cation/carnitine transporter 
2; Octn3, organic cation/carnitine transporter 3; Atb0,+, amino acid transporter system 
B0,+; CT2, L-carnitine transporter 2.  
 
 
